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ABSTRACT
Robustness is an important phenotype for bioenergy microbes to acquire but is difficult to
engineer. Hence, tools for engineering microbial robustness are critical to unlock novel
phenotypes for innovative bioprocessing strategies. The oleaginous yeast, Yarrowia
lipolytica, is an exceptionally robust microbe that can tolerate stressful environments,
assimilate a wide range of substrates, and produce high-value chemicals. In this doctoral
dissertation, the impacts of systems biology and metabolic engineering to reveal
mechanisms and identify genotypes- underlying robust phenotypes are addressed.
The first approach employs adaptive laboratory engineering to generate a platform
strain by which to study superior robust mechanisms. This approach generated the most
solvent-tolerant microorganism reported to date, identified sterols are critical for solvent
tolerance in Y. lipolytica, and reverse engineered high solvent tolerance by increasing
sterol biosynthesis via overexpression of the sterol transcription factor (Chapter I).
Similarly, short-term adaptation of Y. lipolytica to depolymerized plastic waste improved
utilization of all hydrophobic substrates tested and acquired a mechanism enabling
cellular adhesion to the hydrophobic layer (Chapter V).
A more elaborate approach is developed using temporal RNA-sequencing data to
directly predict genotypes underling robust phenotypes. Here, a novel concept was
established that ranks differentially expressed genes by their co-expression connectivity
to predict top-performing genetic targets conferring robustness.

This methodology

identified genes that would normally be overlooked by common differential expression
approaches yet proved to have the highest prediction of genetic targets conferring solvent
tolerance in Y. lipolytica (Chapter III).
We approached engineering an absent genotype (e.g., thiamine auxotroph) using
comparative genomics with a thiamine prototroph strain and discovered the missing gene
for thiamine biosynthesis (Chapter II).

Bioinformatics in conjunction with metabolic

engineering elucidated a promoter tightly regulated by thiamine concentration that
enabled strong expression of the missing gene and restoration of thiamine biosynthesis
in Y. lipolytica (Chapter II).
iv

Finally, we exploited the phenotypic diversity exhibited by non-conventional Y.
lipolytica isolates to reveal key processes and regulators underlying xylose metabolism
and lipid accumulation or degradation from biomass hydrolysate (Chapter IV).
In conclusion, the outcome of this research is to develop strategies to elucidate
and establish genetic tractability of robust phenotypes.
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INTRODUCTION
The genetic diversity of microbial organisms offers a plethora of desirable phenotypes
exploitable for bioprocessing. The selection of microorganism(s) for bioproduction heavily
depends on the strain’s native phenotype(s) and genetic tractability to the required
phenotype(s) to realize economic bioprocessing in a given environment, e.g., carbon
source and chemical production. To this end, genetic tractability of desirable phenotypes
enables greater flexibility for host organism selection. Accordingly, a microorganism
displaying a novel phenotype could be used for biotransformation if the other required
phenotypes are genetically tractable. For example, Saccharomyces cerevisiae produces
high titers of ethanol from glucose but insufficiently assimilates 5-carbon (C5) sugars
(e.g., xylose, arabinose) (1) and has poor tolerance of biomass inhibitors (e.g., furfural,
HMF) (2). For S. cerevisiae to be selected for biotransformation of biomass hydrolysate,
C5 sugars assimilation and tolerance of biomass inhibitors are required phenotypes.
While C5 biomass sugar assimilation is genetically tractable and can be genetically
engineered, tolerance of biomass inhibitors is largely unknown (3), obstructing economic
bioprocessing with S. cerevisiae. For these reasons, linking genotype(s) to phenotype(s)
sanctions efficient and economic biotransformation developmental strategies.
Robustness.
Microbial robustness encompasses the ability to withstand or overcome adverse
conditions which are critical phenotypes to unlock and enable innovative and strategical
biotransformation processes.

These robust phenotypes can include resistance to

chemical inhibitors (e.g., inhibitors arising from substrate processing, metabolic
intermediates, or secreted products), cell growth on diverse or multiple substrates (e.g.,
biomass hydrolysate, hydrophobic substrates), overcoming nutrient limitations (e.g.,
essential vitamin or amino acid auxotroph), or withstanding stressful environments (e.g.,
pH, salinity, temperature).

For example, assimilation of biomass-derived sugars

necessitates microbial tolerance of the inhibitors released in biomass pretreatment steps
(e.g., furfural) (4). Efficient production of biofuels also demands cellular resistance to high
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concentrations of the alcohol (e.g., butanol) or diesel (e.g., fatty acid methyl esters)
produced (5). In situ separation and recovery of hydrophobic, toxic products requires
microbial resilience in the presence of organic solvents (e.g., alkanes, ionic liquids) (6).
Though robustness is broad in scope, engineering any individual robust phenotype
is particularly challenging due to the complexity of toxic/inhibitory modes of action,
biological resistance mechanisms, and genetic regulation controlling cellular metabolism
and physiology.

For instance, metabolic pathway engineering (e.g., substrate

assimilation or product formation) is generally more predictable (i.e., genetically
tractable), enabling a more rational approach (7) than robustness engineering. In fact,
much more is known about how cells respond to chemicals (e.g., stress proteins, efflux
pumps and altered membrane compositions) than how to develop more tolerant strains
(4). To this end, tools for enhancing and engineering microbial tolerance to growth
inhibitors are imperative to unlock novel phenotypes with important implications.
To rationally engineer robustness, knowledge of tolerant mechanisms or inhibitor
modes of action are required. It is therefore critical to elucidate superior metabolic
processes responsible for enhanced tolerance to chemical inhibition. One of the most
frequently described consequence(s) of chemical inhibition is characterized by
membrane damage or reorganization (7). For example, realizing that alcohols primarily
inhibit cell growth by membrane leakage allowed engineering more-robust Escherichia
coli strains by overexpressing a heterologous cis-trans isomerase to help incorporate
trans unsaturated fatty acids into the membrane and restore (i.e., decrease) membrane
fluidity (8). Additionally, pinpointing membrane damage as the major toxic mechanism of
common bioproducts enabled rational engineering of phospholipid composition to
enhance robustness to membrane damaging chemicals (i.e., fatty acids, furfural and
acetate) (9).

These studies highlight the importance of elucidating key metabolic

processes responsible for enhanced tolerance of chemical inhibition to aide rational
design of robust phenotypes.
In contrast to rational engineering, the most successful methods to improve
complex phenotypes employ selection-based approaches such as metabolic evolution
(7). In these cases, a strain is challenged by — and optimized isolates are selected
2

directly from — the inhibiting environment until the desired phenotype is achieved or the
strain’s performance plateaus.

Once the desired phenotype has been successfully

evolutionary-engineered, the strain can either be used as the host organism for
bioproduction or the desired property is transferred to a different production host. The
fundamental requirement of reverse engineering is genetic tractability, that is, the
genotype(s) must be linked to the robust phenotype.

Consequently, successful

identification of the genetic basis for selection-based phenotypes (i.e., nontargeted strain
improvement) has rarely been accomplished, preventing reverse engineering of the
desired phenotype (10).
As forementioned, microbial robustness is often a complex phenotype controlled
by multifaceted genotypes that are either intractable or unknown. A logical approach
toward engineering robustness is to obtain or generate a strain with enhanced phenotypic
performance by which to study superior metabolic and genotypic tolerance mechanisms.
To enhance a complex phenotype with minimal genotypic information, three methods are
commonly employed: random mutagenesis, site-directed evolution and adaptive
laboratory evolution (ALE). While site-directed evolution requires an enzymatic target
(11) and genome-wide random mutagenesis can result in unsuccessful, non-beneficial or
lethal mutations (12), ALE exploits genome-wide natural selection to generate tactical
mutations that benefit phenotypic performance without prior knowledge of genetic targets
(13). Perhaps the most advantageous aspect of ALE is the requirement of a challenging
environment which renders ALE perfect for enhancing robustness to chemical inhibitors.
While ALE methodology is not in itself a novel methodology, ALE can be significantly
optimized when performed on a microorganism that natively exhibits elevated phenotypic
performance (i.e., non-model organisms) to generate an exceptionally novel phenotype.
After an enhanced strain is obtained or generated, mechanisms of robustness are
identified using comparative OMICs.

Specifically, DNA-sequencing for genotype

variances, RNA-sequencing for differentially expressed or co-expressed genes,
proteomics for differentially abundant proteins, metabolomics for affected pathways, and
lipidomics for changes in lipid composition. Together, comparative OMICs provides a
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global overview of cellular changes but rarely provides clear genetic candidates for
reverse engineering or interpretable mechanisms underlying robustness.
Nonetheless, a common approach for reverse engineering complex phenotypes
starts by analyzing transcriptomes or proteomes to identify candidate genes/proteins
conferring the desired phenotype (14-16). Traditionally, samples are generated from case
(e.g., strain grown in stressful environment) and control (e.g., strain grown without
stressful environment) and transcripts are analyzed to identify differentially expressed
genes (17). While most transcriptomics studies involve only static samples (i.e., single
time point), dynamic (i.e., multiple time points) transcriptomics data is more meaningful
since most biological processes are also dynamic (18). To date, dynamic transcriptomic
studies are expensive (e.g., numerous time points, replicates and conditions),
computationally challenging and generate multi-facetted results that are difficult to
interpret and understand (19). Additionally, the results of transcriptomics studies will
produce a long list (e.g., potentially hundreds) of candidate genes that are not
experimentally feasible. Additionally, since validation of candidate genes rely on the
deletion or over-expression of individual genes, logical reduction of this candidate gene
pool is critical to overcome experimental limitations (e.g., vector construction,
transformation efficiencies, screening capacity) (20). Therefore, novel tools to produce a
shortened, feasible list of genetic targets would facilitate an experimentally feasible
reverse-engineering experience.
Outline of Dissertation
Presented in this dissertation are my efforts to understand critical processes and genes
underlying robust phenotypes in the oleaginous yeast Yarrowia lipolytica for reverse
engineering. All chapters begin by obtaining or engineering a strain demonstrating the
desired robust phenotype which is used for comparative OMICs to enable elucidation of
mechanisms and processes underlying robustness and/or genotypes for reverse
engineering.
Chapter 1 This chapter describes how sterols are critical for IL-tolerance in Y.
lipolytica. Using adaptive laboratory evolution, we generated a superior IL-tolerant strain.
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By comparing this strain with wildtype Y. lipolytica, we elucidated sterols as a robust
mechanism underlying IL-tolerance and successfully reverse engineered this robust
phenotype by increasing sterol biosynthesis via overexpression of the sterol transcription
factor.
Chapter 2 This chapter describes the elimination of thiamine auxotrophy in Y.
lipolytica.

Using comparative genomics with thiamine prototroph S. cerevisiae we

identified the missing gene for thiamine synthesis. By discovering a novel thiamineresponsive promoter, we were able to control the expression of this missing gene to
engineer the first thiamine prototrophic Y. lipolytica strain reported to date.
Chapter 3 This chapter describes a new methodology to predict genetic targets
for reverse engineering complex phenotypes from temporal RNA-sequencing data. We
demonstrated that genetic targets chosen by co-expression connectivity predicted the
most IL-tolerant genes in comparison to traditional differential expression approaches.
We used these genetic targets to universally reverse engineer high IL-tolerance in 3 Y.
lipolytica isolates.
Chapter 4 This chapter describes key processes affecting xylose metabolism and
controlling lipid accumulation or degradation in Y. lipolytica.

By investigating the

genotypic and phenotypic diversity of non-conventional Y. lipolytica isolates, we revealed
metabolic processes and regulatory proteins correlated with superior xylose utilization
and lipid accumulation or degradation from biomass hydrolysate.
Chapter 5 This chapter describes upcycling of plastic waste into higher-value
chemicals using Y. lipolytica. Using short-term adaptation on catalytically depolymerized
plastic waste as the sole carbon source, we demonstrated improved hydrophobic
substrate utilization and bioconversion of plastic waste into citric acid and lipids.
Additionally, we highlighted unforeseen technical bottlenecks including depolymerized
plastic stability and unknown aspects of hydrophobic substrate metabolism.
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Abstract
Green organic solvents such as ionic liquids (ILs) have versatile use but are inhibitory to
microbes even at low concentrations of 0.5−1.0% (v/v) ILs. We discovered the oleaginous
yeast Yarrowia lipolytica can grow in 10% (v/v) of 1-ethyl-3-methylimidazolium acetate
([EMIM][OAc]), which makes it more tolerant than any engineered microorganisms and
naturally screened isolates. However, the underlying mechanism of IL tolerance in Y.
lipolytica is not understood. Through adaptive laboratory evolution, in combination with
physiological characterization and omics analysis, we shed light on the underlying
mechanism of how Y. lipolytica restructures its membrane to tolerate different types of
ILs at high levels up to 18% ILs. Specifically, we discovered that sterols play a key role
for exceptional IL tolerance in Y. lipolytica.

Introduction
Robustness is an important beneficial phenotype for any organism to acquire for improved
health or efficient biosynthesis of desirable molecules.1,2 Recently, microbial biocatalysis
in green organic solvents such as ionic liquids (ILs) has become attractive to produce
high-value chemicals, biofuels, and bioproducts.3-5 One key advantage is that ILs can
effectively process complex and recalcitrant substrates such as lignocellulosic biomass
for microbial fermentation.6-8 Furthermore, these ILs can function as extractants for in situ
separation of desirable molecules.9,10 It is thus highly desirable to harness novel microbes
for biocatalysis in organic solvents. However, ILs are inhibitory to microbes even at low
IL concentrations of 0.5−1.0 % (v/v).11,12 These solvents are inhibitory because they
severely disrupt cell membranes and intracellular processes.13-15
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Yarrowia lipolytica is a GRAS (generally-regarded-as-safe) oleaginous yeast of the
phylum Ascomycota with established use in fundamental study of biological processes
and in the biotechnology industry for production of biochemicals, biofuels, and
enzymes.16-18 Recently, Y. lipolytica has emerged as a potential bioenergy microbe for
conversion of lignocellulosic biomass to biofuels because it is capable of accumulating high
levels of neutral lipids
pH 2−11 range

22

19-21

and functioning in harsh fermentation conditions such as wide

and inhibitory biomass hydrolysates

23.

Remarkably, wildtype Y.

lipolytica exhibited robust growth in media containing 10% (v/v) [EMIM][OAc] while
producing 92% maximum theoretical yield of alpha-ketoglutarate from IL-pretreated
cellulose.3 This endogenous IL-tolerant phenotype of Y. lipolytica surpassed most
engineered organisms

24-27

and naturally screened isolates.28,29 Currently, mechanisms

of IL toxicity and superior tolerance in Y. lipolytica are not fully understood.
In this study, we aimed to illuminate the underlying processes of how Y. lipolytica
exhibits robust growth in high (18% v/v) concentrations of ILs. By using the adaptive
laboratory evolution in combination with physiological characterization and omics
analysis, we elucidated how Y. lipolytica restructures its membrane to resist IL disruption
and modulates sterol levels to improve IL tolerance. By disrupting and overexpressing the
sterol biosynthesis pathway, we further validated that sterols play a key role for
exceptional IL tolerance in Y. lipolytica.

Results
Generate robust Y. lipolytica mutants via adaptive laboratory evolution as a basis
for elucidating IL-tolerant mechanism
Y. lipolytica has a novel endogenous metabolism conferring exceptional IL
tolerance. Since wildtype Y. lipolytica can grow in at least 10% (v/v) [EMIM][OAc],3 we
hypothesized that it has a novel endogenous metabolism conferring notable IL
robustness. To test this, we performed adaptive laboratory evolution (ALE) to generate
Y. lipolytica mutants with enhanced tolerance to high concentrations of the benchmark IL,
[EMIM][OAc] (Figure 1-1, Step1). First, wildtype Y. lipolytica was grown in a medium
11

containing 5% (v/v) [EMIM][OAc] and transferred into a medium containing progressively
increased concentrations of [EMIM][OAc], 8% and 10% (v/v). Remarkably, Y. lipolytica
was able to grow in 5%, 8%, and 10% (v/v) [EMIM][OAc] with specific growth rates of
0.063 ± 0.005 1/h, 0.056 ± 0.033 1/h and 0.060 ± 0.004 1/h, respectively, without any
significant growth inhibition (Figure 1-2A). When Y. lipolytica was transferred into a
medium containing 12% (v/v) [EMIM][OAc], it initially exhibited growth inhibition with
significantly reduced specific growth rate of 0.034 ± 0.001 1/h. However, after 16
generations in 12% (v/v) [EMIM][OAc], the specific growth rate was improved up to 0.080
± 0.006 1/h and maintained for another 22 generations. Next, we increased the
concentration of [EMIM][OAc] to 15% (v/v) and continued ALE. The first transfer from 12%
(v/v) to 15% (v/v) reduced the specific growth rate by ~62% but cells recovered within 5
generations (0.078 ± 0.014 1/h) and the growth was maintained for an additional 23
generations. We further increased the concentration of [EMIM][OAc] to 18% (v/v) and
continued serial transfers for another 106 generations. At the end of ALE (200
generations), we isolated the top performing Y. lipolytica mutant, YlCW001, growing in up
to 18% (v/v) [EMIM][OAc] with a specific growth rate of 0.055 ± 0.006 1/h (Figure 1-1,
Step 2).
Exceptional IL-tolerant phenotype of the evolved mutant YlCW001 is stable.
To use YlCW001 for downstream characterization, we subjected it to irreversibility and
stability tests (Figure 1-1, Step 3). For irreversibility testing, three biological replicates of
wildtype and YlCW001 strains were grown in medium containing 8% (v/v) [EMIM][OAc]
to lessen abrupt osmotic shock driven by IL. Mid-exponentially growing cells were then
transferred into the medium containing glucose and 18% (v/v) [EMIM][OAc], and the cell
growth was investigated. While growth of wildtype Y. lipolytica was completely inhibited,
YlCW001 was able to grow with a specific growth rate of 0.059 ± 0.001 1/h (Figure 1-2B),
comparable to that measured from ALE in 18% (v/v) [EMIM][OAc]. These results
confirmed that the improved IL-tolerance for YlCW001 is irreversible.
Further, we investigated stability of YlCW001 by reviving the frozen glycerol stock
in the liquid medium containing glucose and [EMIM][OAc] (Figure 1-1, Step 3). Like the
irreversibility test, we evaluated cell growth of three biological replicates of YlCW001 in
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18% (v/v) [EMIM][OAc] using glucose as a carbon source. The measured specific growth
rate was similar to that from ALE and the irreversibility test (data not shown), proving that
YlCW001 is a stable strain.
YlCW001 exhibits broad tolerance to a wide range of hydrophilic ILs. To test
whether the IL-evolved strain YlCW001 exhibits broad IL-tolerant phenotypes, we
investigated

the

([EMIM][OAc]),

hydrophilic

ILs:

1-ethyl-3-methylimidazolium

methylimidazolium
([AMIM][Cl]),

following

bromide

([EMIM][Br]),

1-butyl-3-methylimidazolium

1-ethyl-3-methylimidazolium
chloride

([EMIM][Cl]),

1-allyl-3-methylimidazolium
acetate

([BMIM][OAc]),

acetate
1-ethyl-3chloride
1-butyl-3-

methylimidazolium chloride ([BMIM][Cl])), and 1-butyl-3-methylimidazolium bromide
([BMIM][Br]). We selected these ILs for testing because they can effectively solubilize
various types of recalcitrant lignocellulosic biomass and are known to be very inhibitory
to microbial growth.30 Since wildtype growth was inhibited in 10% (v/v) and completely
inhibited in 18% (v/v) [EMIM][OAc] (Figure 1-2C), we characterized these strains in two
different concentrations of ILs, 0.6 M and 1.09 M (equivalent to 10% and 18% (v/v) of
[EMIM][OAc], respectively).
Growth characterization in 0.6 M ILs shows that YlCW001 outperformed wildtype
Y. lipolytica for all ILs except [EMIM][Cl], for which similar specific growth rates were
observed (Figure 1-2D). Remarkably, YlCW001 growth was not affected by all tested ILs
regardless of imidazolium alkyl chain length and conjoined anion, excluding [BMIM][OAc],
which at 0.6 M was lethal to both wildtype and YlCW001 (Figure 1-2D). In 1.09 M ILs,
wildtype Y. lipolytica exhibited substantial growth inhibition in [EMIM][Cl] and [EMIM][Br]
and no growth in [AMIM][Cl], [BMIM][Cl], [EMIM][OAc], [BMIM][Br], and [BMIM][OAc]
(Figure 1-2E). Strikingly, the evolved strain YlCW001 displayed robustness in all ILs
except [BMIM][OAc] confirming broad tolerance to ILs (Figure 1-2E).
Inhibition of YlCW001 growth was detected in the following order: [BMIM][OAc] ≫
[BMIM][Br] ≈ [BMIM][Cl] ≈ [EMIM][OAc] > [AMIM][Cl] > [EMIM][Br] ≈ [EMIM][Cl]. While
0.6 M [BMIM][OAc] entirely inactivated growth of both wildtype and YlCW001, the mutant
tolerated 0.3 M [BMIM][OAc] with a specific growth rate of 0.07 ± 0.02 1/h which remained
lethal to wildtype (Figure 1-7).
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Our result demonstrated that Y. lipolytica possesses novel endogenous
metabolism conferring high IL tolerance by generating a novel, exceptionally robust Y.
lipolytica mutant via ALE. The evolved strain YlCW001 is stable and exhibits broad
tolerance towards the hydrophilic ILs in this study. The ability of YlCW001 to exhibit robust
growth in up to 18% IL makes it the most IL-tolerant microorganism reported to date. This
result provides a strong basis for elucidating the underlying mechanism of solvent toxicity
and tolerance in Y. lipolytica.
Elucidate IL-responsive physiology and metabolism in Y. lipolytica strains
Cell membrane and morphology of the evolved mutant resist IL interference.
Since ILs are known to disrupt the cell membrane,31 we hypothesize that the mutant
YlCW001 might have adapted its membrane structure to cope with inhibitory ILs. To test
this hypothesis, we used scanning electron microscopy (SEM) to examine cell
membranes and morphologies of both the wildtype and mutant responsive to 0% and
18% (v/v) [EMIM][OAc], 0.3M [BMIM][OAc], and 0.6M [BMIM][OAc].
As a positive control, we observed healthy morphologies for both the wildtype and
mutant in non-IL media (Figure 1-3A, 1-3B). However, when exposed to 18% (v/v)
[EMIM][OAc], the wildtype developed cavities, dents, and wrinkles along the cell surface,
clearly demonstrating that cell membrane and/or cell wall components were severely
damaged by the IL (Figure 1-3C). This phenotype is consistent with the complete growth
inhibition of the wildtype observed at this high IL concentration (Figure 1-2B, 1-2C). In
contrast, the evolved strain YlCW001 displayed barely any signs of membrane damage
in 18% (v/v) [EMIM][OAc] (Figure 1-3D).
Likewise, when being exposed to a more toxic IL, [BMIM][OAc], the wildtype
exhibited significant morphology deconstruction in both 0.3M and 0.6M [BMIM][OAc]
(Figure 1-3E, 1-3G). Strikingly, YlCW001 displayed no significant morphological defects
(Figure 1-3F, 1-3H) although growth was marginally inhibited in 0.3M and lethal in 0.6M
[BMIM][OAc] (Figure 1-7 and Figure 1-2D).

Additionally, the consequences of IL-

membrane damage are not likely caused by cell death because we observed similar
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morphological defects for the wildtype strain even in 8% (v/v) [EMIM][OAc] (sub-lethal
concentration) after only 6 h of incubation (Figure 1-8).
Intracellular metabolism of Y. lipolytica was perturbed in presence of ILs. To
demonstrate that intracellular metabolism of Y. lipolytica is also perturbed in IL, we
performed untargeted metabolomics and lipidomics for both the wildtype and YlCW001
growing in media containing 0% and 8% (v/v) [EMIM][OAc]. Our results identified a total
of 37 and 40 significantly perturbed pathways in wildtype and YlCW001, respectively,
growing in 8% (v/v) [EMIM][OAc] as compared to the wildtype growing in no IL (Figure 13I and Table 1-S1). Among these pathways, 29 were found perturbed in both wildtype
and

YlCW001.

These

pathways

are

mostly

comprised

of

amino

acid

synthesis/degradation, nucleosides and nucleotides synthesis/degradation, but also
contain vitamin synthesis (coenzyme A, thiamine, folate, and biotin biosynthesis etc.),
carbohydrate biosynthesis/degradation (GDP-mannose biosynthesis, gluconeogenesis,
galactose degradation, etc.), respiration (TCA cycle, glyoxylate cycle, etc.), sterols
biosynthesis, and some of the central metabolic pathways responsible for generating
precursor metabolites and energy (glycolysis, pentose phosphate pathway, etc.)
Furthermore, we found that YlCW001 had a total of 19 perturbed metabolic
processes in media without IL in comparison to the wildtype without IL (Figure 1-3I and
Table 1-S1). Notably, 15 of these pathways were also perturbed in YlCW001 and wildtype
growing in 8% (v/v) [EMIM][OAc] mostly enriched for amino acid biosynthesis/degradation
but also included sterol biosynthesis. Overall, we identified significant perturbation of
intracellular metabolism for both strains subjected to IL. While the bulk of these pathways
are enriched for central carbon metabolism, our untargeted metabolomics and lipidomics
identified sterols biosynthesis as the only lipid pathway significantly perturbed among all
three biological conditions (wildtype 8%, YlCW001 8%, YlCW001 0%) in comparison to
the wildtype without IL (Figure 1-3I).
Remodeling of cell membrane enhanced IL-tolerance in Y. lipolytica. The
outer-surface of the eukaryotic yeast is a multifaceted, permeable barrier composed of a
plasma membrane (i.e., glycerophospholipids, sterols, sphingolipids) and cell wall (i.e.,
chitin, glucan, mannoproteins) that together allow the cell to adapt to a variety of
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environmental conditions to maintain cellular homeostasis.32-35 Based on SEM images,
untargeted

metabolomics,

and

potential

mechanisms

of

IL-toxicity,13,36-39

we

hypothesized that remodeling of cellular membrane and/or cell wall is one key IL stressresponsive process in Y. lipolytica. We aimed to identify critical membrane and cell wall
components conferring exceptional IL-tolerance of both wildtype and YlCW001 strains by
investigating IL-responsive glycerophospholipid, fatty acid, sterol, and chitin metabolism
in the benchmark IL, [EMIM][OAc].
Y. lipolytica reduced chitin in the presence of ILs. Chitin is one of the most
insoluble biopolymers, even for ILs.36,40 In S. cerevisiae, it has been reported that
metabolism of chitin, a cell wall component known to influence membrane rigidity and
elasticity, is increased upon cell wall integrity stresses.41 Since Y. lipolytica contains a
relatively high content of chitin relative to other yeasts (e.g., ~10-15% in Y. lipolytica; ~13% in S. cerevisiae36), we investigated how its membrane chitin is responsive to IL
exposure. Counter-intuitively, we observed a ~2-fold reduction in chitin content for both
strains upon IL-exposure (Figure 1-9). Of note, we were unable to detect any statistically
significant differences in chitin levels between the wildtype and YlCW001 strains as they
behaved similarly in 0% and 8% [EMIM][OAc]. While chitin may contribute to native Y.
lipolytica IL-robustness, our results suggest chitin is not responsible for the enhanced ILtolerance of YlCW001.
Y. lipolytica modulated glycerophospholipid composition in response to ILs.
Upon IL exposure, the backbone and headgroups of the glycerophospholipids are
expected to interact with both cations and anions of ILs. To understand IL toxicity and
tolerance, we next investigated IL-responsive glycerophospholipid metabolism by
performing targeted lipidomics on individual headgroup species (i.e., phosphatidylcholine,
PC; phosphatidylinositol, PI; phosphatidic acid, PA; phosphatidyl glycerol, PG;
phosphatidylserine, PS; phosphatidylethanolamine, PE; and cardiolipins, CL) for both
strains in 0% and 8% (v/v) [EMIM][OAc]. In non-IL media, we found that YlCW001
contained a larger amount of each glycerophospholipid species than the wildtype (Figure
1-4 A-G). In 8% (v/v) [EMIM][OAc], most components of glycerophospholipids, including
PC, PA, PG, and CL, were upregulated in both strains, except that PI, PE and PS
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exhibited different trends. The PE content of both strains in IL significantly decreased
(relative to wildtype 0%) whereas PS levels remained unchanged (Figure 1-4E, 1-4F).
Additionally, the PI content was only statistically increased by YlCW001 subjected to IL
(Figure 1-4B).

In non-IL media, YlCW001 significantly increased both PS and PE

quantities (Figure 1-4E, 1-4F). Taken altogether, we found IL-responsive, upregulated
glycerophospholipid production of all headgroup species except PS and PE.
Interestingly, we also observed greater basal glycerophospholipid content in YlCW001
over the wildtype in 0% IL. These findings of membrane restructuring likely contribute to
IL-toxicity resistance in Y. lipolytica.
ILs modulated the fatty acid composition of Y. lipolytica. Since fatty acids can
modulate membrane fluidity,42 we next analyzed the effect of ILs on the fatty acid profiles
of wildtype and YlCW001 strains. The most striking differences were observed for C16:1
and C18:1 fatty acid moieties (Figure 1-4H). We found that both strains exposed to IL
induced production of C16:1 (7 mol%, p < 0.01) fatty acids unlike the wildtype strain
without IL, which produced none. In contrast, the wildtype without IL contained mostly
C18:1 fatty acids (49 mol%) while all other biological conditions shifted to the diunsaturated C18:2 moiety (29-36 mol%, p < 0.02). Interestingly, YlCW001 in media
without IL behaved similarly to IL-exposed strains, with significant increases in C16 and
C18:2 production. We did not observe a statistically significant difference between total
saturated and unsaturated fatty acid moieties in both conditions. Taken together, ILexposed cells (and YlCW001 0%) produced C16:1 fatty acids (non-existent in wildtype
0%) with statistically significant larger ratios of C16:C18 and (C18:2):(C18:1) moieties in
comparison to the wildtype without IL (Figure 1-10). Shorter chain lengths with higher
degrees of unsaturation in fatty acid moieties of the cell membrane are likely expected to
increase membrane fluidity

35.

These results indicate that fatty acid metabolism is IL-

modulated in Y. lipolytica and altered in YlCW001, even without IL.
YlCW001 increased sterols in the presence of ILs. We next investigated the
functional role of sterols for IL tolerance in Y. lipolytica because i) the sterol biosynthesis
pathway was perturbed in untargeted omics analysis, ii) sterols (e.g., cholesterol) can
impede cation-insertion into the membrane,37 and iii) sterols greatly influence membrane
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fluidity.43,44 In IL, we observed ~2 fold increase (p = 0.013) in ergosterol content of
YlCW001 over the wildtype strain (Figure 1-5D). Counter-intuitively, we found the largest
ergosterol concentrations in both strains without IL. We were unable to identify any other
sterol pathway intermediates (e.g., squalene, lanosterol, etc.), in agreement with literature
concluding ergosterol as the dominant sterol in yeast.45 These results imply that IL affects
sterol biosynthesis, and unlike the wildtype, YlCW001 adapted by enhancing membrane
sterols in response to IL exposure.
Sterol biosynthesis is one key IL-responsive process to improve IL-tolerance in Y.
lipolytica
We hypothesized that ergosterol content is a critical component of the membrane
contributing to the enhanced IL-tolerance of YlCW001 since we observed a greater
ergosterol content in YlCW001 than the wildtype upon exposure to IL (Figure 1-5D). To
validate the key role of sterols, we investigated genetic and enzymatic details of how Y.
lipolytica modulates the sterol biosynthesis pathway in response to IL.
YlCW001 highly upregulated the gene expression of the sterol biosynthesis
pathway in the presence of ILs. We first aimed to analyze the mRNA expression levels
of the sterol biosynthesis genes from the mid-exponentially growing wildtype and
YlCW001 cells cultured in 0% and 8% [EMIM][OAc] (Figure 1-5A). Since the sterol
transcription factors Upc and Ecm22 are known to play a key role in regulating the sterol
biosynthesis in yeast (e.g., S. cerevisiae

46-48),

we also analyzed the transcriptional

response of a functionally conserved homolog (SterTF, YALI0B15818g) of Y. lipolytica
when cells were exposed to ILs. We found that 11 of the 14 sterol pathway genes were
upregulated > 2-fold in IL-exposed YlCW001 as compared to the wildtype in 0% IL (Figure
1-5B). Significantly, seven of these genes, including Ster5 (YALI0B23298g), Ster6
(YALI0F11297g),

Ster8

(YALI0B17204g),

Ster11

(YALI0B17644g),
(YALI0D20878g)

Ster10-1
and

(YALI0E32065g),

SterTF

Ster10-2

(YALI0B15818g)

were

upregulated > 4-fold in IL-exposed YlCW001 over the wildtype in 0% IL. As for the
wildtype in 8% IL, we found only 1 of the 14 sterol pathway genes, Ster10-2
(YALI0B17204g), significantly upregulated against the wildtype without IL. Without IL, the
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sterol genes in YlCW001 were relatively constant or marginally downregulated in
comparison to the wildtype.
Enzymatic inhibition of the sterol biosynthesis pathway reduced IL-tolerance
of Y. lipolytica. To confirm the contribution of sterols in IL-tolerance at the enzymatic
level, we next treated the wildtype and YlCW001 strains with fluconazole, a commonly
used anti-fungal drug that inhibits cytochrome P450 enzyme 14α-demethylase (Ster4,
Figure 1-5A) critical for sterol biosynthesis.49 We characterized growth of the wildtype and
YlCW001 in media containing either 0% or 8% (v/v) [EMIM][OAc] with incremental
concentrations of fluconazole (Figure 1-5C). We expected fluconazole to inhibit sterol
biosynthesis and hence decrease IL-tolerance, specifically to a greater extent in the
wildtype than in YlCW001. In media containing no IL, we found that fluconazole inhibited
growth for both the wildtype and YlCW001 (IC50 = 25 g/mL), (Figure 1-5C). The inhibition
of fluconazole became more prominent in the presence of 8% (v/v) [EMIM][OAc].
Remarkably, YlCW001 could tolerate up to 25 µg/mL fluconazole while this concentration
completely inhibited growth of the wildtype strain (Figure 1-5C).
Overexpression of the sterol pathway validated high solvent tolerance in the
parent Y. lipolytica strain. To evaluate whether increasing expression of the sterol
biosynthesis pathway could reverse engineer high solvent tolerance in the parent Y.
lipolytica strain, we individually overexpressed the 14 annotated sterol biosynthesis and
endogenous sterol transcription factor genes. We screened the individual, steroloverexpressing constructs on plates containing incremental concentrations of
[EMIM][OAc] (Figure 1-5E). We observed that some of the sterol genes showed marginal
improvement (i.e., Ster3, Ster4, Ster6 and Ster12) for IL tolerance. Remarkably,
overexpression of SterTF dramatically enhanced IL tolerance because it simultaneously
activated upregulation of multiple genes governing the sterol biosynthesis to augment
ergosterol production in IL (Figure 1-11).

Taken altogether, the disruption and

overexpression of the sterol biosynthesis pathway validated that sterols are critical
membrane components responsible for exceptional IL-tolerance in Y. lipolytica.
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Discussion
Microbial biocatalysis in ILs is novel for biosynthesis of fuels and chemicals. For instance,
the imidazolium-based ILs (e.g., [EMIM][OAc]) are effective for reducing lignocellulosic
biomass recalcitrance

50

to be used for downstream fermentation but greatly inhibit

microbial growth even at low concentrations.36,51

This incompatibility presents a

significant barrier for novel microbial biocatalysis in ILs. While mechanisms of IL-toxicity
have been proposed,14,25,27 and IL tolerance has been mediated in part by multidrug efflux
pumps,25,26,52 the complete picture is unclear of how cells resist ILs and whether these
cells can adapt to achieve IL-tolerance for industrial compatibility. To illuminate the
mechanisms of IL toxicity and enhanced tolerance (Figure 1-6), we characterized
naturally IL-tolerant Y. lipolytica and its superior evolved mutant, YlCW001, generated by
ALE (Figure 1-2A). As compared to both naturally screened isolates and engineered
strains reported to date, YlCW001 is the most IL-tolerant microorganism capable of
growing in a variety of ILs at high levels up to 18% IL.
Imidazolium-based ILs inhibit the cell by inserting their alkyl chains into the
hydrophobic core of the plasma membrane (Figure 1-6B, 1-6E, 1-6C, and 1-6F).31,37 ILs
with longer alkyl chains become more lipophilic

13,53

and cause greater disruption of the

membrane as supported by growth rates in various ILs ([BMIM] ≫ [AMIM] ~ [EMIM])
(Figure 1-2D, 1-2E). The conjoint anion likely re-associates with the cation imbedded into
the membrane causing greater membrane disturbance.37 The tendency of an anion to
interact with the cation intensifies with increasing basicity, which increases IL toxicity as
demonstrated by reduced growth rates in various ILs ([OAc] ≫ [Br] ~ [Cl]) (Figure 1-2D,
1-2E).
Consequences of IL membrane disruption increase membrane fluidity (e.g., ionic
surfactant)

15,38

and impose lateral pressure on the membrane

39,54

as evidenced by

cavities, dents, and wrinkles in SEM images (Figure 1-3C, 1-3E, 1-3G) and dramatic
remodeling of lipids in Y. lipolytica (Figure 1-4). In addition, harmful interactions between
the IL and membrane result in a cascade of detrimental effects on cellular processes
including DNA damage, enzyme inactivation, and protein degradation,50,55-57 as observed
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by reduced sterol and chitin contents (Figure 1-5D and Figure 1-9) and perturbation of
intracellular metabolism (Figure 1-3I) of IL-exposed wildtype and YlCW001 strains.
Wildtype and YlCW001 strains combatted IL toxicity in part by rewiring membrane
compositions to reduce membrane permeability and bilayer buckling pressure (imposed
by ILs).58,59 Both strains overproduced all glycerophospholipid species except PS and
significantly reduced PE (Figure 1-4F), which is vulnerable to lateral pressure.60,61 In
contrast to the wildtype, YlCW001 is more robust because it adapts to produce more
sterols, e.g., ergosterol upon IL-exposure (Figure 1-5D), that function to maintain
membrane fluidity and stability.43 This novel phenotype is evidenced by a significant
upregulation of sterol biosynthesis genes (Figure 1-5B), improved enzymatic-tolerance to
steroid-inhibiting drug, fluconazole49,62 (Figure 1-5C), and overexpression of the sterol
biosynthesis and transcriptional factor genes (Figure 1-5E). The result is also consistent
with molecular simulations demonstrating sterols impede IL cations from inserting into
artificial membranes.63-65 Interestingly, S. cerevisiae strains evolved in chemical (i.e.,
butanol) and physical (i.e., heat) stresses have shown increased ergosterol levels or
altered sterol compositions that likely function to maintain membrane homeostasis. 44,66
Taken altogether, ILs inhibit cell growth by fluidizing the membrane and inflicting
lateral pressures that destroy cellular homeostasis (Figure 1-6B, 1-6C). Our research
provides strong evidence of how intracellular processes of Y. lipolytica are rewired to
remodel cell membranes upon IL-exposure. Comprehensive metabolic, transcriptomic,
and enzymatic analyses provide strong evidence that sterols (i.e., ergosterol) are critical
membrane components conferring IL-tolerance in Y. lipolytica and enhanced ILrobustness in YlCW001, functioning to impede cation insertion and maintain membrane
homeostasis

64

(Figure 1-6E, 1-6F). This study provides a better understanding of IL

toxicity mechanism and superior tolerance of Y. lipolytica, which can be harnessed for
improvement of organism health and industrial biocatalysis in organic solvents.
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Methods
Strains and plasmids
Strains. Escherichia coli TOP10 strain was used for molecular cloning. Yarrowia
lipolytica (YlSR001, ATCC MYA-2613), a thiamine, leucine, and uracil auxotroph, was
used as the parent strain. The evolved strain YlCW001 was isolated after 200 generations
in gradually increased concentrations of [EMIM][OAc] up to 18% (v/v). By transforming
the constructed plasmids into YlSR001 via electroporation, 67 we created the Y. lipolytica
strains YlSR172-YlSR202 that overexpress the individual sterol biosynthesis (Ster1-13)
and transcription factor (SterTF) genes (Table 1-S4).
Plasmids. A set of 13 sterol biosynthesis genes and 1 sterol transcription factor
gene of Y. lipolytica are listed in Table 1-S2. The plasmid pSR008 containing a
constitutive Y. lipolytica TEF promoter (PTEF(406)), a CYC1 terminator (cyc1t) and an uracil
selection marker was used as the backbone plasmid.68 The plasmids pSR166, pSR170,
pSR171, and pSR172 carrying the genes Ster1, Ster5, Ster6, and Ster7, respectively
were constructed by Gibson assembly 69 of two DNA fragments: i) each of the sterol genes
amplified from Y. lipolytica genomic DNA using the primers listed in Table 1-S3 and ii) the
plasmid backbone amplified from pSR008 using the primers cyc1t_Fwd/pTEF_Rev. The
plasmids pSR167-169 and pSR173-179 were generated by inserting the genes Ster2Ster4 and Ster8-Ster13, respectively, into pSR008 through the AvrII and AscI digestion
and T4 DNA ligase treatment. Specifically, each sterol gene was amplified from Y.
lipolytica genomic DNA using the primers listed in Table 1-S3. The backbone pSR008
was amplified using the primers AvrII_cyc1t_Fwd/AscI_pTEF_Rev. Both the sterol genes
and pSR008 backbone were digested by AvrII and AscI at 37°C for 3 h, then ligated by
T4 DNA ligase at room temperature for 30 min. Likewise, to construct pSR180, SterTF
was

amplified

from

Y.

lipolytica

genomic

DNA

using

the

primers

SterTFYL_Fwd/SterTFYL_Rev and then ligated with pSR008 through the AvrII and AscI
restriction sites. The complete list of constructed plasmids and strains are presented in
Table 1-S4.
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Medium and culturing conditions
Growth medium. ALE, irreversibility testing, and broad IL tolerance studies were
conducted in defined media containing 6.7 g/L of yeast nitrogen base without amino acids
(cat# Y0626, Sigma-Aldrich, MO, USA), 10 g/L of glucose, 100 mg/L of ampicillin, 50 mg/L
of kanamycin, 30 mg/L of chloramphenicol, and various concentrations of ILs. Leucine
(cat# 172130250, Acros Organics, CA, USA) and uracil (cat# 157301000, Acros
Organics, CA, USA) were added to the media at concentrations of 190 mg/L and 20 mg/L,
respectively.
For all other growth studies, 380 mg/L of leucine and 76 mg/L uracil were used. All
ILs, including 1-ethyl-3-methylimidazolium acetate [EMIM][OAc] (>95 % purity), 1-ethyl3-methylimidazolium chloride [EMIM][Cl] (>98% purity), 1-ethyl-3-methylimidazolium
bromide [EMIM][Br] (99% purity), 1-allyl-3-methylimidazolium chloride [AMIM][Cl] (>98%
purity), 1-butyl-3-methylimidazolium acetate [BMIM][OAc] (>98% purity), 1-butyl-3methylimidazolium chloride [BMIM][Cl] (99% purity), and 1-butyl-3-methylimidazolium
bromide [BMIM][Br] (99% purity), were purchased from the Ionic Liquids Technologies
Inc. (IoLiTec, AL, USA). Medium pH was at 5.5 without IL and at 6-7 with ILs. Unless
specifically mentioned, all experiments were performed with biological triplicates.
Adaptive laboratory evolution. ALE experiment was performed by serial dilution
of Y. lipolytica in sequentially increasing concentrations of [EMIM][OAc] in 6-well plates
with 3 mL working volume using an incubating microplate shaker (cat# 02-217-757, Fisher
Scientific, PA, USA) at 28°C and 350 rpm with adhesive, breathable seals to prevent
cross contamination (cat# 50-550-304, Fisher Scientific, PA, USA). For each serial
dilution, the top performing triplicate was transferred during mid-exponential growth phase
into fresh medium at an initial optical density (OD) at 600 nm of 0.2.

Increasing

concentrations of [EMIM][OAc] were selected to achieve a specific growth rate ≥ 0.02 1/h.
The maximum specific growth rates of all three technical replicates were calculated for
each serial dilution using a minimum of three time points per replicate.

After 200

generations of ALE, the top performing replicate culture was spread onto a petri plate
containing defined medium with 10 g/L glucose and 20 g/L agar. The plate was incubated
at 28oC for 36-48 h. Single colonies were isolated and individually streaked onto fresh
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petri plates. This process was repeated once more to ensure isolation of purified colonies.
Purified colonies (from three iterations of plate dilutions) were individually tested in the
same growth conditions and [EMIM][OAc] concentration at which the evolved strain was
originally collected to determine irreversibility. Individual cultures (from purified colonies)
were collected and stored in glycerol at -80°C before streaking onto fresh petri plates,
repeating three plate isolations, and retesting the irreversibility of the purified colonies to
determine stability of YlCW001.
Plate screening for enhanced IL tolerance.

To determine whether

overexpression of the sterol biosynthesis and transcription factor genes enhance ILtolerance, the strains YlSR001, YlCW001, and YlSR001 carrying Ster1-13 and SterTF
were grown in defined medium without uracil in 15-mL culture tubes until mid-exponential
growth phase. Cells were reconstituted in sterile water to achieve starting OD of 2 and
further diluted 10x and 100x. Two microliters of each dilution were spotted on fresh petri
dishes containing defined medium without uracil, 20 g/L agar and 0%, 4%, 8%, 10%, and
12% (v/v) [EMIM][OAc] and incubated at 28°C. Plates containing 0% and 4% (v/v)
[EMIM][OAc] were incubated for 48 h and plates containing 8%, 10% and 12% (v/v)
[EMIM][OAc] for 96 h. Plate screening was repeated three times for each construct.
Analytical methods
Metabolomics. Three biological replicates of the wildtype and YlCW001 were
grown in media containing 0% or 8% (v/v) [EMIM][OAc] and collected at the late
exponential growth phase for metabolomic analysis. Samples were immediately
quenched in liquid nitrogen and stored at -80°C prior to extraction. Metabolites were
extracted from a minimum of 1 x107 cells in 400µL of the extraction solvent by incubating
at

-20°C

for

20

min.70

The

extraction

solvent

consists

methanol:acetonitrile:water containing 0.1M formic acid.

of

40:40:20

(vol)

The soluble fraction was

separated by centrifugation at 13,700 x g, 4°C for 5 minutes. To ensure complete
extraction of cellular metabolites, we repeated extraction 3 times per sample. A total of
1.2 mL of solvent-soluble metabolite samples were subjected to drying under a stream of
nitrogen at 4°C overnight to evaporate solvent. Lyophilized metabolites were
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reconstituted in 300µL of sterile water and analyzed by liquid chromatography mass
spectrometer (LC-MS).
Metabolites were analyzed with an Exactive Plus orbitrap mass spectrometer
(Thermo Scientific, San Jose, CA) equipped with Synergi 2.5 m Hydro-RP 100 (100 x
2.00 mm, Phenomenex, Torrance, CA, USA) set to 25°C. The LC-MS method analyzed
in full scan negative ionization mode with an electrospray ionization source as previously
described.71
Lipidomics. Late exponentially growing wildtype and YlCW001 cells cultured in
0% and 8% (v/v) [EMIM][OAc] were used for lipidomic study. Samples were immediately
quenched in liquid nitrogen and stored at -80°C. After thawing on ice, samples were
centrifuged for 3 minutes at max speed, 4°C before removing supernatant. Next, cell
pellets were re-suspended in 800uL of 0.1N hydrochloric acid:methanol 1:1 (vol) with
400uL of chloroform and disrupted with glass beads using a mini bead beater for 5-minute
intervals until > 95% of cells were visually disrupted. Disrupted cells were vortexed and
centrifuged at 4°C for 5 minutes before extracting the organic phase into glass vials.
Finally, samples were dried under a stream of nitrogen overnight at 4°C and reconstituted
in 300uL of 9:1 (vol) methanol:chloroform before transferring into auto-sampler vials. Lipid
extracts were analyzed in positive and negative ionization modes with an Exactive Plus
orbitrap mass spectrometer (Thermo Fisher Scientific, San Jose, CA) equipped with an
electrospray ionization probe and a Kinetex HILIC column (150 mm x 2.1 mm, 2.5 µm)
(Phenomenex, Torrance, CA, USA) as previously described

72

except that lipid features

were verified with external standards instead of fragments.
Fatty acid quantification. Three biological replicates of wildtype and YlCW001 cells
were grown in 0% and 8% (v/v) [EMIM][OAc] until mid-late exponential phase and cell
pellets were stored at -20°C. The equivalent cell mass of 2 OD was washed once with
0.05 M sodium phosphate solution and incubated in 2:1 (v/v) chloroform:methanol
solution overnight at 4°C. 200 µL of chloroform was extracted and mild methanolysis was
performed as previously described.73

Briefly, 1.5 mL of methanol, 0.3 mL of 8%

methanolic HCL solution and 50 µL of 2 mg/mL pentadecanoic acid was added to ensure
complete transesterification and incubated overnight at 55°C. After cooling to room
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temperature, 1mL of hexane containing 0.005 mg/mL pentadecanoic acid ethyl ester as
internal standard and 1mL of water was added prior to extracting 250 µL of hexane for
GCMS detection of fatty acid methyl esters.
Sterol quantification. Three biological replicates of wildtype and YlCW001 cells
were grown in 0% and 8% (v/v) [EMIM][OAc] until mid-late exponential phase and cell
pellets were stored at -20°C. Sterol quantification was performed with the equivalent cell
mass of 5 OD as previously described 74 using a HP-5MS 30 m x 0.25 mm i.d. x 0.25 µm
column (Agilent Technologies, USA) for separation of sterols.
Chitin determination. The relative quantity of chitin was analyzed for the wildtype
and YlCW001 late-exponentially growing cells in medium containing 0%, 2%, 5%, 8%
and 10% (v/v) [EMIM][OAc].

Cell pellets were washed twice with water before

resuspending 1 OD of cell mass in 1 mL of water containing 50 µg/mL calcofluor white
(CFW) (cat #18909, Sigma-Aldrich), which binds specifically to chitin.75,76 Samples were
incubated at room temperature for 15 minutes at 650 rpms in a thermomixer (cat
#5382000023, Eppendorf). Next, stained cells were washed twice with water to remove
excess CFW prior to fluorescence (excitation: 360/40nm, emission: 460/40nm) and
absorbance (OD) measurements. Results were calculated by normalizing fluorescence
intensity by respective sample OD values.

Chitin determination experiments were

conducted at least twice for each biological condition in technical replicates per
experiment (wildtype 0%, n = 18; wildtype 2%, n = 6; wildtype 5%, n = 15; wildtype 8%, n
= 12; YlCW001 0%, n = 25; YlCW001 2%, n = 6; YlCW001 5%, n = 15; YlCW001 8%, n
= 29; YlCW001 10%, n = 6).
Scanning electron microscope (SEM). Wildtype and YlCW001 cells were
inoculated at 1 OD in 0%, and 18% [EMIM][OAc] and 0.3M and 0.6M [BMIM][OAc] in 6well microtiter plates using an incubating microplate shaker at 28°C and 350 rpm. After
24 hours, cells were collected, immediately washed once with water and incubated in 2%
glutaraldehyde containing 10 mM sodium phosphate buffer overnight at 4°C. Fixed
samples were washed 3 times with water before post-fixing in 2% osmium tetroxide for 1
hour at room temperature. The cell pellets were placed on silicon chips and dehydrated
with successive ethanol baths (50%, 60%, 70%, 80%, 90%, and 100%) for 15 minutes
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each. Finally, the dehydrated samples were dried using critical point drying in carbon
dioxide at 1100 psi and 32°C before SEM imaging with Zeiss Argula using SEM2 detector.
RNA-sequencing. To investigate the transcriptional responses of the sterol
biosynthesis and transcription factor genes to IL exposure in Y. lipolytica, three biological
replicates of YlSR001 and YlCW001 growing in 0% and 8% (v/v) [EMIM][OAc] media
were harvested at the mid-exponential growth phase, immediately quenched in liquid
nitrogen, and stored at -80°C for downstream processing. Total RNA was purified using
the Qiagen RNeasy mini kit (cat #74104, Qiagen, CA, USA) and submitted for Illumina
sequencing at the Joint Genome Institute (JGI).
Fluconazole treatment to investigate importance of sterol biosynthesis for
enhanced IL tolerance.

To investigate correlation of sterol biosynthesis with

enhancement of IL tolerance, we compared growth of the wildtype and YlCW001 in media
containing 0% or 8% (v/v) [EMIM][OAc] and various concentrations of fluconazole (cat#
TCF0677, VWR) which inhibits fungal cytochrome P450 enzyme 14α-demethylase
(Ster4, Figure 1-5A) required for sterol biosynthesis.49 First, we cultured the wildtype and
YlCW001 in media without IL until the mid-exponential phase. Then, cells were washed
by water and resuspended in the fresh media containing 0, 10, 25, 50, 100, and 250
µg/mL fluconazole. Finally, the same conditions were tested with addition of 8% (v/v)
[EMIM][OAc] to observe the requirement of sterol incorporation into the plasma
membrane for IL tolerance. Results were obtained by calculating maximum specific
growth rates for each biological condition. Sterol validation by fluconazole treatment
experiments were conducted twice for each biological condition with sacrificial, technical
replicates using 96-well microtiter plates and Duetz sandwich cover (cat # SMCR1296,
Kuhner) incubated at 28°C and 400 rpms.
Bioinformatics and data analysis
Untargeted LCMS analysis. Metabolomic and lipidomic raw files created by
Xcalibur were imported into XCMS online and analyzed in pairwise jobs against the
control data set, wildtype in 0% IL.77 XCMS resulting metabolic features were exported
and features with intensity fold changes < 2 were removed. These pairwise sets of
‘perturbed’ metabolic features were analyzed with metaboanalyst

78

using ‘MS peaks to
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pathways’ tool with significant feature P-value cutoff = 0.05. This tool uses mummichog
which algorithmically utilizes known metabolic pathways and networks to predict
metabolites and pathways without prior identification of metabolites. 79 The resulting
pathway files from ‘perturbed’ pairwise feature sets were exported and pathways with less
than two significant features (i.e., metabolite features with P-values < 0.05) were
removed.

Next, we filtered the pathways by defining a new parameter, pathway

significance factor (psf) (equation 1), to account for i) total number of metabolites in the
pathway (psize), ii) total identified metabolite features (pfeatures), and iii) total number of
significant metabolite features (psignificant) identified for each pathway.
1

psf = psf

max

×

pfeatures
psize

× p0.5
significant

(1)

In our analysis, we chose a psf cutoff value of 0.58 to illustrate the top 15% most
significantly perturbed pathways identified from our untargeted LCMS analysis.
Targeted LCMS analysis. Lipidomics raw data files created by Xcalibur were
converted to open source mzML format using the ProteoWizard software. 80 MAVEN
software (Princeton University) was applied to performed retention time correction for
each sample and used to manually select known lipids based on retention time and
mass.81,82 Glycerophospholipid headgroup species were analyzed individually and
extracted signal intensities were corrected by cell number that was determined by a
Guava flow cytometer (easyCyte 6HT 2L, EMD Millipore Corp., MA, USA) and a Guava
ViaCount kit (cat #4000-0041, EMD Millipore Corp., MA, USA). The corrected intensities
for each head group class were summed and normalized relative to wildtype in non-IL
media to visualize changes for each glycerophospholipid on a macro scale.
RNAseq analysis. Filtered RNA-sequencing reads were imported and analyzed
within

the

CLC

genomics

workbench

version

11.0.1

(https://www.qiagenbioinformatics.com/). To calculate the differential gene expression,
wildtype in 0% IL was used as a reference.
Identification of the putative sterol transcription factor (SterTF) in Y.
lipolytica. To identify sterol regulatory elements in Y. lipolytica, we first performed BlastP
using the well characterized sterol transcription factors (TFs), Upc2 and Ecm22 of
28

Saccharomyces cerevisiae

46

as the references. Upon identifying a closely related Y.

lipolytica endogenous homolog (SterTF, YALI0B15818g) with respect to Upc2 (Quary
cover 37%; E value 4x10-83; Identity 48%) and Ecm22 (Quary cover 43%; E value 1x1084;

Identity 48%), we further performed the transcription factor affinity prediction (TRAP)

83

for SterTF against the 1050 nucleotide sequences upstream of each steroid

biosynthesis gene to further validate the regulatory elements of SterTF in silico (Figure 112).
Statistics. Statistical analysis was performed with SigmaPlot v.14 software using
one-way analysis of variance (ANOVA) with Holm-Sidak correction or Student’s t-test
between biologically relevant conditions where noted.
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Appendix
Table 1- 1. Untargeted LCMS summary of perturbed pathways with pathway significance
factor > 0.58.
Pathway
size
(Psize)

Total
features
(Pfeatures)

Significant
features
(Psignificant)

Pathway
significance
factor (psf)

adenine and adenosine salvage IV

8

6

4

0.58

alanine biosynthesis

4

4

4

0.78

YlCW001 0%

alanine degradation III

4

4

4

0.78

YlCW001 0%

arginine biosynthesis
de novo biosynthesis of pyrimidine
ribonucleotides

26

17

10

0.80

23

15

7

0.67

21

13

6

0.59

YlCW001 0%

gluconeogenesis
homocysteine and cysteine
interconversion

11

8

5

0.63

YlCW001 0%

isoleucine biosynthesis

15

9

7

0.62

YlCW001 0%

leucine biosynthesis

16

9

8

0.62

YlCW001 0%

lysine biosynthesis

22

12

9

0.63

YlCW001 0%

phenylalanine biosynthesis

11

9

5

0.71

YlCW001 0%

12

9

6

0.71

13

10

5

0.67

YlCW001 0%

phenylalanine degradation
purine ribonucleosides degradation to
ribose-1-phosphate
superpathway of purine nucleotides de
novo biosynthesis

42

21

11

0.64

YlCW001 0%

tryptophan biosynthesis

17

12

7

0.72

YlCW001 0%

tyrosine biosynthesis

11

9

5

0.71

YlCW001 0%

tyrosine degradation

12

9

5

0.65

YlCW001 0%

uridine-5'-phosphate biosynthesis

20

13

6

0.62

YlCW001 0%

22

14

9

0.74

YlCW001 8%

sterol biosynthesis (zymosterol)
4-amino-2-methyl-5diphosphomethylpyrimidine
biosynthesis

11

8

5

0.63

YlCW001 8%

4-aminobenzoate biosynthesis

7

6

4

0.66

YlCW001 8%

alanine biosynthesis

4

4

3

0.67

YlCW001 8%

alanine degradation III

4

4

3

0.67

YlCW001 8%

arginine biosynthesis

26

19

7

0.75

YlCW001 8%

aspartate degradation II

8

7

3

0.59

YlCW001 8%

chitin degradation

15

9

7

0.62

YlCW001 8%

13

10

5

0.67

YlCW001 8%

coenzyme A biosynthesis
dTMP <i>de novo</i> biosynthesis
(mitochondrial)

11

8

5

0.63

YlCW001 8%

folate interconversions

22

14

7

0.65

YlCW001 8%

gluconeogenesis

21

16

8

0.84

YlCW001 8%

glycine biosynthesis from glyoxylate

4

4

3

0.67

YlCW001 8%

glycine biosynthesis from threonine

3

3

3

0.67

YlCW001 8%

glyoxylate cycle

13

10

8

0.84

YlCW001 8%

histidine biosynthesis
homocysteine and cysteine
interconversion

22

16

5

0.63

11

8

8

0.80

Biological
Condition

Perturbed
Pathway

YlCW001 0%
YlCW001 0%

YlCW001 0%
YlCW001 0%

YlCW001 0%

YlCW001 8%
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Table 1-1 continued
YlCW001 8%

isoleucine biosynthesis

15

11

9

0.85

YlCW001 8%

isoleucine degradation

10

8

4

0.62

YlCW001 8%

leucine biosynthesis

16

13

7

0.83

YlCW001 8%

leucine degradation

10

8

4

0.62

YlCW001 8%

lysine biosynthesis

22

16

8

0.80

YlCW001 8%

methionine biosynthesis

18

12

9

0.78

YlCW001 8%

methionine salvage pathway

15

9

7

0.62

YlCW001 8%

p-aminobenzoate biosynthesis

7

6

4

0.66

YlCW001 8%

phenylalanine biosynthesis

11

9

8

0.90

YlCW001 8%

phenylalanine degradation

12

11

7

0.94

YlCW001 8%

16

12

5

0.65

17

11

8

0.71

YlCW001 8%

phosphopantothenate biosynthesis I
salvage pathways of pyrimidine
deoxyribonucleotides
superpathway of purine nucleotides de
novo biosynthesis

42

26

9

0.72

YlCW001 8%

TCA cycle, aerobic respiration

23

15

10

0.80

YlCW001 8%

thiazole biosynthesis III (eukaryotes)

11

9

5

0.71

YlCW001 8%

threonine degradation

29

20

14

1.00

YlCW001 8%

17

13

6

0.73

13

9

5

0.60

YlCW001 8%

tryptophan biosynthesis
tryptophan degradation to 2-amino-3carboxymuconate semialdehyde
tryptophan degradation VIII (to
tryptophol)

12

11

5

0.79

YlCW001 8%

tyrosine biosynthesis

11

10

6

0.86

YlCW001 8%

12

11

5

0.79

YlCW001 8%

tyrosine degradation
UDP-N-acetylglucosamine
biosynthesis

12

9

5

0.65

YlCW001 8%

valine biosynthesis

12

8

6

0.63

YlCW001 8%

valine degradation

10

8

4

0.62

YlCW001 8%

22

13

8

0.65

wildtype 8%

sterol biosynthesis (zymosterol)
4-amino-2-methyl-5diphosphomethylpyrimidine
biosynthesis

11

7

6

0.60

wildtype 8%

4-aminobenzoate biosynthesis

7

6

5

0.74

wildtype 8%

alanine biosynthesis

4

4

4

0.78

wildtype 8%

alanine degradation III

4

4

4

0.78

wildtype 8%

arginine biosynthesis
arginine degradation I (arginase
pathway)

26

18

10

0.85

11

8

5

0.63

8

7

4

0.68

wildtype 8%

aspartate degradation II
galactose degradation I (Leloir
pathway)

11

8

5

0.63

wildtype 8%

GDP-mannose biosynthesis

8

6

5

0.65

wildtype 8%

gluconeogenesis

21

16

8

0.84

wildtype 8%

glycogen degradation

16

9

8

0.62

wildtype 8%

glycolysis III (glucokinase)

18

13

8

0.79

wildtype 8%

glyoxylate cycle

13

10

6

0.73

wildtype 8%

histidine biosynthesis
homocysteine and cysteine
interconversion

22

16

9

0.85

11

8

6

0.69

YlCW001 8%

YlCW001 8%

wildtype 8%
wildtype 8%

wildtype 8%
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Table 1-1 continued
wildtype 8%

inosine-5'-phosphate biosynthesis

16

10

6

0.59

wildtype 8%

isoleucine biosynthesis

15

10

9

0.78

wildtype 8%

isoleucine degradation

10

8

4

0.62

wildtype 8%

leucine biosynthesis

16

13

7

0.83

wildtype 8%

leucine degradation

10

8

4

0.62

wildtype 8%

lysine biosynthesis

22

15

9

0.79

wildtype 8%

7

6

5

0.74

wildtype 8%

p-aminobenzoate biosynthesis
pentose phosphate pathway (nonoxidative branch)

7

7

3

0.67

wildtype 8%

phenylalanine biosynthesis

11

9

8

0.90

wildtype 8%

12

11

7

0.94

13

9

5

0.60

17

11

8

0.71

wildtype 8%

phenylalanine degradation
purine ribonucleosides degradation to
ribose-1-phosphate
salvage pathways of pyrimidine
deoxyribonucleotides
superpathway of purine nucleotides de
novo biosynthesis
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25

12

0.80

wildtype 8%

TCA cycle, aerobic respiration

23

15

8

0.71

wildtype 8%

threonine degradation

29

19

10

0.80

wildtype 8%

17

11

7

0.66

13

8

6

0.58

wildtype 8%

tryptophan biosynthesis
tryptophan degradation to 2-amino-3carboxymuconate semialdehyde
tryptophan degradation VIII (to
tryptophol)

12

11

7

0.94

wildtype 8%

tyrosine biosynthesis

11

9

8

0.90

wildtype 8%

tyrosine degradation

12

11

7

0.94

wildtype 8%

valine degradation

10

8

5

0.69

wildtype 8%

sterol biosynthesis (zymosterol)

22

12

8

0.60

wildtype 8%
wildtype 8%

wildtype 8%

Table 1- 2. Locus tags of the sterol pathway genes and sterol transcription factor.
Genes
ster1
ster2
ster3
ster4
ster5
ster6
ster7
ster8
ster9
ster10-1
ster10-2
ster11
ster12
ster13
sterTF

Locus tag
YALI0A10076g
YALI0E15730g
YALI0F04378g
YALI0B05126g
YALI0B23298g
YALI0F11297g
YALI0C22165g
YALI0B17644g
YALI0F08701g
YALI0E32065g
YALI0B17204g
YALI0D20878g
YALI0A18062g
YALI0D19206g
YALI0B15818g
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Table 1- 3. List of primers used in this study. Bold italics are AscI and AvrII sequences.
Genes

Primers

Sequences

Primers used for constructing plasmids
pSR008Enz
pSR008Gibson
Yli ster1
Yli ster2
Yli ster3
Yli ster4
Yli ster5
Yli ster6
Yli ster7
Yli ster8
Yli ster9
Yli ster10-1
Yli ster10-2
Yli ster11
Yli ster12
Yli ster13
Yli sterTF

AscI_pTEF_Rev

TTGGCGCGCCTTTGAATGATTCTTATACTCAGAAGGAAATGC

AvrII_cyc1t_Fwd

TCCCCCTAGGTCATGTAATTAGTTATGTCACGCTTACATTCAC

cyc1t_Fwd

TCATGTAATTAGTTATGTCACGCTTAC

pTEF_Rev

TTTGAATGATTCTTATACTCAGAAG

Ster1YL_Fwd

cgccgagtcaagacgaaactaaggccttattgaaaATGGGAAAACTCATCGAACTGCTC

Ster1YL_Rev

gaatgtaagcgtgacataactaattacatgaCTAATCTCTCAGAGGAAACATCTTAGAG

Ster2YL_Fwd

TTGGCGCGCC atggtcacccaacagtctgcagcag

Ster2YL_Rev

TCCCCCTAGGctaagtcagctcgctccaaatgtaag

Ster3YL_Fwd

TTGGCGCGCCatgggaatccacgaaagtgtgtcgaaac

Ster3YL_Rev

TCCCCCTAGGtcactggcaatatcccttgaaatacaacccc

Ster4YL_Fwd

TTGGCGCGCCatgatcattctcacgacgctcaacaac

Ster4YL_Rev

TCCCCCTAGGctagttacgctctcgcttgctccacac

Ster5YL_Fwd

ccgagtcaagacgaaactaaggccttattgaaaATGACAGCCAAGAGCAAAACGAC

Ster5YL_Rev

gtgaatgtaagcgtgacataactaattacatgaTTAGTAGATGCCTGGGATGATAGC

Ster6YL_Fwd

ccgagtcaagacgaaactaaggccttattgaaaATGTCTTCGATTCTCGAGAGCATC

Ster6YL_Rev

cgtgaatgtaagcgtgacataactaattacatgaTTACTGCTGCTTCTTGGCCTTC

Ster7YL_Fwd

cgagtcaagacgaaactaaggccttattgaaaATGAACACGGTACTGATCGTCGG

Ster7YL_Rev

gaatgtaagcgtgacataactaattacatgaTTACTTCTTCTCCTTGGTCTCGTTG

Ster8YL_Fwd

TTGGCGCGCCatgatccacaacagaaaaacgcagacg

Ster8YL_Rev

TCCCCCTAGGttagttaatctgatccttcaacttctctctc

Ster9YL_Fwd

TTGGCGCGCCatgtcttccaacatcaaactggctcag

Ster9YL_Rev

TCCCCCTAGGtcagttcttgtcctcgggctttcg

Ster10-1YL_Fwd

TTGGCGCGCCatgaaattcgtcggtctgatttccctg

Ster10-1YL_Rev

TCCCCCTAGGttagatcttaccccaaagagcgtttcg

Ster10-2YL_Fwd

TTGGCGCGCCatgaaactcgtcggattcatctcgctgc

Ster10-2YL_Rev

TCCCCCTAGGtcagatcttaccccataacatgtttc

Ster11YL_Fwd

TTGGCGCGCCatggatatcgctctggagaccatcg

Ster11YL_Rev

TCCCCCTAGGttaatcctgcttggtgtttcgcttgac

Ster12YL_Fwd

TTGGCGCGCCatgaacgctacccaaccggagtcgcacattgtgc

Ster12YL_Rev

TCCCCCTAGGctactccctcttcttaaactgcaacag

Ster13YL_Fwd

TTGGCGCGCCatgtctgctgttcgacaacgtaaaag

Ster13YL_Rev

TCCCCCTAGGttagaaaacataagggatgaagatccaagggac

SterTFYL_Fwd

TTGGCGCGCCatggatatcgctctggagaccatcg

SterTFYL_Rev

TCCCCCTAGGttaatcctgcttggtgtttcgcttgac

Actin rt_Fwd

TCCAGGCCGTCCTCTCCC

Actin rt_Rev

GGCCAGCCATATCGAGTCGCA

ster1 rt_Fwd

GCGAGATCGTGTGGTGCTAC

ster1 rt_Rev

GTCCACGCCGTTGTTGTTGA

ster2 rt_Fwd

CGCACGAGACACACCCAATG

ster2 rt_Rev

GACGACGGTGAGAGGAGCAA

ster3 rt_Fwd

AGGCCCAATGCGAACTCACT

ster3 rt_Rev

AAGCGCGTTGCCAAACTTCA

Primers used for RT-PCR
Yli actin
Yli ster1
Yli ster2
Yli ster3
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Table 1-3 continued
Yli ster4
Yli ster5
Yli ster6
Yli ster7
Yli ster8
Yli ster9
Yli ster10-1
Yli ster10-2
Yli ster11
Yli ster12
Yli ster13
Yli sterTF

ster4 rt_Fwd

CTCGTTTGTCGTGCCCAAGG

ster4 rt_Rev

GTCTCGGACTCGGCCATCTT

ster5 rt_Fwd

ACGTCCAGATTGCCACGTCT

ster5 rt_Rev

AGCTCTCGGCCAATGAACCA

ster6 rt_Fwd

CTCTACTTTGGCCGGTGCGT

ster6 rt_Rev

AAGTGCGAGATGAGCACGGA

ster7 rt_Fwd

CGGACTCGGAAAGGCCATCT

ster7 rt_Rev

GGAGAACCGTCGGAGACAGC

ster8 rt_Fwd

ATGCCGTAGCCAAGGAGGTC

ster8 rt_Rev

GTTGGCTGCGTTGGAGTTGA

ster9 rt_Fwd

TGAGAAGGGCGACGGTATCC

ster9 rt_Rev

TCACCGGCCAGAGGGTAGTA

ster10-1 rt_Fwd

GCCTCTCTGCACGACCGATA

ster10-1 rt_Rev

CCGACAGCAGTGCCAAAGAA

ster10-2 rt_Fwd

CTGTGGGTACCGAGGGTCAC

ster10-2 rt_Rev

ACCTGGCCTCGAACCAGATG

ster11 rt_Fwd

AGGTGGCCAAGTTTCTCCGT

ster11 rt_Rev

TGGTCGTAGGCGTGTTTCCA

ster12 rt_Fwd

CGCATACGTCAAGCCCTGTG

ster12 rt_Rev

TGGGCAGGTACATGCTGAGG

ster13 rt_Fwd

ACCTCCATTGTGCTGGCCTT

ster13 rt_Rev

GTGCTCGTGGCCCATGTAGA

sterTF rt_Fwd

GCGAGATCGTGTGGTGCTAC

sterTF rt_Rev

GTCCACGCCGTTGTTGTTGA
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Table 1- 4. List of plasmids and strains used in this study.
Plasmids/strains
Plasmids
pSR008
pSR166
pSR167
pSR168
pSR169
pSR170
pSR171
pSR172
pSR173
pSR174
pSR175
pSR176
pSR177
pSR178
pSR179
pSR180
Y. lipolytica strains
YlSR001
YlCW001
YlSR009
YlSR172
YlSR173
YlSR174
YlSR175
YlSR176
YlSR177
YlSR178
YlSR179
YlSR180
YlSR181
YlSR182
YlSR183
YlSR184
YlSR185
YlSR186
YlSR187
YlSR188
YlSR189
YlSR190
YlSR191
YlSR192
YlSR193
YlSR194
YlSR195
YlSR196
YlSR197
YlSR198
YlSR199
YlSR200
YlSR201
YlSR202

Genotypes

Source

pSL16-PTEF-cyc1t::URA3
pSL16-PTEF-Yli ster1-cyc1t::ura
pSL16-PTEF-Yli ster2-cyc1t::ura
pSL16-PTEF-Yli ster3-cyc1t::ura
pSL16-PTEF-Yli ster4-cyc1t::ura
pSL16-PTEF-Yli ster5-cyc1t::ura
pSL16-PTEF-Yli ster6-cyc1t::ura
pSL16-PTEF-Yli ster7-cyc1t::ura
pSL16-PTEF-Yli ster8-cyc1t::ura
pSL16-PTEF-Yli ster9-cyc1t::ura
pSL16-PTEF-Yli ster10-1-cyc1t::ura
pSL16-PTEF-Yli ster10-2-cyc1t::ura
pSL16-PTEF-Yli ster11-cyc1t::ura
pSL16-PTEF-Yli ster12-cyc1t::ura
pSL16-PTEF-Yli ster13-cyc1t::ura
pSL16-PTEF-Yli sterTF-cyc1t::ura

[1]
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study

MATA ura3-302 leu2-270 xpr2-322 axp2-∆NU49 XPR2::SUC2

ATCC MYA-2613
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study

YlSR001 + pSR008
YlSR001 + pSR166
YlSR001 + pSR167
YlSR001 + pSR168
YlSR001 + pSR169
YlSR001 + pSR170
YlSR001 + pSR171
YlSR001 + pSR172
YlSR001 + pSR173
YlSR001 + pSR174
YlSR001 + pSR175
YlSR001 + pSR176
YlSR001 + pSR177
YlSR001 + pSR178
YlSR001 + pSR179
YlSR001 + pSR180
YlCW001 + pSR008
YlCW001 + pSR166
YlCW001 + pSR167
YlCW001 + pSR168
YlCW001 + pSR169
YlCW001 + pSR170
YlCW001 + pSR171
YlCW001 + pSR172
YlCW001 + pSR173
YlCW001 + pSR174
YlCW001 + pSR175
YlCW001 + pSR176
YlCW001 + pSR177
YlCW001 + pSR178
YlCW001 + pSR179
YlCW001 + pSR180
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Figure 1- 1. Evolutionary engineering of IL-tolerant Y. lipolytica strains. Step 1: Adaptive
laboratory evolution of Y. lipolytica on various concentrations of [EMIM][OAc]. Step 2:
Single mutant isolation on plates without IL. Step 3: Mutant characterization to elucidate
the underlying mechanism of solvent tolerance.
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Figure 1- 2. (A) Adaptive laboratory evolution of Y. lipolytica grown with increasing
concentrations of [EMIM][OAc]. (B, C) Irreversibility testing of the evolved Y. lipolytica
strain YlCW001 in various concentrations of [EMIM][OAc]. (D, E) Broad tolerance test for
growth of Y. lipolytica wildtype and mutant at various concentrations of 0.6M and 1.09M
ILs. Error bars represent the standard deviation of three independent biological replicates
repeated twice (n=6). Abbreviations: [EMIM][OAc]: 1-ethyl-3-methylimidizolium acetate;
[EMIM][Cl]: 1-ethyl-3-methylimidizolium chloride; [EMIM][Br]: 1-ethyl-3-methylimidizolium
bromide acetate; [BMIM][OAc]: 1-butyl-3-methylimidazolium; [BMIM][Cl]: 1-butyl-3methylimidizollium chloride; [BMIM][Br]: 1-butyl-3-methylimidazolium bromide; and
[AMIM][Cl]: 1-allyl-3-methylimidizolium chloride.
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Figure 1- 3. SEM imaging of the wildtype and YlCW001 cells exposed to (A, B) no IL, (C,
D) 18% (v/v) [EMIM][OAc], (E, F) 0.3M [BMIM][OAc], and (G, H) 0.6M [BMIM][OAc]. (I)
IL-responsive pathways perturbed with respect to wildtype Y. lipolytica growing in medium
without IL with a psf score > 0.58. Biological triplicates were performed for all biological
conditions and results were combined from hydrophilic metabolomics extraction (negative
ionization, n = 3), and hydrophobic lipidomics extractions (negative ionization, n = 3;
positive ionization, n = 3).
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Figure 1- 4. Glycerophospholipid and fatty acid reorganization in wildtype Y. lipolytica
and YlCW001 in 0% and 8% (v/v) [EMIM][OAc]. (A) PC: Phosphatidylcholine; (B) PI:
phosphatidylinositol; (C) PA: phosphatidic acid; (D) PG: phosphatidyl glycerol; (E) PS:
phosphatidylserine; (F) PE: phosphatidylethanolamine; (G) CL: cardiolipin. (H) Fatty acid
distributions. (I) Chemical structures of glycerophospholipid backbone and headgroup
species. All error bars represent standard deviation of biological triplicates (n=3) and
statistical significance was calculated using one-way analysis of variance (ANOVA) with
Holm-Sidak correction against control group, wildtype in 0% IL (degrees of freedom, 3).
Symbols: “*”: p-value < 0.05; “**”: p-value < 0.01; “***”, p-values < 0.001.
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Figure 1- 5. (A) Sterol biosynthesis pathway in Y. lipolytica. Fluconazole is an antifungal
drug that inhibits sterol 14-demethylase (Ster4) (B) Differential gene expression of the
steroid pathway as compared to the wildtype strain in medium without IL (Ster1,
YALI0A10076g; Ster2, YALI0E15730g; Ster3, YALI0F04378g; Ster4, YALI0B05126g;
Ster5,

YALI0B23298g;

YALI0B17644g;

Ster9,

YALI0B17204g;

Ster11,

Ster6,

YALI0F11297g;

YALI0F08701g;
YALI0D20878g;

Ster7,

Ster10-1,
Ster12,

YALI0C22165g;

YALI0E32065g;
YALI0A18062g;

Ster8,

Ster10-2,
Ster13,

YALI0D19206g). (C) Effect of fluconazole inhibiting the steroid pathway on cell growth
relative to wildtype in non-IL, non-fluconazole media. Error bars represent standard
deviation from three technical replicates repeated twice per biological condition (n = 6)
(D) Relative ergosterol content of wildtype and YlCW001 strains in 0% and 8% (v/v)
[EMIM][OAc]. (E) Toxicity plate assay of Y. lipolytica strains expressing the sterol
biosynthesis and transcription factor genes in presence of various concentrations of
[EMIM][OAc]. Error bars represent standard deviation of biological triplicates (n =3) and
statistical significance was calculated between the wildtype and YlCW001 in 8% IL using
the Student’s t-test (t = -4.244 with 4 degrees of freedom). Abbreviation: “**”, p-value =
0.013.

51

A

B
log2 fold change

Sterol biosynthesis pathway

8

Glycolysis

Terpenoid backbone synthesis

6
4

2
0
-2

C

Squalene
Ster-2

Ster-3
Lanosterol
fluconazole

Ster-4

4,4-Dimethyl-cholesta-8,14,24-trienol
Ster-5
14-Demthyl-lanosterol
Ster-6

4-Methylzymosterol-carboxylate
Ster-7
3-Keto-4-methyl-zymosterol
Ster-8

Ster-9
Fecosterol
Ster-10
Episterol

1.0

*

*

0.8
0.6
0.4

*

0.2
0.0
0

10

* No growth

*

* *

*

*

*

*

*

25

50

*

*
*

*
100

*

*
*

*
250

Fluconazole (µg/mL)

Ster-11
Ergostatrienol
Ster-12
Ergostatetraenol
Ster-13
Ergosterol

D

p = 0.013
100%

Relative Ergosterol

Squalene-2,3-Epoxide

4-Methylzymosterol

Relative growth rate

Ster-1

75%

**
50%

**
25%

Zymosterol

0%

0%
8%
wildtype

0%

8%
YlWC001

E

52

A

Wildtype

D

YlCW001

Ionic liquid exposure:
o Insert cation into membrane
o Increase PLs (except PE)
o Decrease ergosterol
o Decrease chitin
o Perturb intracellular metabolism

B

Ionic liquid exposure:
o Insert cation into membrane
o Increase PLs (except PE)
o Decrease ergosterol
o Decrease chitin
o Perturb intracellular metabolism

E

Wildtype

YlCW001

Cell responses:
o Increase membrane fluidity
o Disorder membrane (dents,
wrinkles)

C

Cell responses:
o Increase GLs
o Upregulate steroid pathway
o Increase ergosterol
o Resist cation insertion and
membrane disorientation
o Enhance IL-tolerance

F

Wildtype

YlCW001

Phospholipids (PL)

PE

Ergosterol

Chitin

Cation

Anion

Figure 1- 6. Mechanisms of IL interference and tolerance in wildtype Y. lipolytica and
YlCW001. (A, D) No IL exposure. (B, E) IL exposure and interference. (C, D) Cellular
membrane response.
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Figure 1- 7. Effect of 0.3M [BMIM][OAc] on growth of Y. lipolytica wildtype and YlCW001.
Each data point is an average ± standard deviation of three independent biological
replicates.
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Figure 1- 8. SEM images of wildtype Y. lipolytica cells incubated for 6 hours in (A) no IL,
(B) 2% (v/v) [EMIM][OAc], (C) 8% (v/v) [EMIM][OAc] and (D) 12% (v/v) [EMIM][OAc].
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Figure 1- 9. Effect of various concentrations [EMIM][OAc] on the chitin content in the
membranes of the wildtype and YlCW001. Each experiment was conducted at least twice
for each biological condition in technical replicates, i.e., wildtype 0%, n = 18; wildtype 2%,
n = 6; wildtype 5%, n = 15; wildtype 8%, n = 12; YlCW001 0%, n = 25; YlCW001 2%, n =
6; YlCW001 5%, n = 15; YlCW001 8%, n = 29; YlCW001 10%, n = 6. Each error bar
represents standard deviation of technical replicates and statistical significance was
calculated using one-way analysis of variance (ANOVA) with Holm-Sidak correction
against all pairwise groups (degree of freedom=8, F=18.53).

Asterisks represent

statistical significance against respective strain in 0% IL where *, p-values < 0.01, **pvalues < 0.001.
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Figure 1- 10. Fatty acid molar ratios of wildtype and YlCW001 in 0% and 8% (v/v)
[EMIM][OAc].

(A) Molar ratio of C16:C18 fatty acid moieties.

(B) Molar ratio of

(C18:2):(C18:1) fatty acid moieties. Each error bar represents standard deviation of 3
biological replicates and statistical significance was calculated using one-way analysis of
variance (ANOVA) with Holm-Sidak correction against control group, wildtype in 0% IL
(degree of freedom = 3). *P values < 0.05, **P values < 0.01, ***P values < 0.001.
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Figure 1- 11. (A) Growth kinetics and (B) ergosterol content of SterTF overexpression in
8% (v/v) [EMIM][OAc] relative to wildtype in 0% and 8% (v/v) [EMIM][OAc] at 36 h. Error
bars represent the average and standard deviation of biological triplicates. Statistical
significance was calculated between the wildtype and SterTF-expressing strains in 8%
(v/v) [EMIM][OAc] using one-way analysis of variance (ANOVA) with Holm-Sidak
correction.
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Figure 1- 12. Transcription factor affinity prediction (TRAP) for sterol biosynthesis genes.
TRAP was performed for 1050bp nucleotide sequences upstream of each sterol
biosynthesis gene and pTEF promoter as negative control.
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CHAPTER II
Understanding and eliminating the detrimental effect of thiamine
deficiency on the oleaginous yeast Yarrowia lipolytica.
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Abstract
Thiamine is a vitamin that functions as a cofactor for key enzymes in carbon and energy
metabolism for all living cells. While most plants, fungi and bacteria can synthesize
thiamine de novo, the oleaginous yeast, Yarrowia lipolytica, cannot. In this study, we
used proteomics together with physiological characterization to understand key metabolic
processes influenced and regulated by thiamine availability and identified the genetic
basis of thiamine auxotrophy in Y. lipolytica. Specifically, we found thiamine depletion
results in decreased protein abundance of the lipid biosynthesis pathways and energy
metabolism (i.e., ATP synthase), attributing to the negligible growth and poor sugar
assimilation observed in our study.

Using comparative genomics, we identified the

missing 4-amino-5-hydroxymethyl-2-methylpyrimidine phosphate synthase (THI13) in the
de novo thiamine biosynthesis of Y. lipolytica, and discovered an exceptional promoter,
P3, that exhibits strong activation or tight repression by low and high thiamine
concentrations, respectively.

Capitalizing on the strength of our thiamine-regulated

promoter (P3) to express the missing gene from Saccharomyces cerevisiae (scTHI13),
we engineered the thiamine-prototrophic Y. lipolytica. By comparing this engineered
strain to the wildtype, we unveiled the tight relationship linking thiamine availability to lipid
biosynthesis and demonstrated enhanced lipid production with thiamine supplementation
in the engineered thiamine-prototrophic Y. lipolytica.

Introduction
Thiamine, or vitamin B1, was the first B vitamin discovered. Its activated form, thiamine
pyrophosphate (TPP), functions as a cofactor for key enzymes in carbon metabolism
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including citrate (Krebs) cycle, pentose phosphate and branched chain amino acid
pathways (Figure 2-1) (1). TPP-dependent enzymes, including pyruvate dehydrogenase
(PDH), α-ketoglutarate dehydrogenase (KGDH), transketolase (TKL), branched chain αketoacid dehydrogenase (BCKDC) and acetolactate synthase (AHAS), are essential for
maintaining cell growth and preventing metabolic stress (2-4). Specifically, PDH links the
glycolysis and citrate cycle by catalyzing the conversion of pyruvate into acetyl-CoA (5,
6). KGDH, a key enzyme of the citrate cycle, converts α-ketoglutarate (KGA) to succinylCoA (7, 8). TKL participates in the pentose phosphate pathway by interconverting
pentose sugars to glycolysis intermediates (9). The pentose phosphate pathway is critical
for production of ribose (i.e., RNA), precursor metabolites for aromatic amino acid
pathways, and reducing equivalents (i.e., NADPH) necessary for maintaining redox
balance and lipid synthesis. Hence, TKL activity is critical for RNA, protein, and lipid
production while preventing oxidative stress (10, 11). Meanwhile, AHAS and BCKDC are
responsible for the synthesis and degradation of branched chain amino acids (i.e., valine,
leucine and isoleucine), respectively (12, 13).
In mammals, thiamine deficiency affects the cardiovascular and nervous systems
resulting in tremors, muscle weakness, paralysis and even death (14, 15). Thiamine
deficiency can occur from inadequate intake, increased requirement, or impaired
absorption of thiamine (16). Biochemical consequences of thiamine deficiency result in
failure to produce adenosine triphosphate (ATP), increased acid production (i.e., lactic
acid),

decreased

production

of

acetylated

compounds

(i.e.,

acetylcholine),

neurotransmitters (i.e., glutamate, aspartate, aminobutyric acid), reduced nicotinamide
adenosine dinucleotide phosphate (NADH), defective ribonucleic acid (RNA) ribose
synthesis, and failure to break down branched chain carboxylic acids (i.e., leucine, valine,
isoleucine) (17-19).
While mammals require nutritional supplementation of thiamine from dietary
sources, most bacteria, fungi and plants can synthesize thiamine endogenously (20).
One of these exceptions is the thiamine-auxotrophic oleaginous yeast, Yarrowia lipolytica,
which has recently emerged as an important industrial microbe with broad
biotechnological applications due to its generally regarded as safe (GRAS) status (21),
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metabolic capability (22-26), and robustness (27-29). Hence, Y. lipolytica is an ideal
eukaryotic host to study the fundamental effects of thiamine deficiency on cellular health.
Currently, it is not well understood what causes failure of thiamine biosynthesis in Y.
lipolytica nor how thiamine deficiency affects other processes (e.g., lipid biosynthesis,
energy metabolism, etc.)
Interestingly, Y. lipolytica’s auxotrophy has been exploited for enhanced
production of organic acids (i.e., pyruvate and KGA) by reducing activities of PDH and
KGDH under thiamine-limited conditions (30, 31). Consequently, cell growth is negatively
affected by thiamine limitation and completely prevented when thiamine is depleted from
the media. Not surprisingly, the genes in thiamine metabolism are tightly regulated by
thiamine concentrations (32, 33). To this end, numerous thiamine-regulated promoters
have been discovered in yeast that enable control of genetic expression by adjusting
thiamine concentration in the culture media (34-37). However, endogenous thiamineregulated promoters have not yet been discovered in Y. lipolytica.
In this study, we shed light on the effect of thiamine deficiency on cellular
metabolism in the thiamine auxotroph Y. lipolytica. We identified the missing gene
encoding 4-amino-5-hydroxymethyl-2-methylpyrimidine phosphate synthase (THI13) in
the de novo thiamine biosynthesis pathway of Y. lipolytica and discovered a thiamineregulated promoter, P3, that increases expression in low thiamine concentrations. By
employing P3 to control the expression of scTHI13 derived from Saccharomyces
cerevisiae, we engineered thiamine prototrophy in Y. lipolytica. This enabled us to
elucidate the relationship between thiamine availability and ATP and lipid biosynthesis
and revealed enhanced lipid production in the engineered thiamine-prototrophic Y.
lipolytica.

RESULTS
The effects of thiamine deficiency in Y. lipolytica
Cell growth and organic acid production are influenced by thiamine
limitation and depletion. To demonstrate the effects of thiamine limitation, we
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characterized the thiamine-auxotrophic Y. lipolytica (YlSR001) in 0, 0.5 and 400 µg/L
thiamine (Figure 2-2A). Cell growth was inhibited by limited (0.5 µg/L thiamine) and
depleted (0 µg/L thiamine) concentrations of thiamine but restored in high thiamine (400
µg/L thiamine) containing media (Figure 2B). Glucose consumption profiles were closely
coordinated with cell growth (Figure 2-2C). Within the first 24 hr, only ~2 g/L glucose was
assimilated without thiamine while thiamine-limited cultures consumed ~3 g/L glucose
(Figure 2-2C). After 24 h, growth and glucose consumption were completely stalled under
the no thiamine condition. In contrast, cells continued to utilize glucose even though
growth was significantly inhibited.
Next, we characterized pyruvate and KGA production since the enzymes
converting these organic acids, PDH and KGDH respectively, are TPP-dependent. In high
thiamine media, Y. lipolytica demonstrated slight KGA production (~0.5 g/L KGA) and no
pyruvate accumulation (Figure 2-2D, 2-2E). We observed substantial pyruvate titers in
thiamine limited (~4 g/L pyruvate) and depleted (~2 g/L pyruvate) media (Figure 2-2E),
indicating that PDH is unable to efficiently convert pyruvate to acetyl-CoA. Similarly, KGA
accumulation was enhanced in thiamine-limited media (2 g/L KGA) but KGA titers in
thiamine-depleted media were comparable to high thiamine media likely due to decreased
flux from glycolysis to the TCA cycle through reduced acetyl-CoA production via PDH
(Figure 2-2D). Taken together, Y. lipolytica requires thiamine supplementation for cell
growth and carbon assimilation but produces organic acids under thiamine-limited
conditions.
Proteome of thiamine depletion reveals perturbation of critical metabolic
pathways related to cellular growth. Next, we investigated the proteome of the
thiamine-auxotrophic Y. lipolytica growing in 0 and 400 µg/L thiamine (Figure 2-3A).
Across 2 exponential time points, we identified 535 upregulated and 515 downregulated
proteins (i.e., log2 fold change > |1|) in response to thiamine deficiency (Figure 3B). First,
we looked at metabolic enzymes that require TPP as a cofactor including PDH, KGDH,
transketolase (TKL), branched chain α-ketoacid dehydrogenase (BCKDC) and
acetolactate synthase (AHAS) (Supplementary Table S1).

Interestingly, all proteins

encoding subunits (E1-E3) of BCKDC were upregulated in thiamine depletion
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(Supplementary Table S1). However, none of the other TPP-requiring proteins were
upregulated in media lacking thiamine except for dihydrolipoamide dehydrogenase (E3),
which serves as a subunit for BCKDC, PDH and KGDH (Table 2-S1).
We then mapped the 535 upregulated- and 515 downregulated proteins to their
respective KEGG pathways (Figure 2-3C).

Thiamine deficiency resulted in

downregulation of over 55% of proteins involved in nucleic acid metabolism (i.e.,
pyrimidine and purine metabolism) and genetic processes (i.e., ribosome and DNA
replication). Without thiamine, cells also exhibited decreased protein abundance in lipid
metabolism which includes the synthesis of terpenoids (100% of proteins), steroids (75%
of proteins) and glycerophospholipids (80% of proteins). In contrast, thiamine deficiency
resulted in upregulation of over 65% of proteins contained in carbohydrate (i.e., glycolysis
and citrate cycle), tetrapyrrole, biotin, aromatic (i.e., tryptophan, phenylalanine), branched
chain (i.e., leucine, isoleucine, valine), and other amino acid (i.e., glycine, serine,
threonine) metabolic pathways. Thiamine deficiency also affected proteins associated
with the electron transport chain (ETC), amino acid (i.e., arginine, proline, glutamate,
glutamine, methionine, cysteine) biosynthesis and thiamine metabolic pathways.
A closer look at proteins involved in the ETC and thiamine metabolism revealed
interesting

features.

First,

thiamine-deficient

cells

exhibited

increased

protein

abundances for all four complexes of the ETC but decreased protein abundance for ATP
synthase that is important for ATP generation (Figure 2-3D). The phenomenon correlates
with the stalled assimilation of glucose that is ATP-dependent when cells grow in the
absence of thiamine. Second, all but one of the proteins in thiamine metabolism were
differentially regulated between thiamine-sufficient and thiamine-depleted cultures
(Figure 2-3E). Without thiamine, we observed increased abundance of proteins in the
upper branch of thiamine synthesis but decreased abundance in proteins converting
thiamine monophosphate into thiamine and TPP into thiamine triphosphate. The only
detected protein in thiamine metabolism that was not changed by thiamine concentrations
was thiamine kinase (Thi90p), which is responsible for the conversion of thiamine into its
activated diphosphate form, TPP. Taken together, thiamine concentration influences
regulation of thiamine metabolism, whereby thiamine deficiency severely affects central
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carbon metabolism and elicits increased protein abundance for most carbohydrate, amino
acid and energy pathways but decreased protein abundance for lipid metabolism,
nucleotide metabolism and specifically, ATP synthase.
Restoring thiamine prototrophy in Y. lipolytica
Thiamine metabolism in Y. lipolytica is incomplete. Next, we investigated the
native thiamine metabolism of Y. lipolytica to elucidate underlying genetic deficiency
causing thiamine-auxotrophic behavior.
pathways

between

the

We compared the thiamine biosynthesis

well-characterized

thiamine-prototrophic

Saccharomyces

cerevisiae and our thiamine-auxotrophic Y. lipolytica. Between the two organisms, we
identified that the 4-amino-5-hydroxymethyl-2-methylpyrimidine phosphate synthase
corresponding to THI13 in S. cerevisiae (scTHI13) is missing in Y. lipolytica. scTHI13
converts histidine and pyrodixine into hydroxymethylpyrimidine pyrophosphate (HMPPP), which is likely required for the de novo thiamine synthesis in Y. lipolytica (Figure 23E).
Constitutive expression of the missing thiamine gene does not effectively
restore prototrophy. To enable the de novo biosynthesis of thiamine in Y. lipolytica, we
constructed a vector to express scTHI13 under the constitutive promoter, TEF, frequently
used for genetic overexpression in Y. lipolytica. Unexpectedly, expression of scTHI13
with the TEF promoter only restored the de novo TPP biosynthesis after days of
adaptation in thiamine-depleted media (Figure 2-S1). Additionally, cell growth was highly
deviated between replicates for both times when this experiment was conducted (Figure
2-S1). Though the results were somewhat promising, we endeavored to engineer a true
thiamine-prototrophic Y. lipolytica.
Bioinformatics of thiamine-responsive genes reveals highly regulated
thiamine promoter. We hypothesized that expression of scTHI13 was weak since the
constitutive TEF promoter (38, 39) is dependent on cell growth (40, 41) and thiamine
deficiency prevents cell growth. To this end, we aimed to find a promoter responsive to
thiamine deficiency.

Through BlastP and orthology analysis using the well-studied

thiamine-regulated genes from Pichia pastoris, Saccharomyces cerevisiae and
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Schizosaccharomyces pombe, we identified three candidate genes that are putatively
regulated by thiamine in Y. lipolytica (Table 2-S2). The P1 gene (YALI0E04224g) encodes
a

putative

thiaminase

that

might

exhibit

hydroxymethylpyrimidine

kinase/phosphomethylpyrimidine kinase activity for conversion of thiamine into 4-amino5-hydroxymethyl-2-methylpyrimidine diphosphate.

The P3 gene (YALI0A09768g)

encodes a putative cysteine-dependent adenosine diphosphate thiazole synthase that is
involved in the biosynthesis of thiazole, a thiamine precursor. Thiazole synthase converts
NAD+

and

glycine

into

ADP-5-ethyl-4-methylthiazole-2-carboxylate,

a

thiazole

intermediate. Though the function of P2 (YALI0C14652g) has yet to be characterized, it
harbors a NMT1 domain (Pfam:PF09084) which is required for biosynthesis of the
pyrimidine moiety of thiamine (42); hence, P2 might be thiamine-regulated.
To determine if these promoters (i.e., P1, P2, and P3) are thiamine-regulated, realtime PCR was conducted to quantify mRNA levels of P1, P2, and P3 genes from YlSR001
grown in low (0.5 µg/L) and high (500 µg/L) concentrations of thiamine (Figure 2-4A). The
expression levels of P1 and P3 genes were activated in low thiamine but inactivated in
high thiamine. Remarkably, the P3 gene expression level was substantially higher in low
thiamine than high thiamine. We did not observe transcriptional expression of P2 in either
low or high thiamine concentrations.
We next investigated plasmid expression of these 3 putative thiamine-regulated
promoters from the Y. lipolytica strains that harbor a humanized renilla green fluorescent
protein (hrGFP)-expressing gene under the control of either P1, P2, or P3 promoter
(strains YlSR1002, YlSR1003 and YlSR1004, respectively). For controls, we also built the
native, constitutive TEF promoter and the heterologous NMT1 promoter from S. pombe
that has been well-studied and applied as a thiamine-regulated promoter (43). The hrGFP
intensity was monitored from cells grown at low (1 µg/L) and high (10 mg/L)
concentrations of thiamine (Figure 2-4B). As expected, both P1 and P3 promoters were
activated in low thiamine and inactivated in high thiamine. Under low thiamine conditions,
the hrGFP intensity under promoter P3 was much higher than P1 and TEF promoters by
10.04 ± 0.46-fold and 2.82 ± 0.13-fold, respectively. Not surprisingly, the activity of TEF
promoter was much greater in high thiamine than in low thiamine. The NMT1 promoter
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showed no activity in low thiamine while limited activity was exhibited in high thiamine as
expected due to the species specificity.
We further investigated the sensitivity of the P3 promoter over a range of low
thiamine concentrations (0.5-50 µg/L) (Figure 2-4C). Encouragingly, the P3 promoter
exhibited tight regulation across all incremental thiamine concentrations. Of note, the
activity of the P3 promoter was not affected by poor cell growth in low thiamine
concentrations (Figure 2-4D). Taken together, these data indicate that the endogenous
thiamine-regulated promoters, P1 and P3, can be applied to strain engineering efforts
and are responsive to low thiamine concentrations.
Thiamine prototrophy is restored with thiamine regulated promoter. To
restore the de novo thiamine synthesis in Y. lipolytica, we constructed the vector pSR075
to express the missing thiamine gene, scTHI13, with the thiamine-responsive promoter,
P3 (i.e., YlSR1006). Remarkably, this construct demonstrated robust and reproducible
growth in media lacking thiamine (Figure 5). Cell growth and glucose uptake were similar
despite with low to no added thiamine (Figure 2-5A, 2-5B), but organic acid production
was affected. Organic acid production in low (0.5 µg/L) and depleted (0 µg/L) thiamine
conditions was diminished during the stationary phase (Figure 2-5C, 2-5D). Meanwhile,
KGA accumulation only manifested in high (400 µg/L) thiamine (Figure 2-5C). Taken
together, the thiamine prototroph strain created here, YlSR1006, grows reproducibly
irrespective of thiamine concentrations but produces no organic acids in thiamine-limited
media.
Lipid accumulation is influenced by thiamine concentrations. Finally, we
investigated the relationship between thiamine availability and neutral lipid accumulation.
We cultured both thiamine-auxotrophic (wildtype) and our engineered thiamineprototrophic (YlSR1006) strain with 0 µg/L and 400 µg/L thiamine in MpA (no nitrogen
limitation, Figure 6A) and lipid production (nitrogen limitation with C:N = 100, Figure 26B) media. In non-nitrogen limited media, YlSR1006 produced more lipid than the
wildtype grown with 400 µg/L thiamine supplementation (Figure 2-6A). Interestingly,
YlSR1006 grown without thiamine accumulated lipid similar to the wildtype with 400 µg/L
thiamine. However, under nitrogen-limitation, both the wildtype and YlSR1006 strains
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showed similar lipid production profiles when 400

g/L thiamine was supplemented in

growth medium (Figure 2-6B). In thiamine-lacking medium, while no lipid accumulation
was expected for the wildtype, YlSR1006 was able to accumulate 3.68 ± 0.22 lipid
%DCW, which was ~50% less than YlSR1006 supplemented with 400 µg/L thiamine.
Taken together, thiamine supplementation increased lipid production even for thiamineprototroph YlSR1006, indicating thiamine plays a critical role for lipid biosynthesis in Y.
lipolytica.

DISCUSSION
In this study, we observed the effects of thiamine deficiency on growth, sugar
consumption, organic acid production, and proteome of the thiamine-auxotrophic Y.
lipolytica. The activated form of thiamine, TPP, is an important cofactor for enzymes
involved in vital cellular functions including energy metabolism (44), reducing oxidative
and osmotic stresses (45), and catabolism of sugars (46). Hence, the consequences of
thiamine deficiency are caused by the reduced activity of TPP-dependent enzymes (i.e.,
PDH, KGDH, TKL, AHAS and BCKDC), which causes growth cessation and ultimately
leads to cell death. A comprehensive model that depicts the detrimental effect of thiamine
deficiency on metabolism leading to growth cessation in Y. lipolytica is summarized in
Figure 2-7.
Loss of PDH and KGDH activities result in poor growth, limited carbon assimilation
and accumulation of pyruvate and KGA (Figure 2-2). Failure to metabolize pyruvate via
PDH also inhibits production of acetyl-CoA, the precursor metabolite of the TCA cycle.
The TCA cycle is further inhibited by reduced KGDH activity, preventing synthesis of
NADH required for oxidative phosphorylation (i.e., ETC). Notably, in the model yeast,
Saccharomyces cerevisiae, deletion of KGDH is known to prevent respiratory growth (47),
but the exact mechanism is not well established. In our study, proteomic analysis shows
that thiamine-deficient cells increased protein abundance for the first four complexes of
oxidative phosphorylation (i.e., NADH dehydrogenase, succinate dehydrogenase, and
cytochrome c reductase/oxidase) but decreased protein abundance for ATP synthase
(Figure 2-3D).These new findings indicate that thiamine deficiency negatively affects
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respiratory energy metabolism caused by a malfunctioning TCA cycle via inhibition of
PDH and KGDH as observed by inhibited growth and reduced sugar uptake in thiaminedepleted cells.
Y. lipolytica also decreased protein abundances in glycerophospholipid, terpenoid
backbone and sterol biosynthesis pathways in thiamine-deficient cells (Figure 2-3C).
These phenomena are likely consequences of reduced PDH activity (i.e., reduced pools
of acetyl-CoA) and likely affected by NADPH production by the pentose phosphate
pathway. In the pentose phosphate pathway, TKL interconverts pentose sugars and
hexose sugars, the later which serve as glycolytic intermediates (e.g., fructose-6P,
glyceraldehyde-3P). Hence, loss of TKL activity likely effects the production of ribose-5P
and NADPH which are required for synthesis of lipids, RNA, DNA, purines, pyrimidines,
and antioxidants (48). Interestingly, loss of TKL activity also prevents production of
erythrose-4P, impeding synthesis of folate and aromatic amino acids (i.e., phenylalanine,
tyrosine, and tryptophan) as previously observed in TKL-deletion mutants of S. cerevisiae
(49).
In our study, Y. lipolytica also responded to thiamine deficiency by increasing
protein abundance of enzymes involved in branched chain α-amino acid metabolism (i.e.,
valine, leucine and isoleucine). Consistent with the previous studies with S. cerevisiae,
deletion of BCKDC results in branched chain α-amino acid auxotrophic phenotypes (50).
Interestingly, BCKDC was the only TPP-requiring enzyme with all 3 subunits upregulated
in our thiamine-depleted Y. lipolytica cells. However, this finding might be the result of
leucine supplementation in the media since our Y. lipolytica strain is leucine auxotrophic.
Taken together, thiamine deficiency inhibited cell growth severely limiting energy
production, amino acids (i.e., aromatic and branched chain) and lipid synthesis, ultimately
leading to cell death (Figure 2-7).
Despite thiamine-mediated growth inhibition, Y. lipolytica exhibited strong
upregulation of proteins involved in thiamine metabolism in response to thiamine
depletion (Figure 2-3E).
depletion,

Interestingly, one of the enzymes upregulated in thiamine

cysteine-dependent

adenosine

diphosphate

thiazole

(YALI0A09768g), is driven by the thiamine-regulated promoter, P3.

synthase

While various
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constitutive and inducible promoters are available for Y. lipolytica (51-54), the tightly
regulated, thiamine-responsive P3 promoter is especially useful for strong, inducible
expression in low thiamine conditions. Under optimized conditions, the activity of P3
promoter was 2.82 ± 0.13-fold higher than TEF promoter (Figure 2-4B). Hence, gene
overexpression using the P3 promoter is highly desirable over the constitutive TEF
promoter in low thiamine concentrations. This was demonstrated by restoring thiamine
prototrophy in Y. lipolytica using P3 promoter (Figure 2-5), while the TEF promoter was
not strong enough to accomplish stable thiamine prototrophy (Figure 2-S1). Overall, the
P3 promoter can be used as a thiamine biosensor for applications in synthetic biology
and metabolic engineering.
Surprisingly, thiamine prototroph was restored by overexpressing 1 single gene,
absent from the native genome of Y. lipolytica, for the de novo synthesis of thiamine
(Figure 2-3E, Figure 2-S1). This begs the question, why does Y. lipolytica lack this gene?
We hypothesize that most Y. lipolytica strains are isolated from thiamine-rich sources
(e.g., sausage, oats, plants) (55) while most popular yeasts, including S. cerevisiae, are
isolated from sugar-rich sources (e.g., fruits, molasses, sugarcane) (55). Remarkably,
we observed enhanced lipid production by thiamine supplementation in both thiamineauxotrophic and prototrophic strains, suggesting a relationship between lipid production
and thiamine availability (Figure 2-6A, 2-6B).

This relationship shows promise for

industrial applications of neutral lipid production and establishes a novel direction for
increasing lipid production in Y. lipolytica.

MATERIALS AND METHODS
Plasmids and strains
The list of plasmids and strains used in this study is available in Table 2-1. Plasmid
pSR005 carrying a humanized renilla green fluorescent protein (hrGFP) was constructed
by Gibson assembly method (56) with hrGFP and pSL16-CEN1-1-227 (57). The hrGFP
gene was amplified using the primers hrGFP_Fwd and hrGFP_Rev from pBABE GFP
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(pBABE GFP was a gift from Dr. William Hahn; Addgene plasmid #10668). The backbone
pSL16-CEN1-1-227 was amplified with the primers pSL16_Fwd and pSL16_Rev.
Next, various promoters, TEF(404) (53), NMT1 (58), P1(1000), P2(1000), and
P3(1000) were inserted into pSR005 by Gibson assembly method. Each TEF(404),
P1(1000), P2(1000), and P3(1000) promoter region (size of each promoter is in
parenthesis) was amplified using the primers PTEF_Fwd/PTEF_Rev, PP1_Fwd/PP1_Rev,
PP2_Fwd/PP2_Rev, and PP3_Fwd/PP3_Rev, respectively from the genomic DNA of Y.
lipolytica ATCC MYA-2613. The NMT1 promoter region was amplified using the
PNMT1_Fwd/PNMT1_Rev primers from the genomic DNA of S. pombe (kindly provided by
Dr. Paul Dalhaimer, Department of Chemical and Biomolecular Engineering, University
of Tennessee Knoxville, TN, USA). The backbone pSR005 was amplified by using the
primers pSR005_Fwd/pSR005_Rev. The constructed plasmids are pAT32y, pSR068,
pSR071, pSR072, and pSR073 (Table 2-1).
The plasmid pSR074 was constructed by assembly of (i) THI13sce, amplified using
the primers THI13sce_Fwd1/THI13sce_Rev from the genomic DNA of S. cerevisiae and (ii)
pSR008 backbone, amplified using the primers pSR008_Fwd/pSR008_Rev. The plasmid
pSR075 was constructed by replacing the hrGFP gene with the THI13sce gene from
pSR073.

The

THI13sce

gene

was

amplified

by

using

the

primers

THI13sce_Fwd2/THI13sce_Rev from the genomic DNA of S. cerevisiae and assembled with
the

PP3

promoter

carrying

backbone,

amplified

by

using

the

primers

pSR008_Fwd/pSR073_Rev.
The Y. lipolytica ATCC MYA-2613, obtained from ATCC strain collection, was used
as a parent strain. YlSR101, YlSR109, YlSR1001 and-YlSR1006 (Table 2-1) strains were
generated by transforming the corresponding plasmids via electroporation (59). Each
plasmid was transferred into Y. lipolytica YlSR001 via electroporation to generate strains
used in this study. The YlSR109, YlSR1001-YlSR1004 strains were confirmed by the
respective promoter binding forward primer along with hrGFP_Rev. The YlSR1005 and
YlSR1006 strains were confirmed by TEF(-100)_Fwd or P3(-80)_Fwd together with the
respective gene binding reverse primer. Escherichia coli TOP10 was used for molecular
cloning. Primers used in this study are listed in Table 2-2.
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Media and culturing conditions
Media. For E. coli culture, Luria Bertani medium containing 5 g/L yeast extract, 10
g/L tryptone, and 5 g/L NaCl, 100 mg/L ampicillin as a selection was used. For Y. lipolytica
characterization, MpA defined media was used for all experiments. MpA components are
as follows: 5 g/L (NH4)2SO4, 2 g/L KH2PO4, 0.5 g/L MgSO4, 44 mg/L ZnSO4·7H2O, 79
mg/L CaCl2·2H2O, 0.8 mg/L Biotin, 100 mM HEPES buffer, 90 mM Na 2HPO4, 10 mM
NaH2PO4, trace elements (0.4 mg/L ZnSO4·7H2O, 0.04 CuSO4·5H2O, 0.4 MnSO4·6H2O,
0.2 mg/L Na2MoO4·2H2O, 0.1 mg/L KI, 0.5 mg/L FeSO4·7H2O, 0.5 mg/L H3BO3), 380
mg/L leucine, 20 g/L glucose and various concentrations of thiamine hydrochloride. MpA
media was adjusted to pH of 5.
Culturing. All experiments were conducted in a Kuhner LT-X incubator set to
28°C and 250 rpm unless otherwise stated. Fresh colonies were inoculated in 2mL of
MpA medium containing 400 µg/L thiamine in 15mL culture tubes overnight. Cultures
were centrifuged and resuspended in 2mL of water before transferring 1mL of this
suspension into 100mL of MpA containing 5 µg/L thiamine to scale-up cultures for 2 days
(Figure 2A). Next, cells were washed once with water and resuspended in 100mL of MpA
lacking thiamine for 1 day to eliminate thiamine carry-over (Figure 2A). Finally, cells were
washed twice with water before characterization experiments. All experiments were
conducted in technical triplicates using 500mL baffled flasks unless otherwise stated.
Analytical methods
Real-time quantitative PCR (rt-PCR). Y. lipolytica, grown in MpA medium using
glucose as a carbon source together with either low (0.5 µg/L) and high (500 µg/L)
thiamine, was collected at mid-exponential phase (OD 2 ~ 3). Total RNA was purified by
using the Qiagen RNeasy mini kit (Cat # 74104, Qiagen Inc, CA, USA), and cDNA was
subsequently synthesized by the QuantiTect Reverse Transcription kit (Cat # 205311,
Qiagen Inc, CA, USA). To quantify mRNA expression level of genes (e.g., actin
(YALI0D08272g), P1, P2, and P3), rt-PCR run was performed using the QuantiTect SYBR
Green PCR kit (Cat # 204143, Qiagen Inc, CA, USA) and StepOnePlus™ Real-Time PCR
System (Applied Biosystems, CA, USA). Primers used for rt-PCR are listed in Table 2-2.
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The gene expression level was investigated after normalizing by the actin house-keeping
gene as described elsewhere (25).
Promoter characterization with hrGFP. Fresh colonies of Y. lipolytica promoter
constructs were grown in 2 mL of MpA medium containing 400 µg/L thiamine overnight.
Cultures were washed once with water and transferred into 25mL of MpA containing 5
µg/L thiamine overnight.

Finally, cells were washed twice with water before being

inoculated in MpA medium with various concentrations of thiamine. Incubation was
performed at 400 rpm and 28° using 96-well plates and Duetz-system covers (Cat#
SMCR1296, Kuhner, Switzerland). Sacrificial samples were collected for fluorescence
measurements (excitation at 485 nm and emission at 528 nm) using a synergy HT
microplate reader.
High performance liquid chromatography. Prior to HPLC run, 1 mL of culture
medium was filtered using 0.2 µm filters. Metabolites, substrates and products were
quantified by a Shimadzu HPLC system equipped with UV and RID detectors (Shimadzu
Scientific Instruments, Inc., MD, USA) and the Aminex 87H column (Biorad, CA, USA)
with 10 mN H2SO4 mobile phase at 0.6 mL/min flow rate. The column was maintained at
48 °C (25).
Proteomic analysis. Y. lipolytica were grown in biological triplicate in 0 and 400
µg/L thiamine. Samples were collected at two time points during the exponential growth
phase and processed for LC-MS/MS analysis. Whole-cell lysates were prepared by bead
beating in sodium deoxycholate lysis buffer (4% SDC, 100 mM ammonium bicarbonate,
pH 8.0) using 0.15 mM zirconium oxide beads and cell debris cleared by centrifugation
(21,000 x g for 10 min). Crude protein concentrations were measured by a NanoDrop
OneC (ThermoScientific) using absorbance at 205 nm. Samples were then adjusted to
10 mM dithiothreitol and incubated at 85 °C for 10 min to denature and reduce proteins.
Cysteines were alkylated/blocked with 30 mM iodoacetamide followed by 20 min
incubation at room temperature in the dark. Proteins (300 µg) were then transferred to a
10-kDa MWCO spin filter (Vivaspin 500, Sartorius) and digested in situ with proteomicsgrade trypsin (Pierce) as previously described (60). The tryptic peptide solution was then
filtered through the MWCO membrane by centrifugation (12,000 x g for 15 min), adjusted
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to 1% formic acid to precipitate SDC, and SDC precipitate removed from the peptide
solution with water-saturated ethyl acetate. Peptide samples were then concentrated to
dryness via SpeedVac, resolubilized in solvent A (5% acetonitrile, 95% water, 0.1% formic
acid), and measured by NanoDrop OneC A205 to assess tryptic peptide recovery.
Peptide samples were analyzed by automated 1D LC-MS/MS analysis using a
Vanquish UHPLC plumbed directly in-line with a Q Exactive Plus mass spectrometer
(Thermo Scientific) outfitted with a trapping column coupled to an in-house pulled
nanospray emitter. Both the trapping column (100 µm ID) and nanospray emitter (75 µm
ID) were packed with 5 µm Kinetex C18 RP resin (Phenomenex) to 10 cm and 30 cm,
respectively. For each sample, 3 µg of peptides were loaded, desalted, separated and
analyzed across a 210 min organic gradient with the following parameters: sample
injection followed by 100% solvent A chase from 0-30 min (load and desalt), linear
gradient from 0% to 25% solvent B (70% acetonitrile, 30% water, 0.1% formic acid) from
30-240 min (separation), followed by a ramp to 75% solvent B from 240-250 min (wash),
re-equilibration to 100% solvent A from 250-260 min and a hold at 100% solvent A from
260-280 min. Eluting peptides were measured and sequenced by data-dependent
acquisition on the Q Exactive MS as previously described (60).
MS/MS spectra were searched against the Y. lipolytica proteome concatenated
with common protein contaminants using Proteome Discover v.2.2 (ThermoScientific)
employing the CharmeRT workflow (61, 62). Peptide spectrum matches (PSM) were
required to be fully tryptic with 2 mis-cleavages; a static modification of 57.0214 Da on
cysteine (carbamidomethylated) and a dynamic modification of 15.9949 Da on methionine
(oxidized) residues. False-discovery rates, as assessed by matches to decoy sequences,
were initially controlled at < 1% at both the PSM- and peptide-levels. FDR-controlled
peptides were then quantified by chromatographic area-under-the-curve (AUC), mapped
to their respective proteins, and areas summed to estimate protein-level abundance.
Protein abundance distributions were then normalized across samples using InfernoRDN
(63) and missing values imputed to simulate the MS instrument's limit of detection using
Perseus (64). Significant differences in protein abundance were calculated separately for
each time point according to the following equation:
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Fold change =

WT_00t1,2 − WT_400t1,2
√0.25 + ∑ Variance⁄n

Here, WT_00 and WT_400 represent log2 normalized abundance of a protein in 0 and
400 µg/L thiamine, respectively. The denominator was used to account for error between
replicates. Variance represents the variance of protein abundance between replicates, n
represents the number of replicates, and 0.25 is the pseudo variance term (65). Proteins
with fold changes > |1| were classified as upregulated or downregulated. Pathway
annotations

were

performed

with

ClueGo

(66)

using

KEGG

(https://www.genome.jp/kegg/) database on proteins that were upregulated or
downregulated at both time points.
All raw and database-searched LC-MS/MS data pertaining to this study have been
deposited into the MassIVE proteomic data repository and have been assigned the
following

accession

numbers:

MSV000084437

(MassIVE)

and

PXD015747

(ProteomeXchange). Data files are available at ftp://massive.ucsd.edu/ MSV000084437.
Bioinformatics. Putative native Y. lipolytica thiamine-regulated promoters were
identified by BlastP (67) and orthologs search through the KEGG sequence similarity
database (https://www.kegg.jp/kegg/ssdb/). Reference genes used in this study were (i)
P. pastoris hydroxymethylpyrimidine phosphate synthase thi11 (PAS_chr4_0065) (68),
(ii) S. pombe 4-amino-5-hydroxymethyl-2-methylpyrimidine phosphate synthase nmt1
(NP_588347.1) (58), iii) S. pombe thiamine thiazole synthase nmt2 (NP_596642.1) (69),
and iv) S. cerevisiae thiamine thiazole synthase thi4 (NP_011660.1) (70).
Lipid quantification.

Thiamine-auxotrophic and thiamine-prototrophic strains

were cultured in 0 and 400 µg/L thiamine in MpA media in triplicates as outlined
previously. Lipid samples were taken from 100 µL samples of culture broth (i.e., cells and
supernatant) and incubated at room temperature for 15 minutes in the dark after addition
of 2 µL of 1 µg/mL BODIPY (cat # D3922, Fisher Scientific) (71) which stains neutral lipids
(e.g., triacylglycerols). Lipid standards were created by dissolving 100 mg of corn oil in
20mL ethanol and diluted from 1-.1 mg/mL prior to BODIPY staining procedure. Lipids
were measured using fluorescence (ex: 485 nm/em: 528 nm) and quantified from corn oil
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standards. For dry cell weight (DCW) measurement, 1mL of culture broth was sampled
from each replicate at each time point. Samples were centrifuged at maximum speed for
3 minutes and supernatant was discarded prior to drying samples at 55°C overnight.
DCW was calculated by subtracting the dried cell pellet and tube weight by the empty
tube weight. Finally, % lipid accumulation was calculated by dividing the measured lipid
mg/mL by DCW mg/mL. Statistical significance was calculated using SigmaPlot 14 with
one-way analysis of variance (ANOVA) with Holm-Sidak correction between 0 and 400
µg/L thiamine for each strain respectively. Symbols: “*”: p-value < 0.05.
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Appendix
Table 2-1 List of plasmids and strains.
Plasmids/strains
Plasmids
pSL16-CEN1-1-227
pSR001
pSR008
pSR005
pAT32y
pSR068
pSR071
pSR072
pSR073
pSR074
pSR075
Yeast strains
YlSR001

Description

Source

pSL16-CEN1-1-227
pSL16-PTEF-TCYC1::leu2
pSL16-PTEF-TCYC1::ura3
pSL16-hrGFP-TCYC1::leu2
pSL16-PTEF-hrGFP-TCYC1::leu2
pSL16-PNMT1-hrGFP::leu2
pSL16-PP1-hrGFP::leu2
pSL16-PP2-hrGFP::leu2
pSL16-PP3-hrGFP::leu2
pSL16-PTEF-THI13sce-TCYC1::ura3
pSL16-PP3-THI13sce-TCYC1::ura3

(54)
(26)
(23)
this study
this study
this study
this study
this study
this study
this study
this study

MATA
ura3-302
leu2-270
axp2-deltaNU49 XPR2::SUC2
YlSR001 + pSR001
YlSR001 + pSR008
YlSR001 + pAT32y
YlSR001 + pSR068
YlSR001 + pSR071
YlSR001 + pSR072
YlSR001 + pSR073
YlSR001 + pSR074
YlSR001 + pSR075

YlSR101
YlSR108
YlSR109
YlSR1001
YlSR1002
YlSR1003
YlSR1004
YlSR1005
YlSR1006

xpr2-322

ATCC MYA-2613
(26)
(23)
this study
this study
this study
this study
this study
this study
this study

Table 2-2 List of primers.
Genes

Primers

Sequences

Primers for plasmid construction
pSL16
pSL16_Fwd
GCCTGCACGAGTGGGTGTAATCATGTAATTAGTTATGTCACGCTTAC
pSL16_Rev
CAGGATCTGCTTGCTCACCATAGATCTGTTCGGAAATCAACGG
hrGFP
hrGFP_Fwd
AATCGGTTGAGCATCCGTTGATTTCCGAACAGATCTATGGTGAGCAAGCAGATCCTG
hrGFP_Rev
GTAAGCGTGACATAACTAATTACATGATTACACCCACTCGTGCAGG
PTEF
PTEF_Fwd
CATCCGTTGATTTCCGAACAGATCTAGAGACCGGGTTGGCGGCGTATTTG
PTEF_Rev
TTCAGGATCTGCTTGCTCACCATTTTGAATGATTCTTATACTCAGAAGGAAATGCTTAAC
PNMT1
PNMT1_Fwd
GCATCCGTTGATTTCCGAACAGATCTTTGTATTTCAAAGGACATAATCTAAAATAATAAC
PNMT1_Rev
GGTGTTCTTCAGGATCTGCTTGCTCACCATGATTTAACAAAGCGACTATAAGTCAGAAAG
PP1
PP1_Fwd
GGTTGAGCATCCGTTGATTTCCGAACAGATCTTGAAGTGGGTGAGTCGCCAATTATTC
PP1_Rev
CAGGCCGGTGTTCTTCAGGATCTGCTTGCTCACCATGATCGAATTGAGTCAGCGACG
PP2
PP2_Fwd
CGGTTGAGCATCCGTTGATTTCCGAACAGATCTCAGGTGGTAGCAGCCCAAGACAATG
PP2_Rev
GGTGTTCTTCAGGATCTGCTTGCTCACCATGAATTGACGAACAGGTGTTTTGATG
PP3
PP3_Fwd
CGGTTGAGCATCCGTTGATTTCCGAACAGATCTGAGGGGTAGTCGTAAGTTTCATC
PP3_Rev
CGGTGTTCTTCAGGATCTGCTTGCTCACCATGTTAATTGTAGGTGATATAAGGGGAAG
pSR005 pSR005_Fwd
ATGGTGAGCAAGCAGATCCTG
pSR005_Rev
AGATCTGTTCGGAAATCAACGGATGCTCAAC
THI13sce THI13sce_Fwd1 CATTTCCTTCTGAGTATAAGAATCATTCAAAATGTCTACAGACAAGATCACATTTTTG
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Table 2- 2 continued
THI13sce_Fwd2
CACCCTTCCCCTTATATCACCTACAATTAACATGTCTACAGACAAGATCACATTTTTG
THI13sce_Rev
GAATGTAAGCGTGACATAACTAATTACATGATTAAGCTGGAAGAGCCAATCTCTTG
pSR008
pSR008_Fwd
TCATGTAATTAGTTATGTCACGCTTAC
pSR008_Rev
TTTGAATGATTCTTATACTCAGAAG
pSR073
pSR073_Rev
GTTAATTGTAGGTGATATAAGGGGAAGG
Primers for checking and sequencing
hrGFP_seq hrGFP_Rev
CTTGCCGCAGCCCTCCATGG
TEF_seq
TEF(-100)_Fwd CACCGTCCCCGAATTACCTTTC
P3_seq
P3(-80)_Fwd
CTGCCGTAAATCACATACTGTCGGCTG
Primers for rt-PCR
Actin
Actin rt_Fwd
TCCAGGCCGTCCTCTCCC
Actin rt_Ref
GGCCAGCCATATCGAGTCGCA
P1
P1 rt_Fwd
AGGACAAGGAGCCTGCCAAG
P1 rt_Rev
GGAGGCAATGGCAGAGGCTA
P2
P2 rt_Fwd
TATGCAATCGGCCTCACCGA
P2 rt_Rev
CTTGCCCTCCAGCTGGTCTT
P3
P3 rt_Fwd
GCTGGCTCCTGTGGTCTCTC
P3 rt_Rev
GAACTGCTCGGCAGGCTTTC

Table 2- 3. Protein expression of thiamine-dependent enzymes at both exponentialgrowth time points.
Pathway

Glycolysis

Enzyme

PDH

Subunit

Locus
tag

Fold change
(time 1)

Fold change
(time 2)

E1

YALI0E27005g

-0.21

-0.43

E1
E2
E3

YALI0F20702g
YALI0D23683g
YALI0D20768g

0.02
-0.20
1.62

-0.33
-0.13
2.34

E1

YALI0E33517g

0.92

-0.64

Citrate cycle

KGDH

E2
E3

YALI0E16929g
YALI0D20768g

0.88
1.62

-2.26
2.34

PPP

TKL

N/A

YALI0E06479g

0.82

-0.34

E1-alpha

YALI0D08690g

2.84

1.58

E1-beta
E2
E3

YALI0F05038g
YALI0D23815g
YALI0D20768g

2.81
3.45
1.62

0.79
2.05
2.34

small
large

YALI0C09636g
YALI0C00253g

-0.63
-0.31

0
-0.89

Leucine,
isoleucine and
valine
metabolism

BCKDC

AHAS
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Table 2- 4. List of putative thiamine-regulated genes in Y. lipolytica. Abbreviations: PP:
P. pastoris, SC: S. cerevisiae, and SP: S. pombe.
Genes
thi11PP
nmt1SP
nmt2SP
thi4SC

Functions
4-amino-5-hydroxymethyl-2-methylpyrimidine phosphate synthase
4-amino-5-hydroxymethyl-2-methylpyrimidine phosphate synthase
thiamine thiazole synthase
thiamine thiazole synthase

Orthologs
YALI0E04224g (P1)
YALI0C14652g (P2)
YALI0A09768g (P3)
YALI0A09768g (P3)
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Pentose Phosphate
Pathway

Glycolysis

TKL

Pyruvate

AHAS
Branched
chain AAs

DNA, RNA,
Antioxidants,
Lipids, Purines,
Pyrimidines,
Aromatic AAs,
Folate

PDH

BCKDC

Acetyl-CoA

Lipids, Sterols

Electron
Transport
Chain

Succinyl-CoA TCA

KGA

KGDH
Figure 2- 1. Metabolic map of thiamine-dependent enzymes (green) in relationship to
central (black) and peripheral (blue) pathways. Abbreviations: TPP: thiamine
pyrophosphate dependent enzymes, PDH: pyruvate dehydrogenase enzyme complex,
KGDH: a-ketoglutarate dehydrogenase, TKL: transketolase, AHAS: acetolactate
synthase, BCKDC: branched chain α-ketoacid dehydrogenase, TPP: thiamine
pyrophosphate, AAs: amino acids, TCA: citrate (Krebs) cycle, KGA: alphaketoglutarate.dehydrogenase.
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Figure 2- 2. Growth characterization of the thiamine-auxotrophic Y. lipolytica YlSR001 in
0 (red), 0.5 (blue) and 400 (purple) µg/L thiamine. (A) Scheme of thiamine depletion
design experiments. (B) Cell growth profiles. (C) Glucose consumption profiles. (D) KGA
production profiles. (E) Pyruvate production profiles.
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Figure 2- 3. Proteomics of the thiamine-auxotrophic Y. lipolytica YLSR001 grown in 0
(red) and 400 (purple) µg/L thiamine.

(A) Growth profiles and proteomics samples

indicated by arrows. (B) Venn diagram representing upregulated and downregulated
proteins at both exponential time points. (C) Thiamine-responsive proteins on metabolic
pathways. Bar graphs represent the percentage of proteins upregulated in 0 (red) or 400
(purple) µg/L thiamine for each pathway (D) Electron transport chain and ATPase. (E)
Thiamine metabolism of Y. lipolytica. Enzymes: Thi4P (YALI0A09768p, thiamine thiazole
synthase),

Thi11p

(YALI0E04224p,

phosphate

synthase),

Thi6p

4-amino-5-hydroxymethyl-2-methylpyrimidine

(YALI0C15554p,

bifunctional

hydroxyethylthiazole

kinase/thiamine-phosphate diphosphorylase), PHO (YALI0A12573p, acid phosphatase),
Thi80p (YALI0E21351p, thiamine diphosphokinase), Thi13p (4-amino-5-hydroxymethyl2-methylpyrimidine phosphate synthase), and ADK (YALI0F26521p, adenylate kinase).
Abbreviations: PDH: pyruvate dehydrogenase enzyme complex, KGDH: a-ketoglutarate
dehydrogenase, TKL: transketolase, AHAS: acetolactate synthase, BCKDC: branched
chain

α-ketoacid

dehydrogenase,

TPP:

Thiamine

pyrophosphate,

HET-P:

hydroxyethylthiazole phosphate, HMP-PP: hydroxymethylpyrimidine pyrophosphate, TP:
thiamine monophosphate, TPP: thiamine pyrophosphate, TPPP: thiamine triphosphate.
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Figure 2- 4. Thiamine-responsive promoter characterization. (A) Chromosomal gene
expression of thiamine-responsive genes using rt-PCR. (B) hrGFP protein expression.
(C, D) Sensitivity of thiamine-responsive promoters in presence of increasing thiamine
concentrations.
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Figure 2- 5. Expression of pP3-scTHI13 in YlSR1006 restores the de novo thiamine
biosynthesis in Y. lipolytica. (A) Cell growth profiles. (B) Glucose consumption profiles.
(C) KGA production profiles. (D) Pyruvate production profiles. Growth characterization
was conducted in 0 (red), 0.5 (blue) and 400 (purple) µg/L thiamine. Abbreviations: KGA,
alpha-ketoglutarate.
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Figure 2- 6. Lipid production is influenced by thiamine availability. (A) Lipid accumulation
profiles for the thiamine-auxotrophic wildtype YlSR001 and thiamine-prototrophic strain
YlSR1006 in 0 and 400 µg/L thiamine. (B) Lipid accumulation profiles for thiamineauxotrophic and prototrophic strains in lipid production (C:N = 100) media with 0 and 400
µg/L thiamine. Statistical significance was calculated with one-way analysis of variance
(ANOVA) with Holm-Sidak correction between 0 and 400 µg/L thiamine for each strain
respectively. Symbols: “*”: p-value < 0.05.
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CHAPTER III
Co-expression Connectivity Predicts Genetic Targets Underlying
Solvent Tolerance in Yarrowia lipolytica
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Abstract
Microbial tolerance to solvents such as ionic liquids (ILs) is a robust phenotype beneficial
for effective bioconversion of renewable substrates to chemicals and fuels. While most
microbes become inhibited in 1%-5% (v/v) IL such as 1-ethyl-3-methylimidazolium
acetate ([EMIM][OAc]), we have recently created a robust Yarrowia lipolytica (YlCW001)
that can tolerate up to 18% (v/v) IL. Currently, genotypes conferring this high IL tolerance
in YlCW001 still remain to be discovered. By using dynamic RNA-sequencing data, we
formulated a novel co-expression connectivity metric capable of identifying key processes
affected by IL and genes conferring high IL-tolerance that might be overlooked by
traditional differential expression approaches. Upon exposure to IL, we found that the
wildtype increased expression of genes involved in mitochondrion process while the
mutant (YlCW001) upregulated genes associated with lipid metabolism. From the genes
upregulated by the mutant in IL, genetic targets were selected from genes upregulated
by the mutant in IL based on fold change, co-expression connectivity and gene ontology
associations.

Upon

characterizing

these

genetic

targets

using

single-gene

overexpression screening and dual-gene library enrichment selection, we identified the
best combination of non-intuitive genotypes conferring IL-tolerance. By validating these
genotypes in three Y. lipolytica isolates, we demonstrate this strategy is effective for
identification of genotypes underlying complex phenotypes.
Keywords: Yarrowia lipolytica; ionic liquid; solvent tolerance; resequencing; dynamic
RNA-sequencing; reverse engineering; co-expression connectivity; genetic targets.

Introduction
Biocatalysis in organic solvents has been widely studied for decades, offering a plethora
of unique strategies for substrate solubilization (1), enhanced enzymatic activity (2), and
product recovery (3). More recently, the use of ionic liquids (ILs) has emerged to replace
organic solvents in bioprocessing (4). Considered as green solvents, ILs offer a novel
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reaction medium for biotransformation with superior results in comparison to conventional
organic solvents due to their ability to dissolve a wider range of compounds and their
adjustable properties for enzyme stabilization and activation (e.g., lipases, alcohol
dehydrogenases, proteases, and oxidoreductases) (5). Importantly, ILs are a promising
biomass pretreatment technology that effectively reduces recalcitrance, achieving
efficient dissolution of lignocellulosic biomass and permitting enzymatic accessibility to
the sugar polymers (i.e., cellulose and hemicellulose) for saccharification (6-8).
Fermentation of the sugars released by IL pretreated biomass could be directly
assimilated by microbial cell factories if not for the toxic properties ILs impose on
microorganisms (9, 10). For these reasons, microbial high solvent tolerance is a desirable
phenotype for the conversion of renewable feedstocks to replace petroleum derived
chemicals and fuels.
While

most

studies

have

focused

on

isolated

enzymes,

whole

cell

biotransformation in ILs offers greater diversity of chemical products and biofuels with
improved economics due to the high cost of purified enzymes. Preceding screens for ILtolerant microorganisms identified the non-conventional oleaginous yeast, Yarrowia
lipolytica, as one of the top performers in benchmark IL, 1-ethyl-3-methylimidazolium
acetate ([EMIM][OAc]) (11). We further demonstrated the use of wildtype Y. lipolytica in
IL-pretreated cellulose by achieving 92% of the theoretical yield of alpha ketoglutaric acid
(KGA) in 10% (v/v) [EMIM][OAc] (12). More recently, we employed adaptive laboratory
evolution (ALE) to generate a platform strain with enhanced activity in high concentrations
of IL (18% (v/v) [EMIM][OAc]), which also outperformed wildtype Y. lipolytica in all
imidazolium-based ILs tested (13). We discovered the IL-robust mutant’s upregulation of
steroid biosynthesis gene expression and demonstrated sterols are critical to this
phenotype by overexpressing the steroid biosynthesis transcription factor and enhancing
the performance of wildtype Y. lipolytica in IL (13).
In this study, we aim to better understand the IL-tolerant phenotype of the mutant
strain using dynamic (i.e., time series) RNA-sequencing to identify key genotype(s)
conferring IL-tolerance. To effectively utilize dynamic transcriptomics data, we showcase
a new metric to facilitate selection of genetic targets and reduce the number of candidate
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genes for reverse engineering. Specifically, we investigate the efficacy of identifying
genetic targets conferring IL-tolerance by selecting the most connected genes from a coexpression network of upregulated genes in the IL-tolerant MT. By single and dual
overexpression of genes selected by fold change, connectivity, and ontology, we show
that connectivity is a promising metric to reveal key genotype(s) behind complex
phenotype(s) and use these genetic targets to reverse engineer high solvent-tolerance in
the Y. lipolytica clade.

Results
Genotype of the IL-tolerant evolved strain YlCW001
To connect genetic mutations with enhanced IL-tolerance, we re-sequenced the evolved
strain YlCW001 (MT) and analyzed the mutations.

Across the entire genome, we

detected a total of 648 variants but only 40 genes contained variants that caused an
amino acid change (Figure 3-1A). These 40 mutated genes (MGs) are randomly
distributed across the 6 chromosomes of Y. lipolytica and held a total of 68 mutations
(i.e., variants) including 35 single nucleotide variants (SNV), 12 deletions, 11 multiple
nucleotide variants (MNV), 8 insertions and 2 replacements (Figure 3-1B). The most MGs
were located in chromosome A (13 MGs) followed by chromosome E (9 MGs) and
chromosome F (7 MGs) while the remaining chromosomes contained between 5 and 3
MGs (Figure 3-1A). By performing gene ontology (GO) associations for the 40 MGs using
cluego, IMG, and blastP against Saccharomyces cerevisiae, we were able to assign the
functional annotations for 68% of the MGs (Figure 3-1C). Kinases represent the most
abundant GO terms containing 3 MGs, followed by transporters, transcription factors,
mRNA processing, regulation, nuclear pore complex and membrane components (2 MGs
each).
Basal gene expression differences between the WT and MT strains without IL
exposure
We first examined the basal changes in gene expression between the WT and MT strains
growing in medium without IL (Figure 3-2A). Temporal RNAseq data for both the WT and
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MT strains were collected at the early and mid-exponential growth phases and subjected
to the gene classification analysis. The results identified 470 upregulated genes and 88
increasing genes in the MT strain relative to the WT strain cultured without IL (Figure 32B). These genes with greater expression in the MT strain were annotated for
mitochondrion, nucleus, chromosome, membrane protein complex, microbody,
respirasome and transmembrane signal receptors (Figure 3-2C). For the WT strain, this
resulted in 329 upregulated genes and 167 increasing genes relative to the MT strain
cultured without IL (Figure 3-2B). These genes were involved in cell periphery, cell cortex,
cell wall organization/biogenesis, endoplasmic reticulum, and the Golgi apparatus (Figure
3-2C). Interestingly, 5 of the MGs were differentially expressed between the MT and WT
cultured without IL. The MT upregulated 3 of these MGs involved in ribosomal biogenesis
(YALI0B08734g), mRNA binding (YALI0F12375g) and 1 gene of unknown function
(YALI0C13002g) while the WT upregulated an expansin-like protein (YALI0E17941g) and
a mitogen-activated protein kinase (YALI0A18590g).
IL-responsive gene expression
Wildtype response. Next, we aimed to understand gene expression changes for
the WT strain exposed to IL (Figure 3-3A). This RNA-seq pairwise set lead to the greatest
perturbation of gene expression relative to all other data sets with only ~62% of genes
classified as no change. This resulted 365 upregulated- and 240 increasing genes for
the WT growing in 8% (v/v) IL (Figure 3-3B). These IL-induced genes were enriched for
mitochondrion (including mitochondrial transmembrane transport and respirasome),
genetic processing (i.e., nucleus, chromosome, chromatin-binding/regulation, DNAbinding transcription factors, ribosome, and signal transduction), microtubule processing,
and microbody (Figure 3-3C). In contrast, 365 upregulated- and 240 increasing genes
were identified for the WT cultured without IL (Figure 3-3B). However, only 3 annotated
processes were enriched more than 2-fold which included cell cortex, cell wall
organization/biogenesis and the endoplasmic reticulum (Figure 3-3C).
Mutant response. Likewise, we compared gene expression changes for the MT
strain exposed to IL (Figure 3-4A).

The gene classification analysis identified 564
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upregulated- and 385 increasing genes for the MT strain growing in 8%(v/v) IL relative to
the MT strain without IL (Figure 3-4B). These IL-induced genes for the MT strain were
enriched for lipid processes (i.e., membrane, cellular lipid metabolic process, membrane
traffic protein, Golgi apparatus, endoplasmic reticulum), cell periphery (including cell
cortex, cytoskeleton and microtubule process), intracellular vesicles (i.e., vacuole,
cytoplasmic vesicle, vesicle-mediated

transport),

and

genetic processes

(i.e.,

chromosome, chromatin/chromatin-binding/regulator, DNA-binding transcription factor,
signal transduction) (Figure 3-4C).

The MT strain cultured without IL lead to 668

upregulated- and only 50 increasing genes (Figure 3-4B).

These gene sets were

annotated for anion and mitochondrial transmembrane transport, respirasome and the
ribosome (Figure 3-4C). This pairwise set also identified 9 of the MGs among the
classified genes. Of these, 5 were upregulated in IL (YALI0A18381g, YALI0B04268g,
YALI0B18194g, YALI0F12793g, YALI0E07139g), 2 were increasing in IL (YALI0C16247g
and YALI0F16665g), 1 was upregulated without IL (YALI0F16665g) and 1 gene was
classified with changed regulation (YALI0F08107g).
Enhanced IL-responsive gene expression
Mutant enhanced IL-response. We reasoned that the best candidates for reverse
engineering high solvent tolerance would be found by comparing WT and MT gene
expression in IL (Figure 3-5A). Our gene classification of time series RNAseq data
revealed 202 over expressed- and 319 increasing- genes for the MT strain in IL relative
to the WT strain in IL (Figure 3-5B). These genes used by the MT were associated with
lipid processes (i.e., membrane, membrane traffic protein, Golgi apparatus, endoplasmic
reticulum),

cell

periphery

(including

cell

cortex,

cytoskeleton,

cell

wall

organization/biogenesis and microtubule process), intracellular vesicles (i.e., vacuole,
cytoplasmic

vesicle,

vesicle-mediated

transport)

and

genetic

processes

(i.e.,

chromosome, chromatin/chromatin-binding/regulator and signal transduction) (Figure 35C). The WT upregulated 327 genes and increased 223 genes relative to the MT when
both strains were cultured in IL for the MT (Figure 3-5B). These genes dominated by the
WT were associated with mitochondrion, mitochondrial transmembrane transport,
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respirasome and the ribosome (Figure 3-5C). Interestingly, 8 of the MGs were identified
in the classified genes.

Four of these were classified as changed regulation

(YALI0A13233g, YALI0A18381g, YALI0C13002g and YALI0F23287g), 3 were increased
by the MT (YALI0A09108g, YALI0C16247g and YALI0F16665g) and 1 was upregulated
by the MT (YALI0E07139g).
A new metric to select genetic targets for reverse engineering. Traditionally,
genetic targets are selected based on greatest fold change between strains or conditions
and/or gene ontology if the system is well understood. However, our analysis identified
202 candidate genetic targets that were upregulated across 2 time points by the MT in IL
relative to the WT in IL (Figure 3-5B) that varied in fold change across the two time points.
Further, gene ontology associations for the many of these genes are vague and ILtolerance is not a fully understood mechanism in Y. lipolytica. For these reasons, we
sought another metric to help narrow the candidate list of genetic targets.
We began exploring the co-expression network of the genes differentially
expressed and regulated between the MT and WT strains in IL and found interesting
network topology where each group of classified genes showed tight co-expression
(Figure 3-6A). In other words, genes that were upregulated or increased by the MT in IL
were separated from genes that were upregulated or increased by the WT in IL and these
gene clusters were connected by genes classified as changed regulation. Since coexpressed networks of genes is often used in systems biology to infer or explain a
relationship, we hypothesized that genes with greater connectivity in the subnetwork of
upregulated genes by the MT in IL would be the most influential genes conferring ILtolerant phenotype of the MT strain. In other words, we hypothesized that gene coexpression connectivity could be a metric to predict the best genetic targets conferring ILtolerance from these 202 upregulated genes (Figure 3-6B).
Selection of genetic targets. For each of the 202 genes upregulated by the MT
in IL, the average fold change between the 2 transcriptomics time points (i.e., X (early)
and Y (mid) scores) and the degree of each gene from the co-expression subnetwork
(i.e., containing only the 202 genes upregulated by the MT strain in IL relative to the WT
in IL) was calculated (Figure 3-6B). These genes were divided into 4 quadrants based
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on the 75th percentile of average fold change and on the 75th percentile of degree.
Quadrant 1 represents genes that were in the 75th percentile of both average fold change
and degree, quadrant 2 represents genes that belong only in the 75 th percentile of degree,
quadrant 3 represents genes that were not in either 75th percentiles of degree or average
fold change, and quadrant 4 represents genes that belong in both 75 th percentiles of
degree and average fold change (Figure 3-6C). We then selected genetic targets from
the following target groups: the top 5 genes based on average fold change (quadrant 4);
the top 5 genes based on degree (quadrant 2); the top 5 genes based on average fold
change overlapping with degree (i.e., overlap by fold change, quadrant 1); the top 5 genes
based on degree overlapping with average fold change (i.e., overlap by degree, quadrant
1); and 9 genes based on gene ontology associations related to membrane, transport,
kinase, cell wall and myosin complex (quadrants 1, 2 and 4) (Figure 3-6C).
Single gene overexpression. Each of the 29 selected genetic targets were tested
for their efficacy in conferring IL-tolerance by individually overexpressing each gene in
the WT strain and phenotype characterization in 11% IL (Figure 3-7). In this extremely
harsh concentration of IL, genes chosen from overlap by degree exhibited the best cell
growth in IL among all the other target groups except genes chosen by GO term (Figure
3-7A). Of all the target groups, only 6 of genes caused a decrease in cell mass including
3 genes chosen from overlap by fold change (#1, #2 and #4), 2 genes chosen by GO
terms (#21 and #27), and 1 gene chosen by degree (#19).
Six genes exhibited a statistical increase in cell mass in this high concentration of
IL (#23, #10, #9, #25, #8 and #28). Interestingly, these genetic targets were selected
from only 2 target groups of genes chosen from i) overlap by degree and ii) GO
association (Figure 3-7B). The 3 genes conferring enhanced IL-tolerance chosen from
overlap by degree included a membrane traffic protein (#8, YALI0B22396g), a kinase
activator (#9, YALI0B15180g) and a microtubule binding motor protein (#10,
YALI0F02673g). The 3 genes exhibiting increased IL-robustness selected by GO terms
were annotated as an integral component of the membrane (#23, YALI0B12738g), a
mitogen activated kinase (#25, YALI0D19470g), and a heavy chain myosin (#28,
YALI0F13343g).
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Discussion
ILs inhibit microbial catalytic activity by affecting numerous cellular processes and
components which makes IL-tolerance a difficult phenotype to engineer.

Currently,

reverse engineering complex phenotypes requires extensive characterization to
understand key mechanisms and often leads to numerous genetic targets for further
experimentation.

Here, we aimed to facilitate reverse engineering IL-robustness by

exploiting a superior IL-tolerant MT strain and using co-expression to predict genetic
targets. By comparing transcriptomes between WT and MT strains in IL, we discovered
the best genetic targets were predicted using co-expression connectivity in conjunction
with differential expression and found key cellular processes underlying the superior ILtolerant phenotype of the MT strain.
The drastic differences in gene expression between WT and MT strains even when
cultured without IL (Figure 3-2B) indicates that the mutations (Figure 3-1) acquired
through 200 generations of ALE irreversibly changed basal regulation of gene expression
in the MT strain. However, the significant differences in basal gene expression are likely
governed by changes in epigenetics and mutations in non-coding DNA regions (e.g.,
promoters) since only 5 of the mutated genes were found differentially expressed.
Upon exposure to IL, only the WT increased expression of genes associated with
mitochondrion processes (i.e., respirasome and mitochondrial transmembrane transport)
(Figure 3-3C) suggesting ILs hinder mitochondrial function and oxidative phosphorylation.
Interestingly, ILs interfered with ion transport across the mitochondrial membrane,
negatively affecting mitochondria function and membrane potential in S. cerevisiae (14).
In

contrast,

the

WT

repressed

genes

associated

involved

in

cell

wall

organization/biogenesis (Figure 3C) which explains the reduced cell wall chitin content
when Y. lipolytica is exposed to IL (13).
The MT strain, however, induced expression of genes associated with lipid
metabolism (e.g., membrane, endoplasmic reticulum, Golgi apparatus, membrane traffic
proteins, cytoplasmic vesicle, etc.) (Figure 3-4C) which is supported by our previous
discovery that biogenesis of sterols is critical for IL-tolerance in Y. lipolytica. These results
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postulate other lipid metabolic processes (e.g., vesicle-mediated transport) underlying the
superior IL-tolerance of the MT strain as seen by that the drastic remodeling of lipid
composition in IL (13). Both WT and MT strains responded to IL by increasing expression
of genes associated with genetic processing (i.e., chromatin-binding/regulation,
chromosome, transcription factors, and signal transduction) (Figure 3-3C, 3-4C)
indicating ILs severely affect gene regulation and signal transduction.
Aiming to understand genotype(s) conferring high solvent tolerance, we reasoned that
the best gene candidates would be found by comparing WT and MT expression in IL.
Most of the genetic targets increased cell mass in IL indicating our strategy of exploiting
genes used by the MT strain in this comparison was successful, though we did not test
genes from other pairwise comparisons (e.g., WT 8% IL vs. WT 0% IL). Strikingly, coexpression connectivity (i.e., overlap by degree) had the highest statistical prediction of
IL-tolerant genetic targets (Figure 3-7A). Though limited by the number of genes tested
in our study, this metric is a promising approach to predict genetic targets for reverse
engineering other complex phenotypes. While co-expression networks have been used
to infer gene function, gene association and gene regulation, this is the first study where
co-expression was used a metric to select genetic targets for reverse engineering to our
knowledge.
Unfortunately, the top 6 performing genetic targets have not previously been
characterized in Y. lipolytica but these genes have orthologs in the model yeast S.
cerevisiae except for #23. TRS23 (#8, YALI0B22396g) is associated with regulation of
traffic from endoplasmic reticulum to Golgi and autophagy. CLB5 (#9, YALI0B15180g) is
a non-essential B-type cyclin involved in replication of DNA whereby deletion increases
sensitivity to rapamycin, caffeine, hydroxyurea, doxorubicin, and many other chemicals.
CIN8 (#10, YALI0F02673g) is a non-essential kinesin motor protein involved in mitotic
spindle assembly and chromosome segregation. Cells deleted for CIN8 in S. cerevisiae
exhibited abnormally large cell size, poor growth, increased mitophagy and increased
sensitivity to heat and various chemicals. SPS1 (#25, YALI0D19470g) is required for
prospore membrane closure. Finally, MYO1 (#28, YALI0F13343g) is a class II myosin
heavy chain that plays a critical role in cytokinesis.
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To further validate our methodology, we duplicated the 29 genetic target
overexpression plasmids with a different selection marker and combined the 2 sets of 29
overexpression plasmids into a library stock at equimolar concentrations. This library was
transformed into Y. lipolytica and 3 biological replicate transformants were enriched in
0%, 12% and 13% (v/v) IL for 2 rounds. We are currently sequencing the enriched
cultures to identify combinations of genes enriched by IL and hence responsible for
increased IL-tolerance. Additionally, we plan to validate the most enriched combinations
of genes by overexpressing them in 3 Y. lipolytica isolates. We expect these results to
successfully and universally reverse engineer high solvent tolerance in the Y. lipolytica
clade and further establish utilization of co-expression connectivity as a metric for
predicting genotypes underlying robust phenotypes.

Materials and Methods.
Strains
The Y. lipolytica strain, ATCC MYA-2613, a thiamine, leucine, and uracil auxotroph, was
purchased from American Type Culture Collection and used as the parent strain (WT).
The evolved strain YlCW001 (MT) was isolated after 200 generations in gradually
increased concentrations of [EMIM][OAc] up to 18% (v/v) (13). The TOP10 Escherichia
coli strain was used for molecular cloning. IL-gene overexpressing genes were generated
by transforming constructed plasmids into the WT Y. lipolytica strain via electroporation
(15).
Plasmids
The plasmid pSR001 (12) (harboring leucine selection marker, TEF promoter and CYC1
terminator) was used as the backbone plasmid for individual IL-gene overexpression
cassettes. pSR001 was linearized by PCR amplification and each genetic target was
amplified from Y. lipolytica genomic DNA.

Plasmids were constructed with Gibson

assembly (16) using the linearized pSR001 backbone and each individual amplified ILgene. The complete list of primers, plasmids and strains are presented in Table 3-1.
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Medium and culturing conditions
Growth medium. All cultures were conducted in defined media containing 6.7 g/L of yeast
nitrogen base without amino acids (cat# Y0626, Sigma-Aldrich, MO, USA), 20 g/L of
glucose, 380 mg/L leucine (cat# 172130250, Acros Organics, CA, USA), 76 mg/L uracil
(cat# 157301000, Acros Organics, CA, USA), and various concentrations of 1-ethyl-3methylimidazolium acetate [EMIM][OAc] (>95 % purity) (IoLiTec, AL, USA).
Analytical methods
Variant detection (mutation analysis). Resequencing quality filtered reads of WT
(GCA_009372015.1) and MT (GCA_009194645.1) strains from whole genome
resequencing (17) were subjected to variant detection within the CLC genomic workbench
software version 11.0.1 (https://www.qiagenbioinformatics.com/) using the reference
genome Clib122 (GCA_000002525.1) (18). Types of nucleotide changes are classified
in different categories including single nucleotide variances (SNV), multiple nucleotide
variants (MNV), insertions, deletions, and replacements.
RNA-sequencing. Samples were collected in biological triplicates for RNAsequencing from wildtype (WT) and evolved mutant YlCW001 (MT) strains at early- and
mid-exponential growth phases in 0% and 8% (v/v) [EMIM][OAc].

Samples were

immediately quenched in liquid nitrogen and stored at -80°C until RNA isolation. Total
RNA was purified using the Qiagen RNeasy mini kit (cat #74104, Qiagen, CA, USA) prior
to submission at the Joint Genome Institute (JGI) using Illumina sequencing. Filtered
RNA-seq reads were analyzed within the CLC genomics workbench version 11.0.1
(https://www.qiagenbioinformatics.com/) using RNA-seq analysis tool to produce
transcripts per million (TPM) values for each gene/sample which was used for all further
transcript-analyses.
Gene expression classification. Gene TPM values were floored to a value of 5
and averaged into log2-scaled values to compare biological conditions (BC) in the
following pairwise sets: i) MT 0% IL versus WT 0% IL, ii) WT 8% IL versus WT 0% IL, iii)
MT 8% IL versus MT 0% IL, and iv) MT 8% IL versus WT 8% IL (Figure 3-8 Step 1). For
each pairwise set, X (i.e., early exponential fold change), Y (i.e., mid exponential fold
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change) and Z (i.e., genes that are regulated differently during exponential growth) scores
were calculated for each gene (Figure 3-8 Step 2). For each equation, the numerator
calculates fold changes while the denominator accounts for error by dividing the fold
change by the square root of pseudo variance (0.25) and the summation of variance (V)
divided by respective number of replicates for each sample in the numerator.
Next, genes were categorized based on the values of X, Y and Z into 1 of 6 classes:
BC1 upregulated, BC1 increasing, BC2 upregulated, BC2 increasing, changed regulation,
and no change (Figure 3-8 Step 3). The upregulated class represents genes with greater
expression values at both early- and mid-exponential samples (i.e., X and Y values). The
increasing class represents genes without a significant change in expression value at the
early-exponential sample (i.e., X) but a greater expression value at mid-exponential
sample (i.e., Y). The changed regulation class represents genes that were neither
upregulated nor increasing but with a regulation score greater than 1.5 (i.e., Z). The no
change class represents genes that failed to meet the requirements of upregulated,
increasing or changed regulation classifications.
Gene ontology enrichment. Gene ontology (GO) for genes containing variants
identified from resequencing (i.e., mutated genes) were identified using ClueGo (19),
integrated microbial genomes (IMG) (20) and blastP against model yeast S. cerevisiae
with E-value < 1 E-10. Annotations were combined and curated manually to classify
mutated gene ontology.

GO terms associated with classified genes were manually

retrieved from Panther database (21) and mapped to classified genes to calculate the
number of genes associated with each annotation term. GO terms were defined as
enriched if the sum of upregulated and increasing genes in an annotation term were equal
to or greater than double the sum of upregulated and increasing genes between the two
biological conditions in each pairwise data set.
Correlation network construction and genetic targets selection. Pearson
correlation was conducted on early- and mid-exponential WT 8% IL and MT 8% IL
sample-gene TPM values using a stringent cutoff of 0.95. Next, this correlation network
was reduced by removing all genes except those classified as upregulated by the MT 8%
IL in pairwise set iv (i.e., MT 8%IL vs WT 8%IL) and used to calculate degree. These
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genes were ranked according to their degree and their average fold change between the
two transcriptomic time points (i.e., average of X and Y scores) and the 75 th percentiles
were calculated for both criteria. Finally, we chose 29 genetic targets (i.e., IL-genes) from
the top 5 genes ranked by fold change, the top 5 genes degree, the top 5 genes
overlapping in both 75th percentiles by fold change, the top 5 genes overlapping in both
75th percentiles by degree, and 9 genes in the 75th percentiles of either criterion with
relevant gene ontology terms (e.g., membrane, kinase, transport, cell wall and myosin
complex).
Statistics. One-way analysis of variance (ANOVA) with Holm-Sidak correction
was used for all statistical analyses with SigmaPlot v.14 software.
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Appendix
Table 3- 1. Primers used for genetic target overexpression.
Gene ID

Locus Tag
N/A

pSR001

#1

N/A

YALI0E10417g

Primer
2

TTTGAATGATTCTTATACTCAGAAG

3
79

TCATGTAATTAGTTATGTCACGCTTAC

91
80

#2

YALI0C21758g

92
81

#3

YALI0B16324g

93
82

#4

YALI0D08118g

94
83

#5

YALI0E00792g

95
84

#6

YALI0F06402g

96
85

#7

YALI0E07491g

97
86

#8

YALI0B22396g

98
87

#9

YALI0B15180g

99
88

#10

YALI0F02673g

100
89

#11

YALI0C03377g

101
90

#12

YALI0E12419g

102
103

#13

YALI0E21549g

115
104

#14

YALI0E17545g

Sequence

116

ccttctgagtataagaatcattcaaaATGCGCGCCATTGAGGGCCTGGGC
gcgtgacataactaattacatgaTTAGAAACCGGTGAAGCCCGACTGCATGGAG
ccttctgagtataagaatcattcaaaATGTCTCGACAAAAAAAATCGCGAGAAATCC
GG
gcgtgacataactaattacatgaTTAAGATGCAGAAACTCTTGACCGTCGTCGG
ccttctgagtataagaatcattcaaaATGTCGAACAAGCCTCGAGACCTGCCCGAG
CC
gcgtgacataactaattacatgaTTACTGTTGGCCAGTGAGCCCCTGGTGTCTTT
TGAGG
ccttctgagtataagaatcattcaaaATGCCAATATTTGGGTATTACCGCTTTGGG
gcgtgacataactaattacatgaTTACAATCTCTCAACAGGCCCCTCGAAATCAG
CCTC
ccttctgagtataagaatcattcaaaATGCTATCCACGTGTGCTTCCAATCTCGAGA
AGC
gcgtgacataactaattacatgaCTACCGGACCACTGGTTTGGCGATACGCACG
ccttctgagtataagaatcattcaaaATGTCGGAATTCATTCTCAACGAGGTGTACA
CAG
gcgtgacataactaattacatgaTTAGACCTTACCCACCACCTTGAAACCCTCGG
C
ccttctgagtataagaatcattcaaaATGGAGTCTTCTATTTCAGTGGCCGTCAGAG
TAC
gcgtgacataactaattacatgaCTACTGTGTCACCCTCTGGGGCATCCCCAGC
ccttctgagtataagaatcattcaaaATGACCGTGTATGCACTCTACATTCTCAACA
AAG
gcgtgacataactaattacatgaCTAGCTCACCGACTCGAGGTACTTGTTGAGAT
GCAGG
ccttctgagtataagaatcattcaaaATGAACTTTCCAGTGAGTACTAATGACCCGG
AC
gcgtgacataactaattacatgaTTAGATAAATAGGTTAGTTTCGTAAGAATTGAC
ACC
ccttctgagtataagaatcattcaaaATGTCTTCGCGCCACAACAGTTTGGGAATGA
GG
gcgtgacataactaattacatgaCTACTGCTTTCTATACTTCCTCGGAGGCACCAA
CCTG
ccttctgagtataagaatcattcaaaATGTCGACAAAATCGCCTGTCACTCCTCGAT
ACG
gcgtgacataactaattacatgaCTATCTAATACCCACAGTGGAAATCTCCTTGCT
CTGG
ccttctgagtataagaatcattcaaaATGACACAGATTATCCATAACGCCACCATCC
CC
gcgtgacataactaattacatgaTTACAGCTTGGCCTTGTTGAGACCCAGAACAA
CATCG
ccttctgagtataagaatcattcaaaATGAAAATCGGCGGTCTGTGGAAAAAATTCC
CCG
gcgtgacataactaattacatgaTTACTGAAAGTAAGTTCTCACTCTCTGTTGAAT
GGC
ccttctgagtataagaatcattcaaaATGCTCAAGCAACTGGAAAATATTCTTGAGT
CGC
gcgtgacataactaattacatgaCTACAACCGCCCTCTCATCTCCTTCTGAGAAT
GCC
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Table 3-1 continued
105
#15

YALI0C21296g

117
106

#16

YALI0A18722g

118
107

#17

YALI0B03476g

119
108

#18

YALI0D16247g

120
109

#19

YALI0E34852g

121
110

#20

YALI0F27423g

122
111

#21

YALI0D12232g

123
112

#22

YALI0C08096g

124
113

#23

YALI0B12738g

125
114

#24

YALI0C18183g

126
127

#25

YALI0D19470g

132
128

#26

YALI0C21802g

133
129

#27

YALI0B09273g

134
130

#28

YALI0F13343g

135
131

#29

YALI0E29557g

136

ccttctgagtataagaatcattcaaaATGGACACTCCGACCCGTCCCCGAGCCGAT
CTG
gcgtgacataactaattacatgaCTACACCTTCAGTTTGGCCTCAAGCTTCATAAA
ATCC
ccttctgagtataagaatcattcaaaATGTCACTTCCATACGCCCCACTAACCCATA
TGC
gcgtgacataactaattacatgaCTAATCTAGTTCTGCAAAGAAACCCTTGTAAG
ccttctgagtataagaatcattcaaaATGGCAAGACCAGCTCGACGACGGTCTTCC
GG
gcgtgacataactaattacatgaTTATGCTCCCAGCTGATCCAGGCGAACATTCA
TATCC
ccttctgagtataagaatcattcaaaATGACACAAACGCACAATCTGTTTTCGCCAA
TC
gcgtgacataactaattacatgaTTACATCTTGTACGCAGGGTAATCAGTGTAGC
CC
ccttctgagtataagaatcattcaaaATGAAGTTCCTCGTTTGTCTTCTGGTTCTGG
CGC
gcgtgacataactaattacatgaTTAAACCAAAGTCTTGACCTCAAAGAATCGC
ccttctgagtataagaatcattcaaaATGTTTGGCATCTTTTCGCGCATTCCCGTGG
AGC
gcgtgacataactaattacatgaCTAACTGCTCGTAGTGGCCACCTCAACAGGCT
CG
ccttctgagtataagaatcattcaaaATGATCATCAGCCTGACTGTGACCGTTAAAA
CG
gcgtgacataactaattacatgaTCAAACAACCTCTTCTCGGACAAAGCCCCGGC
ccttctgagtataagaatcattcaaaATGGAGCACTTCACTGCGCACGATGGGTCG
TTCC
gcgtgacataactaattacatgaTTACATAATAACACAATCGTCGGCCTCCTTGGT
CACC
ccttctgagtataagaatcattcaaaATGGACACGAAACGAAGCCTTTCAGGGGCT
CCCC
gcgtgacataactaattacatgaCTACCTCGTCAGACCAACTCCTAATCCTACCG
ccttctgagtataagaatcattcaaaATGTTGCCACGAGCCCTGAGTCGCCACGTG
G
gcgtgacataactaattacatgaCTACTTATAGTCTGCGACTTCTTCAACGTCACC
AGGG
ccttctgagtataagaatcattcaaaATGGCATCGGCAAGCTCAGAACTATCACGG
CTGG
gacataactaattacatgaCTAGTAACGATCGTACTCTTCGAACTCCTCGATCC
ACCG
ccttctgagtataagaatcattcaaaATGAAGCTCGAAATCAAGGTGAGTAATTGAG
CG
gcgtgacataactaattacatgaTTACAAGGTGTTGGCAGCCTCATCAACCTCCT
CC
ccttctgagtataagaatcattcaaaATGCCTTCCGAATCCACCCCTCTCATTGGCC
GAC
gcgtgacataactaattacatgaTTACATATCCGAGGGATAGTAGAAGAAGGCAA
TGGCG
ccttctgagtataagaatcattcaaaATGTGCGTGATGATGTTTTGTTTCAGCTGGA
TTG
gcgtgacataactaattacatgaTTAAACAAAGGAGGGCTCAAAGTTGGAGTTGT
TGTTG
ccttctgagtataagaatcattcaaaATGTCGGAACATTCGTTTGCCAACAACTTTT
GGG
gcgtgacataactaattacatgaCTAAATGTCAGCCAAAAAGTTGCTGGGAGCTA
GACC
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Figure 3- 1. Mutated genes of IL-tolerant mutant (MT, YlCW001) Y. lipolytica which
include 68 variants across 40 genes that change amino acid residues. (A) Chromosomal
location of mutated genes depicting log2 fold changes at the mid-exponential RNA-seq
sample between the MT in 8% [EMIM][OAc] verses WT in 0% IL (purple), WT in 8% IL
(blue) and MT in 0% IL (green). (B) Types of variants in the mutated genes. (C) Gene
ontology of the mutated genes.
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Figure 3- 2. Basal differences in gene expression between the MT and WT in 0% IL. (A)
Growth of MT and WT in 0% IL. (B) Distribution of classified genes. (C) Number of
classified genes in each category of gene ontology. Stars represent ontology terms where
the sum of upregulated and increasing genes in a biological condition is at least twice
greater than the other biological condition.
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Figure 3- 3. IL-responsive gene expression of the WT strain. (A) Growth of WT in 8%
and 0% IL. (B) Distribution of classified genes. (C) Number of classified genes in each
category of gene ontology. Stars represent ontology terms where the sum of upregulated
and increasing genes in a biological condition is at least twice greater than the other
biological condition.
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Figure 3- 4. IL-responsive gene expression of the MT strain. (A) Growth of MT in 8%
and 0% IL. (B) Distribution of classified genes. (C) Number of classified genes in each
category of gene ontology. Stars represent ontology terms where the sum of upregulated
and increasing genes in a biological condition is at least twice greater than the other
biological condition.
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Figure 3- 5. Enhanced IL-responsive gene expression of the MT strain verses the WT
strain in 8% IL. (A) Growth of MT and WT in 8% IL. (B) Distribution of classified genes.
(C) Number of classified genes in each category of gene ontology. Stars represent
ontology terms where the sum of upregulated and increasing genes in a biological
condition is at least twice greater than the other biological condition.
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Figure 3- 6. (A) Correlation (Co-expression) network of classified genes between the MT
and WT in 8% IL. (B) Subnetwork of co-expressed genes upregulated by the MT in 8%
IL illustrating gene connectivity by degree. (C) Genetic targets selected by degree, fold
change or gene ontology.
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Figure 3- 7. Individual overexpression of genetic targets in 11% IL. (A) Box and whisker
plot for each group of genetic targets depicting all replicate maximum OD 600nm for all
associated genes contained within each group. (B) Max OD600nm for genetic targets
cultured in 11% IL. *p-value ≤ 0.05 (n ≥ 9 for each gene and n=27 for the empty vector
control).
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Figure 3- 8. Gene classification methodology. Step 1: For each pairwise set of biological
conditions, gene TPM values are floored to a minimum of 5, averaged, and converted into
log2 scale. Step 2: Fold change (X and Y) and regulation (Z) scores are calculated
between biological conditions. Step 3: Genes are classified based on the scores of X, Y
and Z into upregulated or increasing for a biological condition, changed regulation, or no
change.
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Chapter IV
Exploring Proteomes of Robust Yarrowia lipolytica Isolates Cultivated
in Biomass Hydrolysate Reveal Key Processes Impacting Complex
Sugar Utilization, Lipid Accumulation, and Degradation
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ABSTRACT
Yarrowia lipolytica is an oleaginous yeast exhibiting robust phenotypes beneficial for
industrial biotechnology. The phenotypic diversity found within the undomesticated Y.
lipolytica clade from various origins illuminates desirable traits not found in the wellcharacterized laboratory strain CBS7504, which include superior xylose utilization, lipid
accumulation, and growth on undetoxified biomass hydrolysates. Currently, the related
phenotypes of lipid accumulation and degradation when metabolizing non-preferred
sugars associated with biomass hydrolysates (i.e., xylose) are poorly understood, making
it difficult to control and engineer in Y. lipolytica. To fill this knowledge gap, we analyzed
the genetic diversity of five undomesticated Y. lipolytica strains and identified singleton
genes and genes exclusively shared by strains exhibiting desirable phenotypes including
superior growth, xylose utilization, lipid accumulation and/or degradation properties in
undetoxified biomass hydrolysates. Strain characterizations from controlled bioreactor
cultures revealed that the unconventional strain YB420 used xylose to support cell growth
and maintained high lipid levels while the laboratory strain CBS7504 degraded cell
biomass and lipids when xylose was the sole remaining carbon source. From proteomic
analysis, we identified carbohydrate transporters, xylose metabolic enzymes and pentose
phosphate pathway proteins stimulated during the xylose uptake stage for both strains.
Furthermore, we distinguished proteins in lipid metabolism (e.g., lipase, NADPH
generation, lipid regulators, β-oxidation) activated by YB420 (lipid maintenance
phenotype) or CBS7504 (lipid degradation phenotype) when xylose was the sole
remaining carbon source. Overall, the results relate genetic diversity of undomesticated
Y. lipolytica strains to complex phenotypes of superior growth, sugar utilization, lipid
accumulation and degradation in biomass hydrolysates.
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IMPORTANCE
Yarrowia lipolytica is an important industrial oleaginous yeast due to its robust phenotypes
for effective conversion of inhibitory lignocellulosic biomass hydrolysates into neutral
lipids. While lipid accumulation has been well characterized in this organism, its
interconnected lipid degradation phenotype is poorly understood during fermentation of
biomass hydrolysates. Our investigation into the genetic diversity of undomesticated Y.
lipolytica strains, coupled with detailed strain characterization and proteomic analysis,
revealed metabolic processes and regulatory elements that are correlated with superior
growth, sugar utilization, and lipid accumulation or degradation exhibited by these natural
variants. This study provides a better understanding of the robust metabolism of Y.
lipolytica and suggests potential metabolic engineering strategies to enhance its
performance.
Key words: bioreactor characterization, proteomic analysis, xylose metabolism, xylose
transporters, lipid accumulation, lipid degradation, lipid regulators.
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INTRODUCTION
Yarrowia lipolytica is an important oleaginous yeast for industrial biotechnology.
Wildtype strains can accumulate a remarkable 40% of cell weight in neutral lipids from
lignocellulosic biomass or agricultural wastes (1). These microbial lipids are a promising
alternative to petroleum and animal oils for the sustainable production of advanced fuels
and oleochemicals. In addition, Y. lipolytica is exceptionally robust to chemical inhibitors
and stressful environments, which are critical biocatalyst properties to achieve
sustainable production of chemicals from low-cost biomass feedstocks. It can tolerate
broad pH ranges (2), high salt concentrations (3), and organic solvents (e.g., ionic liquids)
(4, 5); in fact, most Y. lipolytica isolates exhibit robust growth in up to 60% (v/v)
undetoxified dilute acid-pretreated switchgrass hydrolysates that are normally inhibitory
to microbes (6). Thus, a better understanding of the mechanisms that underpin Y.
lipolytica’ s natural robustness would not only enable development of niche strains for
novel biocatalysis regimes but would also provide fundamental knowledge that may be
applied to other industrially-relevant organisms.
Recently, significant research has focused on manipulating the metabolism of
conventional laboratory strain CBS7504 (W29) for enhanced lipid production and
utilization of pentose (e.g., xylose) and hexose (e.g., glucose) sugars in inhibitory
lignocellulosic biomass hydrolysates. To increase lipid production in Y. lipolytica,
numerous metabolic engineering strategies have been implemented that successfully
redirected carbon flux to lipid metabolism (7) including overexpression of lipid
biosynthesis enzymes (8) and/or disruption of the competitive β-oxidation pathway (9)
and altered expression of regulators of lipid accumulation (10). The most lipogenic Y.
lipolytica strain reported to date achieved 90% lipid content by simultaneous restoration
of leucine and uracil biosynthesis, overexpression of diacylglycerol transferase (DGA1),
deletion

of

peroxisome

biogenesis

enzyme

peroxin-10

(PEX10),

deletion

of

multifunctional β-oxidation enzyme (MFE1), and optimization of culture conditions (11).
To maximize lipogenesis from biomass hydrolysates requires efficient utilization of
both hexose and pentose sugars. Y. lipolytica does not efficiently use xylose as a sole
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carbon source, albeit it processes genes for the complete xylose catabolic pathway (12).
Activation of this cryptic pathway has been accomplished through adaptive evolutionary
approaches resulting in improved xylose utilization (13). Furthermore, overexpression of
endogenous xylose catabolic genes (14-16) and heterologous expression of xylose
reductase and xylose dehydrogenase from Scheffersomyces stipitis (16, 17) have
successfully increased xylose consumption rates. Several transporters have also been
identified in Y. lipolytica showing increased expression levels during xylose assimilation
and combinatorial overexpression of the endogenous xylose dehydrogenase with several
of these transporters has also achieved improved growth on xylose (18). While the
production phenotypes are well characterized, fundamental understanding of complex
phenotypes responsible for superior growth, sugar utilization, and lipid accumulation--or
degradation--during fermentation of biomass hydrolysates are still lacking.
Complementary to these engineering efforts, recent investigation into the genetic
diversity of undomesticated Y. lipolytica strains revealed emergent robust phenotypes not
present in the conventional strain W29. Characterization of fifty-seven undomesticated Y.
lipolytica isolates on inhibitory undetoxified biomass hydrolysates revealed select strains
with superior growth, lipid production, and pentose-sugar assimilation relative to the
conventional laboratory strain CBS7504 (6). In this study, Y. lipolytica’ s natural genetic
diversity is further explored using a combination of detailed strain characterization and
proteomic analysis. Coupled together, these analyses uncover the underlying
mechanisms behind these poorly understood complex phenotypes during fermentation of
biomass hydrolysates. The results presented here will aid engineering efforts to better
control lipid accumulation or degradation phenotypes to optimally produce advanced
biofuels and/or oleochemicals from biomass hydrolysates.
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RESULTS
Comparative genomics reveals unique genotypes of undomesticated Yarrowia
strains
Phylogenetic tree of Y. lipolytica isolates shows close similarity between
genomes. Phylogenetic species analysis distinguished the first evolutionary split dividing
the Yarrowia clade into two ancestral roots (Figure 1A). The first root contained the nonconventional YB419 and conventional strains CLIB122 with CBS7504 (W29).

The

second root contained the remaining four non-conventional isolates, depicting YB392 and
YB420 as the most divergent from YB567 followed by YB566. This result was surprising
since YB392, YB419 and YB420 were all isolated from corn milling plants within Illinois
(19). Interestingly, the closest related species to the Yarrowia clade is Sugiyamaella
lignohabitans, an efficient pentose utilizing and facultative anaerobic yeast (20).
Undomesticated Y. lipolytica isolates contain unique genes not found in
laboratory strains. The undomesticated strains were characterized for unique genes
that may contribute to their distinctive phenotypes. A singleton gene signifies a gene
appearing exclusively in one of the genomes within the pangenome (i.e., laboratory
strains CBS7504 (W29) and CLIB122; undomesticated strains YB392, YB419, YB420,
YB566 and YB567). Of the undomesticated Y. lipolytica strains, YB419 contained the
most singletons (23 genes) followed by YB420 (17 genes), while the remaining 3 isolates
contained 5 or less singletons (Figure 4-1B, Table 4-1).
Exclusively shared genes between strains exhibiting enhanced xylose
assimilation and lipid accumulation. Two of the undomesticated strains, YB566 and
YB567, outperformed all other Y. lipolytica strains in assimilating xylose from switchgrass
hydrolysates (SGH) (6).

We hypothesized that these two strains contain a shared

genotype that was not found in other strains and was perhaps responsible for enhanced
xylose assimilation. There are 10 genes exclusively shared between these two xyloseutilizing strains (Figure 4-1B, Table 4-2).

Similarly, we sought exclusive genotypes

associated with Y. lipolytica strains with superior lipid accumulation from SGH, namely
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YB392, YB419 and YB420 (6). Six genes are exclusively shared among these three
lipogenic strains (Figure 4-1B, Table 4-3).
Y. lipolytica strains of different origins thrive in undetoxified biomass hydrolysates
and exhibit distinct phenotypes. Growth characterization of CBS7504 and YB420 Y.
lipolytica strains were performed in computer-controlled bioreactors (Figure 4-2A). The
conventional Y. lipolytica strain CBS7504 grew well in undetoxified biomass hydrolysates,
achieving maximum cell mass (39.3 ± 3.3 OD600nm) within 28 hours of fermentation from
the co-utilization of 2.9 ± 0.05 (%w/v) glucose and 0.8 ± 0.03 (%w/v) xylose (Figure 42B). Lipids accumulated during growth, reaching a maximum of 2.1 ± 0.6 g/L at 21 hours
into the fermentation (Figure 4-2D). Upon glucose exhaustion, cell mass and accumulated
lipid levels steadily declined for the remaining 48 hours of fermentation despite the
continued consumption of xylose. At 72 hours of fermentation, CBS7504 consumed a
total of 2.1 ± 0.02 (%w/v) xylose and produced 0.91 ± 0.008 (%w/v) xylitol (yielding 0.44
± 0.002 xylitol/xylose). The undomesticated Y. lipolytica strain YB420 also grew robustly
in undetoxified biomass hydrolysates, but showed contrasting phenotypes with CBS7504.
Over 45 hours of fermentation, YB420 showed less co-utilization of glucose (2.8 ± 0.03
[%w/v]) and xylose (0.4 ± 0.03 [%w/v]) and less lipid production (1.6 ± 0.5 g/L) than
CBS7504 (Figure 4-2C, 4-2E). However, upon glucose depletion, YB420 maintained cell
mass and lipids while consuming a total of 2.1 ± 0.01 (%w/v) xylose and producing 0.61
± 0.04 (%w/v) xylitol (yielding 0.30 ± 0.006 xylitol/xylose). The differences observed in
both the rate of xylose consumption and the maintenance of lipid levels prompted a
systems-level comparison of the two strains.
Proteomic analysis reveals key processes impacting sugar utilization and lipid
degradation
Proteome alterations in growth stages. Proteomic samples were collected
during the exponential growth phase when glucose was assimilated (S1 and S2) and
stationary phase when xylose was assimilated (S3 and S4) for both strains in biomass
hydrolysate cultures. Differences in protein abundances were compared for S2, S3 and
S4 against S1 for each strain (Figure 4-3A, 4-3B, 4-3D and 4-3E). As expected, there
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were only minor proteome differences between glucose assimilation phase samples (S1
and S2) (Figure 4-3C, 4-3F). However, Y. lipolytica strains dramatically altered their
proteomes during stationary phase samples (samples S3 and S4) when xylose was
assimilated, and lipid levels were maintained by YB420 but degraded by CBS7504
(Figure 4-3B, 4-3E). For CBS7504, 673 protein abundances changed throughout the
stationary phase (samples S3 and S4) while 800 protein abundances were changed in
YB420. Since the largest proteome differences were found between exponential (S1 and
S2) and stationary (S3 and S4) phase samples, we chose to characterize xylose
assimilation and lipid degradation phenotypes using proteins with significant changes in
abundance at S3 and/or S4 relative to S1.
Proteome alterations in xylose assimilation. CBS7504 consumed xylose faster
than YB420 but converted more of it into xylitol (0.44 ± 0.002 %w/w of xylose) rather than
maintaining cell mass or lipid content (Figure 4-2B, 4-2C). This led us to investigate
protein abundances in the pentose phosphate pathway (PPP) where xylose is introduced
into cellular central metabolism. Despite the quick assimilation of xylose, during xylose
assimilation (S3 and S4) CBS7504 only upregulated the protein abundance of
transketolase (TKL, YALI0D02277g) in the PPP (Figure 4-4A, Table 4-4). Interestingly,
CBS7504 downregulated the protein abundance of ribose-phosphate pyrophosphokinase
(PRS1, YALI0B13552g) which converts ribose-5-phosphate into 5-phosphoribosyl 1pyrophosphate (PRPP) to feed downstream biosynthetic pathways (i.e., histidine,
pyrimidine and purine metabolism) associated with cell growth, correlating with the
decreased cell mass, increased xylitol production and lipid degradation phenotypes of
CBS7504. Meanwhile, during xylose assimilation (S3 and S4) YB420 accumulated less
xylitol (0.30 ± 0.006 %w/x of xylose) and maintained cell mass and lipid content (Figure
4-2C). Regarding the PPP, six proteins were upregulated, and none downregulated in
YB420 during the stationary phase (Figure 4-4B, Table 4-4). Not surprisingly, these
upregulated proteins include xylitol dehydrogenase (Xyl2, YALI0E12463g) and
xylulokinase (Xyl3, YALI0F10923g) which together convert xylitol into xylulose-5P.
Notably, YB420 also upregulated 2 proteins annotated (in panther database) for xylulose
kinase (YALI0D15114g) and ribulokinase (YALI0E13321g) activities. Additionally, YB420
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increased

the

protein

abundance

of

D-arabinitol

2-dehydrogenase

(ADH,

YALI0F02211g).
Transporters. In total, 87 transporters were identified with statistically significant
abundance changes when comparing stationary phase (S3 and/or S4) to exponential
growth phase (S1) (Figure 4-4C, Table 4-4). While most are annotated for ion and
inorganic molecular entity transmembrane transport activities, we focused on the 28
active transmembrane transporters to identify those with altered protein abundances
during xylose assimilation. Specifically, six of these transporters are annotated with
carbohydrate transmembrane transporter activity and have been studied for xylose
assimilation in Y. lipolytica (Figure 4-4D) (13). YALI0C06424g is a carbohydrate
symporter with the largest increase in abundance for both strains. This protein is similar
to Snf3p and Rgt2p proteins of Saccharomyces cerevisiae that are involved in glucose
sensing and signaling as well as fructose and mannose transport (21). Both CBS7504
and YB420 strains also increased the abundance of YALI0F06776g, an observation that
is in agreement with previous transcriptomics data measuring Y. lipolytica’s growth
response to xylose as the sole carbon source (13). Though these two transporters
exhibited similar upregulation patterns during growth on xylose across both strains, albeit
with varied magnitudes, other transporters were more strain specific: YALI0D00363g,
YALI0F25553g, and YALI0C04730g. YALI0D00363g was strongly upregulated in S4 for
CBS7504, but not in YB420, while YB420 increased the protein abundance of
YALI0F25553g at both S3 and S4 and YALI0C04730g S3 but not in CBS7504.
Interestingly,

individual

overexpression

of

these

3

carbohydrate

symporters

(YALI0D00363g, YALI0F25553g or YALI0C04730g) supported growth on plates
containing xylose as the sole carbon source (18). Lastly, YALI0D01111g was
downregulated in CBS7504 during xylose assimilation S3 and S4 and at S4 in YB420.
Proteome alterations in lipid metabolism.

CBS7504 demonstrated lipid

degradation while YB420 maintained lipid content during the stationary/xylose
assimilation growth stage samples (S3 and/or S4) (Figures 4-2D, 4-2E, and 4-5A). To
understand the cause of lipid degradation/maintenance, we compared proteins involved
in fatty acid degradation and triacylglycerol (TAG) metabolism. In the TAG synthesis
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pathway, CBS7504 increased the abundance of both bifunctional glycerol-3phosphate/glycerone-phosphate O-acyltransferase (SCT1, YALI0C00209g), converting
glycerol-3-phosphate (gly-3P) into lysophosphatidic acid (LPA), and acyl-CoA dependent
diacylglycerol acyltransferase I (DGA1, YALI0E32769g), which converts diacylglycerol
(DAG) into TAG (Figure 4-5B, Table 4-5). Likewise, YB420 increased the of abundance
DGA1, but also lysophosphatidate acyltransferase (ALE1, YALI0F19514g) and
phosphatidic acid phosphohydrolase (PAP, YALI0D27016g), which together convert LPA
into TAG (Figure 4-5C, Table 4-5). However, YB420 downregulated the abundance of
diacylglycerol

diphosphate

phosphatase/phosphatidate

phosphatase

(LPP1,

YALI0B14531g) which has the same metabolic function as PAP (KEGG E.C.3.1.3.4).
Considering the β-oxidation pathway, both strains showed increased protein
abundance of acyl-coenzyme A oxidases 1 (POX1, YALI0E32835g), 2 (POX2,
YALI0F10857g), and 6 (POX6, YALI0E06567g) and multifunctional β-oxidation protein
(MFE1, YALI0E15378g) (Figure 4-5A, 4-5B). However, CBS7504 also showed increased
abundance of POX3 (YALI0D24750g), POX4 (YALI0E27654g) and 3-oxyacyl-thiolase
(POT1, YALI0E18568g), all involved in the breakdown of TAGs into free fatty acids (FFA).
Both

strains

decreased

the

abundance

of

acetyl-CoA

carboxylase

(ACC1,

YALI0C11407g) but CBS7504 also decreased abundance of fatty acid synthase subunit
1 (FAS1, YALI0B15059g).

Interestingly, YB420 increased the abundance of malic

enzyme (ME, YALI0E18634g), which generates NADPH pools that are required for the
FAS complex in oleaginous organisms (22), but shows little to no involvement in lipid
production in Y. lipolytica (23-25).
Lipase. In total, ten lipases were identified with statistically significant abundance
changes during the stationary phase (S3 and/or S4) relative to exponential growth phase
(S1) (Figure 4-5B, 4-5C; Table 4-5). While none include the well-studied triacylglycerol
lipase 3 (TGL3, YALI0D17534g) or TLG4 (YALI0F10010g), four of the identified lipases
are annotated for TGL activity (PTHR23025). Interestingly, CBS7504 increased the
protein abundance of all four TGLs in stationary phase while YB420 only increased the
protein abundance of one.
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NADPH generation. We identified five differentially abundant proteins involved in
the generation of NADPH, the reducing equivalent required to sustain fatty acid synthesis
(Figure 4-5B, 4-5C; Table 4-5). While both YB420 and CBS7504 strains increased the
protein abundance of sorbitol dehydrogenase (MnDH1, YALI0B16192g) during stationary
phase. Only YB420 increased abundances of the other 4 proteins including malic enzyme
(ME, YALI0E18634g), succinate semialdehyde dehydrogenase (UGA2, YALI0F26191g),
6-phosphogluconolactonase (SOL3, YALI0E11671g) and NADP-dependent glucose-6phosphate dehydrogenase (ZWF1, YALI0E22649g).
Regulators of lipid synthesis. Nitrogen limitation (i.e., high carbon to nitrogen
ratio) is a common technique to increase lipid synthesis from glucose (26), and numerous
studies have reported regulators of lipid accumulation and genes affected by nitrogen
limitation. Our analysis identified eight of these regulators with statistically significant
abundance changes during the stationary phase (S3 and/or S4) relative to exponential
growth phase (S1) – all of which have been previously reported to influence lipid
accumulation (10, 27, 28). Of these, YB420 increased the protein abundance of HLH
transcription factor YAS2 (YALI0E32417g), a subunit of the SWI/SNF chromatin
remodeling complex POR1 (YALI0D12628g), AMP-activated serine/threonine protein
kinase SNF1 (YALI0D02101g) and heat shock transcription factor HSF1 (YALI0E13948g)
(Figure 5C, Table S5).

Meanwhile, CBS7504 increased the protein abundance of

cytoplasmic pre-60S factor REI1 (YALI0B08734g) and decreased the protein abundance
of a zinc finger protein (YALI0E30789g), sterol regulatory element binding protein UPC2
(YALI0B15818g) and SNF1-activating kinase 1 SAK1 (YALI0D08822g) (Figure 4-5B,
Table 4-5).
Proteome alterations in regulatory elements.

In total, 46 gene-specific

regulator proteins (from panther and TFDB) were identified with statistically significant
abundance changes during the stationary phase (S3 and/or S4) relative to exponential
growth phase (S1) (Figure 4-6). Thirteen of these regulatory proteins had significant
changes in both CBS7504 and YB420.

The protein with the largest increase in

abundance, YALI0C07821g, is annotated as glucose transport transcription regulator
RGT1-related (PTHR31668) but only has the conserved domain, GAL4 (smart00066) with
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S. cerevisiae RGT1p. Interestingly, four of these regulatory proteins have distinct, strain
specific abundance patterns: RFX1, ASG1, STP1, and FHL1. RFX1, regulatory factor X
in S. cerevisiae, is a major transcriptional repressor of DNA-damage-regulated genes
(29). ASG1, an activator of stress-related genes, activates genes in β-oxidation,
glucogenesis, glyoxylate cycle, triacylglycerol breakdown, peroxisomal transport, and
helps assimilate fatty acids in S. cerevisiae (30). STP1, involved in species-specific tRNA
processing, activates transcription of amino acid permease genes and is directly involved
in pre-tRNA splicing in S. cerevisiae (31, 32).

Finally, FHL1 (fork-head like) in S.

cerevisiae functions as a transcription regulator of ribosomal protein transcription (33).

DISCUSSION
Lipid accumulation and lipid degradation patterns from cultures fermenting xylose
(a non-preferred sugar prevalent in biomass hydrolysates) are complex phenotypes
making them difficult to control and engineer in Y. lipolytica (14, 34, 35). By comparing
proteomes of natively robust unconventional Y. lipolytica strain YB420 with the
conventional strain CBS7504, we identified key proteins supporting cell growth and lipid
accumulation with xylose as the sole remaining carbon source.
Once all the glucose was consumed, YB420 continued to accumulate lipids and
sustained cell mass from xylose, while CBS7504 degraded lipids, decreased cell mass
and produced more xylitol (Figure 4-2). This more efficient use of xylose, demonstrated
by YB420, is supported by the greater number of PPP proteins upregulated during xylose
assimilation, including Xyl2 and Xyl3 which are critical for flux of xylose through the PPP
(Figure 4-4B).

Meanwhile, the almost unchanged abundances of proteins found in

CBS7504 in the PPP agrees with the increased xylitol secretion, decreased cell mass
and lipid degradation phenotypes observed (Figure 4-4A). Interestingly, both strains
showed similar xylose uptake profiles despite varying cell mass and lipid profiles. This
suggests that transporters YALI0C06424g and YALI0F06776g are likely responsible
and/or specific for xylose uptake, as indicated by increased protein abundances for both
transporters across each strain only during the xylose assimilation phase (Figure 4-4D).
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In lipid metabolism, YB420 increased proteins involved in TAG biosynthesis while
CBS7504 increased proteins involved in β-oxidation and TAG lipase activity, strongly
supporting the lipid maintenance and lipid degradation phenotypes of YB420 and
CBS7504 respectively (Figure 4-5). Accordingly, YB420 increased the abundance of
NADPH-generating enzymes which supply critical reducing-equivalents for lipid synthesis
and xylose assimilation, including SOL3, ZWF1, ME and UGA2.

Previously,

overexpression of SOL3 increased lipid yield, titer and content (28). SOL3 does not
produce NADPH directly, but instead catalyzes the intermediate reaction of the oxidative
PPP that feeds into NADPH-producing enzymes, ZWF1 and NADP+-dependent 6phosphogluconate dehydrogenase (28). Additionally, the promoters of ZWF1 along with
ME and UGA2 exhibited increased expression levels in response to nitrogen limitation, a
condition which results in increased lipid accumulation (25).

Taken together, the

increased protein abundance of NADPH-producing enzymes supports the lipid
maintenance phenotype observed by YB420.
Several regulators previously reported to influence lipid accumulation in Y.
lipolytica were captured by the proteomic analysis. Of these, YB420 cultures showed
increased protein abundances of YAS2, POR1, SNF1 and HSF1. In a previous report,
overexpression of YAS2 did not increase lipid accumulation in glucose minimal media but
did significantly increase lipogenesis when acetate was the sole carbon source,
suggesting indirect involvements in lipid biosynthesis in Y. lipolytica (28). Overexpression
of POR1 in Y. lipolytica resulted in ~18% increased lipid content in glycerol media but
showed growth defects in glucose media (27).

Conversely, deletion of SNF1 was

reported to increase fatty acid accumulation without the need for nitrogen limitation (10)
and overexpression of HSF1 resulted in decreased lipid accumulation with glycerol as the
sole carbon source (27). We also identified one regulator (REI1) with increase protein
abundance and three regulators (YALI0E30789g, SAK1 and UPC2) with decreased
abundance by CBS7504 during lipid degradation. Previously, overexpression of UPC2
decreased lipid accumulation while overexpression of YALI0E30789g and REI1
increased lipid accumulation, which does not support the lipid degradation phenotype of
CBS7504 in our study (27). Furthermore, deletion of SAK1 has been shown to result in
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increased fatty acid content (10) but in our study, decreased SAK1 protein levels were
accompanied by lipid degradation in CBS7504.
In conclusion, our characterization of Y. lipolytica isolates with phenotypic and
genetic diversity sheds light on those proteins supporting lipid accumulation or
degradation during fermentation of non-preferred biomass sugar xylose. However, these
results suggest that the regulation machinery of pentose and lipid metabolism in Y.
lipolytica is complex and multifaceted, with many aspects remaining undiscovered and
unexplained.

MATERIALS AND METHODS
Strains
Y. lipolytica strains CBS7504 (W29), YB392, YB419, YB420, YB566 and YB567 were
used. CBS7504 is from CBS-KNAW Culture Collection in Utrecht, the Netherlands. All
other strains are from ARS (NRRL) Culture Collection, Peoria, IL. The strains were stored
in 20% glycerol at -80°C.
Medium and culturing conditions
Switchgrass hydrolysate preparation.

Liberty switchgrass, that had been

pelleted and cut with a 4mm knife mill, was used. The biomass was hydrolyzed at 20%
solids w/w (6). A 20-gram dry weight of biomass was added to stainless steel vessels.
Then 80 mL of 0.936 % sulfuric acid w/ 3.72 g/L Pluronic F-68 was added to each vessel.
Eleven vessels per oven run were filled. The 12th vessel was filled with 80 mL of water
and contained the thermocouple. The vessels were placed in a Mathis Labomat Infrared
Oven. The following settings were used for the program: Temperature = 160°C, Heat
Ramp = 2.6°C, Mix settings = 50 rpm, 60 seconds to the left and 60 seconds to the right,
and cooling temperature = 40°C. Once the vessels have cooled, 4.0 mL of 1.0 M citrate
buffer was added to each vessel. Then pH of the pretreated biomass was adjusted to 4.55.0 with 30% calcium hydroxide. The vessels were placed back in the Mathis oven for
mixing at room temperature. The contents of 11 vessels were transferred to a Fernbach
flask with a solid rubber stopper. The following enzymes were added: 29.7 mL Cellic
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Ctec3 and 5.5 mL Cellic NS-22244. The Fernbach was incubated at 50°C with shaking at
125 rpm for 3 days. After 3 days the solids were removed using a 0.2 mm filter unit. The
liquid fraction was stored at 4°C. Multiple batches were made over the course of a week.
The batches were pooled. The liquid was then pH adjusted to 6.0 using 10N sodium
hydroxide. After pH adjustment the SGH was filter sterilized and frozen at -20°C until
week of use. The SGH was thawed at 4°C overnight. Prior to use, it was amended to a
whole hydrolysate with 2.31 g/L (NH4)2SO4, 1.81g/L Difco vitamin assay casamino acids,
0.018 g/L DL-tryptophan, and 0.072 g/L L-cysteine, and then diluted to 50% v/v with water.
The diluted and amended hydrolysate is referred to 50% SGH form here on.
Culturing conditions. The yeast stocks were streaked on YPD Agar plates and
incubated at 28°C for 24-48 hours. The plates were stored at 4oC until use. YPD media,
2 mL in a 16 mL tube, was inoculated by loop for pre-seed cultures. Pre-seed cultures
were incubated at 28°C with shaking at 250 rpm for 18 hours. 0.5 mL of pre-seed culture
was transferred to 10 mL 50 % SGH in 50 mL baffled flasks for seed cultures. Seed
cultures were incubated 24 hours at 28oC with 250 rpm.

The seed cultures were

centrifuged to remove supernatant and resuspended in sterile water to A 600 = 50. 150 mL
of 50% SHG was inoculated at an A600 = 0.75. DasGip DasBox bioreactors were used
for experimental cultures. Each strain was inoculated in triplicate. The following settings
were used for the bioreactors: Beginning volume = 150 mL; Vessel = 250 mL;
Temperature = 28°C; pH Set Point = 6.0; Agitation = 900 rpm; Aeration = 9.0 L/h;
Base/Acid control: use 2 M HCl and 2 M NaOH for automatic dosing; Data Collection =
dissolved oxygen, temperature, and pH. Cognis Clerol FBA 3107 antifoam was used to
control foaming. After inoculation, 200uL of antifoam was added to each vessel. Antifoam
was then added by pipet as need for duration of culture growth. A 1.2 – 1.5mL sample
was taken for A600, residual sugars and lipids 3 times a day. A 1.0mL aliquot was
removed from each sample for residual sugars and lipid analysis. The 1.0mL aliquot was
centrifuged to remove the supernatant for residual sugar analysis. The cell pellet was
washed twice with deionized water and resuspended up to 1.0mL with water. The
samples were frozen at -20°C until analysis. The remaining sample was diluted for A 600
measurement. Duplicate samples (2.0 mL) for proteomic analysis were taken once the
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OD reaches ˂4.0, 2-3 hours later, at 44-48 hours and a final sample at 68-72 hours.
Samples were kept cold while processing. The samples were centrifuged to remove
supernatant, washed with 1.0mL of chilled water and then centrifuged again to remove
water. The washed cell pellets were the stored at -80°C.
Analytical methods
Lipid quantification. Lipid analysis was done using a sulfo-phospho-vanillin
colorimetric assay as previously reported by Dien et al. (36). For each sample, 1.0mL of
sulfuric acid was added to a glass tube and 50 mL of sample (diluted with water if needed).
The tube was heated at 100°C in a dry bath for 10 minutes. After heating, the tubes were
cooled in a room temp water bath for 10 minutes. Once cooled, 2.5 mL of the vanillinphosphoric acid solution was added to each tube. The tubes were mixed and placed in
a 37°C incubator for 15 minutes. They are then cooled in a room temp water bath. The
absorbance is then measured at 530 nm. The Vanillin-phosphoric acid solution (0.12g
vanillin, 20 mL water, and 80 mL 85% o-phosphoric acid) is made fresh daily for assays.
A blank with 50uL water and four calibration standards are used for the standard curve.
The

calibration

standards

are

dilutions

of

corn

oil

dissolved

in

2:1

(v/v)

chloroform/methanol and 50 mL of each standard was processed in duplicate along with
the samples.
Metabolites and sugar quantification. Residual sugars were measured on a
Thermo High-Performance Liquid Chromatography system. The system used a Biorad
HPX-87H column and a refractive index detector. The column was kept at 65°C with
0.6mL/min of 5mM sulfuric acid as a mobile phase.
LC/MS for proteomic analysis. Y. lipolytica cells harvested at the time points
detailed above were resuspended in 100 mM Tris-HCl, 10 mM dithiothreitol, pH 8.0 and
bead beat with 0.5 mm zirconium oxide beads in a Geno/Grinder® 2010 (SPEX
SamplePrep) for 5 min at high speed (1750 rpm). Samples were adjusted to 4% SDS and
incubated at 95°C for 10 min. Crude lysate was then cleared via centrifugation (21,000 x
g) and quantified by corrected absorbance (Scopes) at 205 nm (NanoDrop OneC; Thermo
Fisher). Samples were then treated with 30 mM iodoacetamide for 20 min at room
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temperature in the dark. Three hundred micrograms of crude protein were then processed
by protein aggregation capture (PAC) (37). Briefly, 300 ug of magnetic beads (1 micron,
SpeedBead Magnetic Carboxylate; GE Healthcare UK) was suspended in each sample
and protein aggregation was induced by adjusting the sample to 70% acetonitrile.
Aggregated proteins were then washed with 1 mL of neat acetonitrile followed by 70%
ethanol, and aggregated protein pellet digested with 1:75 (w/w) proteomics-grade trypsin
(Pierce) in 100 mM Tris-HCl, pH 8.0 overnight at 37°C and again for 4 h the following day.
Tryptic peptides released from the beads were then acidified to 0.5% formic acid, filtered
through a 10 kDa MWCO spin filter (Vivaspin500; Sartorius), and quantified by NanoDrop
OneC.
Peptide samples were analyzed by automated 1D LC-MS/MS analysis using a
Vanquish UHPLC plumbed directly in-line with a Q Exactive Plus mass spectrometer
(Thermo Scientific) outfitted with a trapping column coupled to an in-house pulled
nanospray emitter as previously described (38). The trapping column (100 µm ID) was
packed with 10 cm of 5 µm Kinetex C18 RP resin (Phenomenex) while the nanospray
emitter (75 µm ID) was packed with 15 cm of 1.7 µm Kinetex C18 RP resin. For each
sample, 3 µg of peptides were loaded, desalted, and separated by uHPLC with the
following conditions: sample injection followed by 100% solvent A (95% H 2O, 5%
acetonitrile, 0.1% formic acid ) chase from 0-30 min (load and desalt), linear gradient 0%
to 30% solvent B (70% acetonitrile, 30% water, 0.1% formic acid) from 30-220 min
(separation), and column re-equilibration at 100% solvent A from 220-240 min. Eluting
peptides were measured and sequenced by data-dependent acquisition on the Q
Exactive MS as previously described (39).
Bioinformatics and data analysis
Comparative genomics. The following genome assemblies of Y. lipolytica strains
were

downloaded

from

NCBI

as

genbank

files:

CBS7504/CLIB89/W29

(GCA_001761485.1), CLIB122 (GCA_000002525.1), YB392 (GCA_003367865.1),
YB419 (GCA_003367925.1), YB420 (GCA_003367965.1), YB566 (GCA_003367945.1)
and YB567 (GCA_003367845.1).

These were imported individually into a KBase
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narrative as genomes and combined into a genome set using the Build GenomeSet v1.0.1
application. A phylogenetic tree was constructed using Insert Set of Genomes Into
Species Tree 2.1.10 application with neighbor public genome count of 20. Orthologue
genes and unique genes shared between isolates were identified with the Compute
Pangenome application using the genome set of the 7 isolates as the input. Finally,
Pangenome Circle Plot - v1.2.0 application was used to produce a list of singleton genes
for each base genome identified from the pangenome.
Proteomics. MS/MS spectra were searched against the Y. lipolytica CLIP122
proteome (UniProt; Nov18 build) appended with non-redundant proteins from strain YB420 and common protein contaminants using the MS Amanda v.2.0 algorithm in
Proteome Discoverer v.2.3 (ThermoScientific). Peptide spectrum matches (PSM) were
required to be fully tryptic with 2 mis-cleavages; a static modification of 57.0214 Da on
cysteine (carbamidomethylated) and a dynamic modification of 15.9949 Da on methionine
(oxidized) residues. Peptide spectrum matches (PSM) were scored and filtered using the
Percolator node in Proteome Discoverer and false-discovery rates initially controlled at
< 1% at both the PSM- and peptide-levels. Peptides were then quantified by
chromatographic area-under-the-curve, mapped to their respective proteins, and areas
summed to estimate protein-level abundance. Proteins without 3 valid values in a
minimum of 1 biological condition were removed and remaining protein abundances were
log2 transformed.

Missing values were imputed to simulate the mass spectrometer’s

limit of detection using Perseus v1.6.10.43 (i.e., normal distribution, width of 0.3, down
shift of 1.9 and mode changed to total matrix) (40). Significant differences in protein
abundance were calculated via T-test for each sample (S2, S3 and S4) against control
group (S1 sample) for each strain using FDR of 0.05, 250 permutations and s0 of 1.
All raw mass spectra for quantification of proteins used in this study have been
deposited in the MassIVE and ProteomeXchange data repositories under accession
numbers MSV000085941 (MassIVE) and PXD020854 (ProteomeXchange), with data
files available at ftp://massive.ucsd.edu/ MSV000085941.
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Bioinformatics.
Pathway proteins were annotated using KEGG database (40) and from literature
sources where cited. Ontology associations and orthologs for regulator proteins were
identified using panther database (41).
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Appendix
Table 4- 1. Singleton genes of YB392, YB419, YB420, YB566 and YB567.
Genome

Locus Tag

YB392

B0I71DRAFT_23206

YB392

B0I71DRAFT_165597

YB392

B0I71DRAFT_132072

YB392

B0I71DRAFT_140658

YB392

B0I71DRAFT_39083

YB419

B0I72DRAFT_42591

YB419

B0I72DRAFT_173937

YB419

B0I72DRAFT_34279

YB419

B0I72DRAFT_7217

YB419

B0I72DRAFT_133747

YB419

B0I72DRAFT_148340

YB419

B0I72DRAFT_20302

YB419

B0I72DRAFT_176868

YB419

B0I72DRAFT_176347

YB419

B0I72DRAFT_164308

YB419

B0I72DRAFT_15024

YB419

B0I72DRAFT_2773

YB419

B0I72DRAFT_148966

YB419

B0I72DRAFT_138964

YB419

B0I72DRAFT_134698

YB419

B0I72DRAFT_128204

YB419

B0I72DRAFT_141486

YB419

B0I72DRAFT_6483

YB419

B0I72DRAFT_26882

YB419

B0I72DRAFT_159127

YB419

B0I72DRAFT_164433

YB419

B0I72DRAFT_172193

YB419

B0I72DRAFT_142595

YB420

B0I73DRAFT_171833

YB420

B0I73DRAFT_39464

YB420

B0I73DRAFT_141110

YB420

B0I73DRAFT_11141

YB420

B0I73DRAFT_166406

YB420

B0I73DRAFT_141163

YB420

B0I73DRAFT_129575

YB420

B0I73DRAFT_168289
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Table 4-1 continued
YB420

B0I73DRAFT_10053

YB420

B0I73DRAFT_20235

YB420

B0I73DRAFT_129528

YB420

B0I73DRAFT_138424

YB420

B0I73DRAFT_26166

YB420

B0I73DRAFT_136916

YB420

B0I73DRAFT_162507

YB420

B0I73DRAFT_141781

YB420

B0I73DRAFT_144199

YB566

B0I74DRAFT_176766

YB566

B0I74DRAFT_42025

YB567

B0I75DRAFT_2109

Table 4- 2. Exclusively shared genes between xylose consuming strains YB566 and
YB567.
YB567

YB566

B0I75DRAFT_157292

B0I74DRAFT_172414

B0I75DRAFT_40401

B0I74DRAFT_40877

B0I75DRAFT_11481

B0I74DRAFT_21615

B0I75DRAFT_140064

B0I74DRAFT_140479

B0I75DRAFT_154119

B0I74DRAFT_152545

B0I75DRAFT_155102

B0I74DRAFT_149309

B0I75DRAFT_128836

B0I74DRAFT_174097

B0I75DRAFT_134495

B0I74DRAFT_134394

B0I75DRAFT_169517

B0I74DRAFT_163910

B0I75DRAFT_137511

B0I74DRAFT_138950
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Table 4- 3. Exclusively shared genes between lipid accumulating strains YB392,
YB419 and YB420.
YB392

YB419

YB420

B0I71DRAFT_39511

B0I72DRAFT_38745

B0I73DRAFT_40681

B0I71DRAFT_12264

B0I72DRAFT_37180

B0I73DRAFT_14480

B0I71DRAFT_131081

B0I72DRAFT_138926

B0I73DRAFT_133629

B0I71DRAFT_9972

B0I72DRAFT_12030

B0I73DRAFT_6620

B0I71DRAFT_130434

B0I72DRAFT_134889

B0I73DRAFT_131291

B0I71DRAFT_129034

B0I72DRAFT_135679

B0I73DRAFT_132750

Table 4- 4. Proteomics analysis of xylose metabolism and transporters.
Difference against S1 (t-test)
CBS CBS YB420
YB420
S3
S4
S3
S4
1.97
4.05

Name
ribose-phosphate
pyrophosphokinase
NADP+-dependent
glucose-6-phosphate
dehydrogenase
6phosphogluconolactonase
ribose 5-phosphate
isomerase B

Symbol

Locus Tag

Accession

PRS1

YALI0B13552g

Q6CER7

ZWF1

YALI0E22649g

Q6C4Y7

1.13

1.46

SOL3

YALI0E11671g

Q6C682

1.12

1.08

RPIB

YALI0F01628g

Q6C393

3.65

2.05

Transketolase

TKL

YALI0D02277g

Q6CAJ3

3.14

3.98

Xylitol dehydrogenase
D-arabinitol 2dehydrogenase

Xyl2

YALI0E12463g

Q6C648

1.73

1.98

ADH

YALI0F02211g

Q6C367

1.42

1.57

Xylulokinase

Xyl3

6.77

6.92

YALI0F10923g

Q6C246

2.56

3.45

ribulo and xylulose kinase

YALI0D15114g

Q6C916

1.68

1.69

2.48

2.40

ribulo kinase

YALI0E13321g

Q6C615

1.30

2.09

2.98

3.55
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Table 4- 5. Proteomics analysis of lipid metabolism, lipid regulators, lipase and NADPH
generating proteins.
Difference against S1 (t-test)
YB420
S3

YB420
S4

Q6C138

2.66

2.12

YALI0D27016g

Q6C7L9

2.06

2.37

POX6

YALI0E06567g

Q6C6T0

1.71

1.78

1.77

1.99

POX1

YALI0E32835g

O74934

3.36

3.71

0.822

2.54

LPP1

YALI0B14531g

Q6CEM4

-3.62

-3.15

Acyl-coenzyme A oxidase 3

POX3

YALI0D24750g

O74936

Acyl-coenzyme A oxidase

POX5

YALI0C23859g

F2Z630

1.95

1.57

Diacylglycerol acyltransferase

DGA1

YALI0E32769g

Q6C3R2

acylglycerol lipase

YJU3

YALI0C14520g

Q6CBY1

Acyl-coenzyme A oxidase 2
Acyl-CoA:sterol
acyltransferase

POX2

YALI0F10857g

O74935

2.72

ARE1

YALI0F06358g

Q6C2N7

Acyl-coenzyme A oxidase

POX4

YALI0E27654g

F2Z627

3-ketoacyl-CoA thiolase
Glycerol-3-phosphate
acyltransferase

POT1

YALI0E18568g

SCT1

2nd step of β-oxidation
Acetyl-CoA Carboxylase

Name/Description
Lysophospholipid
acyltransferase

Symbol

Locus Tag

ALE1

YALI0F19514g

Phosphatidate phosphatase

PAP

Acyl-coenzyme A oxidase
Acyl-coenzyme A oxidase 1
Lipid phosphate phosphatase
1/Diacylglycerol
pyrophosphate phosphatase 1

Accession

CBS
S3

1.37

4.40

CBS
S4

1.15

3.40

2.72

3.54

-0.204

-2.14

2.72

1.34

1.71

3.66

3.97

4.30

4.67

1.31

1.51

Q05493

1.16

1.44

YALI0C00209g

Q6CDI7

1.57

1.45

MFE1

YALI0E15378g

F2Z6I5

1.54

1.57

1.42

1.56

ACC1

YALI0C11407g

Q6CC91

-1.50

-1.63

-1.44

-1.73

Fatty acid synthase 1

FAS1

YALI0B15059g

P34229

-1.25

-1.22

Malic enzyme

ME

YALI0E18634g

Q6C5F0

TAG lipase

YALI0B09361g

F2Z5Z7

7.28

8.52

TAG lipase

YALI0A20350g

F2Z685

2.88

2.03

TAG lipase

YALI0E17655g

Q6C5J1

2.86

2.82

TAG lipase

2.11

2.23

0.356

3.98

2.40

1.72

YALI0E08492g

Q6C6L5

2.87

1.08

Mannitol dehydrogenase
Succinate semialdehyde
dehydrogenase

MnDH1

YALI0B16192g

Q6CEE9

3.32

2.99

UGA2

YALI0F26191g

Q6C0B4

1.13

1.26

6-Phosphogluconolactonase
NADP+-dependent glucose-6phosphate dehydrogenase
HLH transcription factor,
upregulates cytochrome p450
genes in response to alkanes
with YAS1; some similarity to
INO4/INO2
from Saccharomyces
cerevisiae

SOL3

YALI0E11671g

Q6C682

1.12

1.08

ZWF1

YALI0E22649g

Q6C4Y7

1.13

1.46

YAS2

YALI0E32417g

Q6C3S8

2.45

3.26
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Table 4-5 continued
Y.
lipolytica YALI1D12628gPOR1
Subunit of the SWI/SNF
chromatin remodelingcomplex
involved in transcriptional
regulation

POR1

YALI0D12628g

Q6C9A9

0.255

1.31

Snf1 kinase

SNF1

YALI0D02101g

Q6CAK0

1.48

2.50

Snf1 Activating Kinase 1
Cytoplasmic pre-60S factor,
putative similar to S.
cerevisiae YBR267W REI1
Cytoplasmic pre-60S factor
Conserved hypothetical
protein weakly similar
to Ajellomyces
dermatitidis C2H2 finger
domain-containingprotein
Conserved hypothetical
protein some similarities
with S. cerevisiae YGL073w
HSF1 heat shock transcription
factor
Conserved hypothetical
protein some similarities
with S. cerevisiae YDR213W
UPC2 Sterol regulatory
element binding protein

SAK1

YALI0D08822g

Q6C9S1

-3.07

-1.83

REI1

YALI0B08734g

Q6CFB1

2.14

1.51

YALI0E30789g

Q6C407

-1.79

-2.30

HSF1

YALI0E13948g

Q6C5Z0

1.55

1.51

UPC2

YALI0B15818g

Q6CEG5

-2.95

-3.92
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Figure 4- 1. (A) Phylogenetic tree of Yarrowia lipolytica isolates with 20 closest neighbor
species. (B) Pangenome of Y. lipolytica reference strains CLIB122122 and CBS7504
(W29) and non-conventional strains YB392, YB419, YB420, YB566 and YB567. Bold,
strain; parenthesis, total genes; outer petals, singleton genes, middle petals, uniquely
shared genes between lipid producers (blue) and xylose consumers (green); middle
circle, core genes.
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Figure 4- 2. (A) Workflow of bioreactor characterization of Yarrowia lipolytica isolates
CBS7504 (B, D) and YB420 (C, E) in 50% SGH. Dotted lines, time of glucose depletion
where xylose is the sole remaining carbon source.
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Figure 4- 3. Proteomic analysis of Y. lipolytica (A-C) CBS7504 and (D-F) YB420 strains.
(A, D) Number of proteins with significant abundance changes relative to S1. (B, E)
Heatmap of significant proteins with changed abundance relative to S1. (C, F) Venn
diagram illustrating the number of proteins with significant abundance changes between
samples.
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Figure 4- 4. Pentose phosphate pathway proteome of (A) CBS7504 and (B) YB420.
Increased protein abundance during xylose assimilation, red; decreased protein
abundance during xylose assimilation, blue; pathways, rectangles; proteins, bold font;
metabolites, plain text.

(C) All transporters and (D) carbohydrate transporters with

significant protein abundance changes in the xylose assimilation phase. CBS7504, blue;
YB420, orange. Abbreviations: TKL (transketolase, YALI0D02277g); PRS1 (ribosephosphate

pyrophosphokinase,

YALI0B13552g);

Xyl1

(xylose

reductase,

YALI0D07634g); Xyl2 (xylitol dehydrogenase, YALI0E12463g); Xyl3 (xylulokinase,
YALI0F10923g); ZWF1 (NADP+-dependent glucose-6-phosphate dehydrogenase,
YALI0E22649g); SOL3 (6-phosphogluconolactonase, YALI0E11671g); RPIB (ribose 5phosphate isomerase, YALI0F01628g); TAL (transaldolase, YALI0F15587g); RPE1
(ribulose-phosphate

3-epimerase,

YALI0C11880g);

GND1

(6-phosphogluconate

dehydrogenase, YALI0B15598g).
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Figure 4- 5. (A) Schematic of growth characterization phenotypes for CBS7504 and
YB420 when xylose was the sole remaining carbon source. Proteomic analysis of lipid
metabolism showing increased (red) and decreased (blue) protein abundance when
xylose was the sole remaining carbon source for CBS7504 (B) and YB420 (C). Proteins,
circles;

metabolites,

regular

font;

pathways,

bold

font.

Abbreviations:

TAG

(triacylglycerol); DHAP (dihydroxyacetone phosphate); Gly-3P (glycerol-3-phosphate);
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Figure 4- 6. Regulator proteins with significant protein abundance changes in the xylose
assimilation phase. CBS7504, blue; YB420, orange.
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Chapter V
Harnessing Yarrowia lipolytica for Biological Upcycling of Plastic
Waste into Citric Acid and Lipids
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Abstract
Sustainable processes for recycling plastic waste are needed to reduce environmental
pollution associated with increased plastic production, incineration, and landfill storage.
Currently, most recycling strategies generate lower quality polymers that do not support
an economic and sustainable return. Here, we present an alternative strategy using the
yeast, Yarrowia lipolytica, for biological upcycling of catalytically depolymerized plastic
(DP) waste into higher-value chemicals.

While hydrophobic substrate (i.e., DP)

metabolism is not fully understood, short-term adaptation of Y. lipolytica to the DP oil
effectively increased utilization of the DP and sequential conversion into citric acid and
triacylglycerol.

Interestingly, adapted Y. lipolytica exhibited cellular adhesion to all

hydrophobic substrates tested and significantly improved growth on the model alkane
substrate hexadecane. Taken together, Y. lipolytica is a promising microbial host for
upcycling plastic waste into higher-value chemicals and an emerging model organism to
further elucidate mechanisms and genes underlying hydrophobic metabolism.
Keywords
Plastic

waste;

upcycling;

Yarrowia

lipolytica;

hydrophobic

substrate;

catalytic

depolymerization; alkane; hexadecane; organic acid production; lipid production;
adaptive engineering; cell adhesion.

Introduction
Plastic waste pollutes all major ecosystems worldwide, negatively impacting wildlife and
human health (1). Approximately 9% of all generated plastic waste was recycled, 12%
incinerated, and 79% amassed in landfills as of 2015 (2). In 2050, an estimated 12,000
metric tons of plastic waste will occupy landfills if current trends in plastic production or
plastic waste management are not altered (2). Yet, sustainable processes remain elusive
166

since current recycling concepts produce polymers of lower quality and cost (3). Hence,
plastic waste must be converted into higher-value chemicals to render this process
economically sustainable and cost competitive. Here, we demonstrate that biological
upcycling of catalytically depolymerized plastic (DP) waste is an advantageous strategy
due to the wide plethora of valuable chemicals microorganisms can produce.
One promising microbial host for this process is the oleaginous yeast Yarrowia
lipolytica which can assimilate hydrophobic substrates (HS) including alkanes generated
by catalytic depolarization of plastic (4). Additionally, Y. lipolytica efficiently produces
valuable chemicals (e.g., organic acids and lipid-derived products), has an established
genetic toolkit (5), is generally regarded as safe (GRAS certified) (6), and is extremely
robust (e.g., broad ranging pH, high salinity and organic solvents) (7-9), which are all
important characteristics for a bioproduction microbe.
Numerous studies demonstrating utilization of alkanes as a carbon source by Y.
lipolytica date as far back as 1954, yet several aspects of this complex alkane metabolism
are not fully understood (10). Specifically, i) how Y. lipolytica accesses the hydrophobic
alkanes, ii) identification of a specific alkane transport system and iii) the carbon-number
range of alkanes that support cell growth.
There are two proposed mechanisms enabling Y. lipolytica to access HS, secretion
of an emulsifier named liposan (11) and direct adhering of the cells to the HS with a
protrusion structure on the cell surface (12). However, identification of the genes
encoding the proteins (i.e., genetic tractability) responsible for either of these mechanisms
have not yet been discovered (13).
Further, identification of genes and mechanisms responsible for the transport of
alkanes into Y. lipolytica cells remains unknown. However, disruption of two different
genes altered growth phenotypes in a carbon-chain dependent manner. Specifically,
disruption of an adenine nucleotide transporter protein ANT1 (providing ATP for acyl-coA
synthase) diminished growth on short chain alkanes (mainly C10 and C11) but did not
affect growth on C16 (14). Similarly, disruption of an ABC transporter ABC1 prohibited
growth on long-chain alkanes (C14-C16), reduced growth on medium-chain alkanes (C12
and C13) but did not alter growth on short-chain alkanes (C10 and C11) (14).
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Finally, the maximum carbon-number range of alkanes that support the growth of
Y. lipolytica has not been explored. This is important because depending on the plastic
feedstock and catalysis conditions, the depolymerized plastic will contain mixtures of
alkanes and alkenes with a broad range of carbon chain lengths. While shorter alkanes
(i.e., C1-C8 alkanes) do not support growth of Y. lipolytica cells (15), growth on longer
chain alkanes (>C18) have not been reported to our knowledge.
Here, we investigate the biological upgrading of depolymerized plastic waste using
Y. lipolytica. Specifically, we characterize the efficacy of Y. lipolytica to utilize the complex
mixture of DP using short term adaptation, address the stability of the depolymerized
plastic to identify potential limitations for biological upcycling, and demonstrate production
of citric acid and lipids directly from the depolymerized plastic waste. We expect the
results of this study to help guide catalytic selectivity goals, address potential stability
issues with depolymerized plastic, and stimulate potential applications of biological
upcycling plastic waste into higher-value chemicals.

Materials and Methods
Strains. Wildtype Yarrowia lipolytica Po1f was obtained from the American Type Culture
Collection (ATCC MYA-2613) and was used as the parent strain for short-term adaptation
to produce the adapted Y. lipolytica strain.
Medium and culturing conditions
Catalytic depolymerized plastic waste. Low-density polyethylene (LDPE) was used as
the source of plastic waste. Batches of LDPE were catalytically depolymerized into DP
oil and kindly provided by Dr. Laursen (UTK, CBE) and Max Mortensen after flushing vials
containing the DP with nitrogen (Figure 5-1A). These vials of DP oil were stored at -20C
until experimentation unless otherwise stated. The DP oil was composed of alkanes and
alkenes ranging from 11 to 29 carbons (Figure 5-1B, 5-1C).
Media. Minimal defined media contained yeast nitrogen base without amino acids (Sigma
#Y0626) and supplemented with 380 mg/L leucine and 76 mg/L uracil. Nitrogen limited
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media contained yeast nitrogen base without amino acids and ammonium sulfate (Sigma
#Y1251) and supplemented with 380 mg/L leucine, 76 mg/L uracil, 100 mM HEPES
(Fisher #BP310), 90 mM dibasic phosphate, 10 mM monobasic phosphate, 0.73 g/L
ammonium sulfate and adjusted to pH of 5 with 6 N hydrochloric acid. Glucose, DP, and
purchased alkanes were used as carbon sources at concentrations mentioned throughout
the text.
Culturing conditions.

For each experiment, seed cultures were generated by

inoculating a single colony from a fresh petri dish into a 14 mL culture tube in 3 mL of
minimal media containing 20 g/L glucose and incubated overnight. Sub-seed cultures
were generated by transferring 1.5 mL of the seed culture into 50 mL of minimal media
containing 20 g/L glucose using a 500 mL baffled flask and incubated overnight until midexponential growth phase. For nitrogen limited experiments, sub-seed cultures were
incubated for 2 days in nitrogen limited media containing 20 g/L glucose. Cells were
centrifuged and washed once in sterile water prior to starting main experiments in 50 mL
baffled flasks with 10 mL working volume and 3 technical replicates. Cells were incubated
using a MaxQ6000 air incubator set to 250 rpms and 28 ℃.
Analytical methods
Lipid quantification. 1.2 mL of cell culture was transferred into a pre-weighted 1.5 mL
centrifuge tube, washed twice with water, and resuspended to a total volume of 1.2 mL in
water. 100 µL aliquots of each sample were transferred into a single well in duplicate
using a 96-well plate. The remaining 1 mL of the cell culture sample was centrifuged at
max speed for 5 minutes before removing the supernatant. The cell pellet was dried at
50 ℃ until a constant weight was obtained (e.g., 2-3 days) and used to calculate dry cell
weight (DCW). A corn oil standard was prepared at 5 mg/mL l in ethanol and used to
generate working standards ranging 0.05-1 mg/mL in water. 2 µL of 1 µg/mL Bodipy
435/503 (Fisher #D3922) in DMSO was added to each well and the plate was shaken in
the dark for 15 minutes before measuring fluorescence (excitation 485nm; emission
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528nm) to measure lipid concentrations. Lipid %DCW was calculated by dividing the
average lipid concentration for 2 replicates/sample by the sample DCW.
Metabolites and sugar quantification. 1 mL cell culture samples were centrifuged at
max speed for 2 minutes and the supernatant was transferred to a new centrifuge
tube. Glucose and organic acids were measured after filtering supernatant samples with
0.2 µm filters using a Shimadzu high performance liquid chromatography system
equipped with UV and RID detectors (Shimadzu Scientific Instruments, Inc. MD, USA)
and an Aminex 87H column (Biorad, CA, USA) at a flow rate of 0.6 mL/min, oven
temperature of 48 ℃ with 10 mM sulfuric acid mobile phase (16).
HS quantification by GCMS. 10 mL of sacrificial flask replicates were transferred into a
15 mL tube and stored at - 80 ℃. Samples were thawed before adding chloroform
containing 800 mg/L ethyl pentadecanoate as the internal standard. Samples were
incubated at 4 ℃ on a tube rotator overnight to ensure complete cell lysis and
extraction. Samples were vortexed well and centrifuged at 3500 rpm for 5 minutes before
transferring 250 µL of solvent into a GCMS vial through a 0.2 µM filter. Gas
chromatography mass spectroscopy (GCMS) and nuclear magnetic resonance (NMR)
were performed by Max Mortensen and advised Dr. Laursen (UTK, CBE).

Results
Growth and adaptation of Y. lipolytica on synthetic oil. Preliminary characterization
with wildtype Y. lipolytica showed cell growth (i.e., turbidity) in culture tubes containing
5% (v/v) DP oil as the sole carbon source and in culture tubes containing a mixture of 5%
(v/v) DP oil and 5 g/L glucose after 2 days of cultivation (Figure 5-2A). To confirm cell
growth on DP oil, we repeated this experiment using baffled flasks to provide better
aeration for cell growth. We found that 2% (v/v) DP oil as the sole carbon source
supported growth of wildtype Y. lipolytica cells achieving 0.67 ± 0.09 OD600nm in 4 days of
cultivation (Figure 5-2B). However, cell growth was not detected using 5% or 10% (v/v)
DP oil (data not shown). Notably, maximum cell mass (i.e., OD 600nm) in the mixture of
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glucose and DP oil was reduced by ~53% in comparison to cell growth in glucose alone
(Figure 2B). Attempting to improve cell growth on DP oil, we employed a short-course
adaptation experiment by subjecting wildtype Y. lipolytica to 5 successive transfers in 2%
(v/v) oil (Figure 5-2C). Short-term adaptation improved growth performance in DP oil,
enabling the adapted strain (maximum OD600nm of 2.69 ± 0.55) to increase cell mass
~1.9-fold relative to the wildtype (maximum OD600nm of 1.43 ± 0.04) using 2% (v/v) DP
oil as the sole carbon source (Figure 5-2D).

Additionally, the adapted strain

demonstrated superior growth on hexadecane (C16 alkane), which is a component of the
plastic oil (Figure 5-2D). Of note, the adapted strain exhibited cellular adhesion to the
hydrophobic layer of both DP oil and hexadecane even after centrifugation (Figure 52E).
Stability analysis of synthetic oil.

During our experiments using plastic oil, we

observed reduced cell growth from oil stored at room temperature (RT) for long periods
of time (~2-3 months). To confirm this hypothesis, we combined fresh DP oil batches and
partitioned half of the oil for storage at RT and half of the oil for storage at -20℃ (Figure
5-3A). Growth characterization of adapted Y. lipolytica at 3 and 6 weeks of storage
showed no statistical differences in cell growth between the two storage conditions, albeit
RT-stored oil resulted in greater deviation of growth between replicates (Figure 53B). After 9 weeks, the deviation in cell growth between replicates became prominent for
RT-stored oil (Figure 5-3B). Finally, after 14 weeks of storage, the adapted strain was
unable to grow in the RT-stored oil while growth was not affected from oil stored at -20℃
(Figure 3B). Qualitative physical observations of the RT-stored oil at 14 weeks included
increased melting point and increased viscosity (Figure 5-3C).

To understand the

unstable components of the oil, we subjected oil from both storage conditions at 14 weeks
to 2D NMR and GCMS which has not yet resulted in identification of differences in oil
components.
Lipid and citric acid production from synthetic oil. Next, we aimed to upcycle plastic
waste into higher-value chemicals, specifically triacylglycerol lipids and citric acid, using
nitrogen limited media. Using 2% (v/v) DP oil, adapted Y. lipolytica achieved a maximum
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cell growth of 3.34 ± 0.32 OD600nm while producing 2.33 ± 0.12 g/L citric acid and
accumulating 10.09 ± 0.42 lipid %DCW (Figure 5-4A-C). In 2% (v/v) hexadecane,
maximum cell growth (11.74 ± 0.36 OD600nm) and citric acid production (14.6 ± 0.77 g/L
citric acid) were significantly higher in comparison to the DP oil (Figure 5-4A, 54B). However, both hexadecane and DP oil carbon sources exhibited similar lipid levels
by day 4 (Figure 5-4C). Cells grown in 20 g/L glucose showed the lowest lipid level (6.93
± 1.17 lipid %DCW) with moderate citric acid titer (4.28 ± 0.37 g/L citric acid) and
intermediate

cell

growth

(7.34

±

0.14

OD600nm)

between

the

3

carbon

sources. Interestingly, both hexadecane and DP oil GCMS profiles showed complete
consumption despite the differences in cell growth and citric acid production (Figure 54D).

Discussion
Increased demand for- and production of- plastic has led to a significant increase in
waste. To avoid the negative environmental impacts associated with plastic waste
necessitates economic strategies to recycle plastic into useful chemicals. Here, we
aimed to upcycle plastic waste by harnessing Y. lipolytica for the bioconversion of
catalytically DP. By maintaining the DP in frozen storage conditions and adapting Y.
lipolytica to the DP, we demonstrated production of citric acid and triacylglycerol from
plastic waste as the sole carbon source.
Although well-studied for utilization of HS, wildtype Y. lipolytica exhibited poor
growth on the DP oil (Figure 5-2B, 5-2D). Further, cell growth in the mixture of glucose
and DP oil was reduced in comparison to cell growth in glucose only, indicating that the
plastic oil contains toxic components that hinder cell growth (Figure 5-2B). Short term
adaptation, however, not only improved cell growth on DP oil but also on hexadecane
(Figure 5-2D), suggesting alkane metabolism was cryptic and required activation as
previously observed in xylose metabolism (17). Yet, the question arises about the drastic
differences in cell growth between pure hexadecane and the mixture of alkanes contained
in the DP. Is reduced growth because of inhibitory components in the DP oil? Or does
Y. lipolytica lack the metabolic capacity required to support cell growth on the longer
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carbon-chain alkanes contained in the DP? To answer these questions, we are currently
testing growth of Y. lipolytica on alkanes and alkenes ranging from C11-C28 and
performing detailed NMR on the DP to identify potential inhibitory components.
During our experiments using DP, we observed inhibition of cell growth (even for
the adapted strain) from oil stored at room temperature for long periods of time (~3
months), indicating unstable components were contained within the DP (Figure 53B). Fortunately, the oil remained stable if stored frozen immediately after catalytic
depolymerization, but the question arises concerning what makes the DP unstable.
Specifically, what chemical(s) arise that inhibits growth of Y. lipolytica and can the
catalytic depolymerization processing be optimized to prevent or minimize this
unstably? Due to the complexity of the DP mixture, we were only able to detect small
shifts in NMR spectra between inhibitory- and fresh-DP oil that have not provided any
clear hypotheses to date. In parallel, we are analyzing the inhibitory- and fresh-DP oil
using GCMS to help resolve compositional changes in the unstable DP oil.
Albeit with room for improvement, Y. lipolytica showed promise as the biological
host for upcycling plastic waste into higher-value chemicals by producing citric acid and
neutral lipids directly from DP (Figure 5-4A-C). Cells grown with hexadecane as the sole
carbon source consumed all hexadecane, produced ~6-fold more citric acid, and
achieved ~3.5 greater cell mass in comparison to cells grown on DP oil. However, GCMS
analysis revealed most of the DP components (i.e., <C26 alkanes) were consumed where
the question arises about the carbon flow (Figure 5-4D). In other words, DP-grown cells
assimilated most of the DP yet did not achieve similar cell growth or citric acid titers in
comparison to hexadecane-grown cells. We hypothesize that assimilated DP is either
converted and secreted as an extracellular emulsifier (e.g., liposan) (18) or functionalized
into an intermediate metabolite of alkane degradation (i.e., aldehyde, alcohol or fatty
acid). To date, GCMS has not identified any alcohol, aldehyde or fatty acid intermediate
metabolites. However, fatty acids are not readily detectable by GCMS without first
converting them into esters. Hence, we are performing transesterification on extracted
fatty acids to conclude whether fatty acids are accumulating in DP-grown cells. In parallel,
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we are analyzing emulsification activity of these cultures to determine if DP is being
converted into the compositionally controversial emulsifier (13).
Additionally, for all HS tested, the adapted strain grew as a mixture of adhering
cells (i.e., located in the HS top layer) and planktonic cells (i.e., located in the aqueous
phase) (Figure 5-2E) which are understood to emerge once the hydrophobic layer has
become saturated with adhering cells (13). While the mechanism(s) underlying HS
accessibility and transport are not fully understood, we observed evidence via
microscopic images of both surface-mediated (i.e., extracellular emulsifier acting as
surfactant, Figure 5-4E) and direct interfacial (i.e., cell attachment to HS droplets, Figure
5-2E) transport mechanisms enabling cells to access and assimilate the HS (19).
In conclusion, our work demonstrates a promising platform for upcycling plastic
waste by catalytic depolymerization and subsequent bioconversion of the DP into highervalue chemicals with the bioenergy microbe, Y. lipolytica. These results suggest further
adaptation engineering of Y. lipolytica could improve cell growth and chemical production
from DP. Further work concerning mechanisms and genes governing HS accessibility,
uptake, and regulation of HS metabolism is critical to unlock the full potential of Y.
lipolytica for upcycling plastic waste (20). To address this challenge, we have conducted
proteomic samples of Y. lipolytica (planktonic and adhering) cells cultured in glucose,
hexadecane, or DP oil to elucidate proteins required for- and mechanisms underlying- HS
metabolism.
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Figure 5- 1. (A) Condensation flow reactor scheme to generate DP. (B) Images and (C)
composition of DP oil.
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Figure 5- 2. Growth of wildtype Y. lipolytica in (A) culture tubes and (B) baffled flasks. (C)
Short-term adaptation of Y. lipolytica in DP oil to generate adapted strain. (D) Growth
comparison of wildtype and adapted Y. lipolytica in glucose, hexadecane and DP oil. (E)
Image of adapted Y. lipolytica cultured in DP oil after centrifugation and microscopic
image of adhering cells. *p-value < 0.001 using one way analysis of variance Holm-Sidak
method.
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Figure 5- 3. (A) Workflow to generate DP oil stored at RT or -20°C for stability
characterization. (B) Growth of adapted Y. lipolytica on DP oil stored at RT or -20°C after
3, 6, 9 and 14 weeks. (C) Images of DP oil stored in RT at week 0 and week 14. *p-value
< 0.001 using one way analysis of variance Holm-Sidak method.
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Figure 5- 4. Production of citric acid and lipids from DP oil using adapted Y. lipolytica. (A)
Growth, (B) citric acid production, (C) lipid accumulation, (D) and DP oil consumption
profiles. (E) Fluorescent image of adapted Y. lipolytica cultured in DP oil and stained with
Bodipy (as described in lipid quantification method).
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CONCLUSION AND FUTURE DIRECTION
Knowledge of genotypes and mechanisms underlying robustness are essential for
reverse engineering these traits, but also for understanding processes affected by- or
attributing to- these complex phenotypes. The goal of this dissertation was to elucidate
genotypes and cellular processes responsible for robust phenotypes displayed by Y.
lipolytica by ascertaining differences between robust and non-robust strains using multiOMICS strategies.
In the case of an absent phenotype, thiamine auxotrophy, comparative genomics
with thiamine prototrophic yeast S. cerevisiae and knowledge of the thiamine biosynthesis
pathway proved sufficient for identification of the missing gene causing Y. lipolytica’s
thiamine auxotroph. However, restoring thiamine biosynthesis with this gene required a
thiamine-regulated promoter to efficiently express this gene, highlighting the complexity
of gene regulation underlying seemingly simple phenotypes.
In the case of divergent phenotypes by members of the Y. lipolytica clade,
comparative proteomics revealed global changes and allowed for speculation of proteins
governing xylose metabolism and lipid degradation or accumulation. We found singleton
or exclusive genes that might be responsible for the diverging lipid and xylose metabolic
phenotypes, but unfortunately our proteomics analysis did not identify these novel
proteins. This study also highlights the importance of further investigation of gene
regulation (e.g., cis and trans regulatory elements) in controlling cellular phenotypes.
In the case of native phenotypes (i.e., the phenotype already exists), we found
adaptive laboratory engineering particularly useful which produced platform strains by
which to study superior mechanisms of robustness. Specifically, short-term adaptation
on depolymerized plastic oil generated a strain with dramatically improved utilization of
hydrophobic substrates (HS) but also with pronounced characteristics hypothesized to
enable cellular accessibility of the HS. With this strain, we expect to identify genes
responsible for cellular adhesion to the hydrophobic layer and perhaps other mechanisms
empowering HS metabolism. Multi-OMICS analysis will be critical for addressing these
fundamental knowledge gaps.
183

Regarding solvent tolerance, long-term adaption in ionic liquid (IL) generated a
superior solvent tolerant strain that exhibited remarkable and broad tolerance to all ILs
tested. Extensive characterization of this strain led us to multiple mechanistic hypotheses
of solvent tolerance such as lipid remodeling but relied on previous findings to establish
the mechanism (i.e., sterols strengthening membrane) attributing to our success in
identifying a genotype (i.e., overexpression of the sterol transcription factor) for reverse
engineering solvent-tolerance. In this project, the system studied was the whole cell and
numerous characterization experiments were necessary to identify sterols were affected
by ILs and critical for IL-tolerance. However, what if we could produce genes conferring
IL-tolerance from a single transcriptomics experiment?

If so, this would minimize

characterization efforts by significantly reducing the size of the system from the whole cell
to handful of genes that would allow for rapid determination of genotypes and
mechanisms underlying robust phenotypes.

However, our temporal transcriptomics

experiment resulted in a large list of candidate genes (i.e., 202 genes) leading to another
scientific question - which genes should we chose and how should we choose them?
Traditional approaches advocate selection of the most differentially expressed
gene(s), but is the most abundant gene transcript truly the best predictor of genetic
targets? And with this question an idea was formulated: Since genes that are coexpressed can infer a relationship (e.g., controlled by the same regulation machinery,
involved in the same metabolic pathway, functionally related etc.), could we predict the
genotype underlying a phenotype by choosing genes with the highest connectivity in a
co-expression network of upregulated genes during the phenotype? In other words, we
hypothesized that the most connected genes (of genes upregulated by the robust mutant)
would have the greatest influence on conferring to the robust phenotype. Though limited
to 29 gene candidates, our results discovered gene connectivity as a promising metric to
predict genetic targets conferring solvent tolerance in Y. lipolytica. To better understand
the implications of our results, future studies could address other phenotypes, different
strains, and test more genetic targets with alternative metrics of gene selection.
Overall, this work extensively contributes to experimental strategies and analyses
aiming to elucidate processes and genotypes underlying robustness for reverse
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engineering either absent (thiamine auxotroph), genetically diverse (lipid and xylose
metabolism), or native phenotypes (HS metabolism and IL tolerance). Understanding and
harnessing gene functions and regulation are critical to control metabolic processes for
metabolic engineering and synthetic biology applications.
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